In vitro reporter gene assays for assessment of PPAR- and Nrf2-mediated health effects of tomato and its bioactive constituents by Gijsbers, L.
In vitro reporter gene assays for assessment of 
PPAR- and Nrf2-mediated health effects of  
tomato and its bioactive constituents
Linda Gijsbers
Thesis commiTTee
Promotors
Prof. dr. ir. I.M.C.M. Rietjens 
Professor of Toxicology
Wageningen University
Prof. dr. ir. J. Keijer
Professor of Human and Animal Physiology
Wageningen University
co-promotor
Dr. ir. J.M.M.J.G. Aarts
Assistant professor, Sub-department of Toxicology
Wageningen University
other members
Prof. dr. R.J. Bino, Wageningen University
Prof. dr. A. Bast, Maastricht University
Dr. ir. P.C.H. Hollman, RIKILT, Wageningen UR
Dr. ir. H.T. Besselink, BioDetection Systems, Amsterdam
This research was conducted under the auspices of the Graduate School VLAG (Advanced 
studies in Food Technology, Agrobiotechnology, Nutrition and Health Sciences).
In vitro reporter gene assays for assessment of 
PPAR- and Nrf2-mediated health effects of 
tomato and its bioactive constituents
Linda Gijsbers
Thesis
submitted in fulfilment of the requirements for the degree of doctor
at Wageningen University
by the authority of the Rector Magnificus
Prof. dr. M.J. Kropff,
in the presence of the
Thesis Committee appointed by the Academic Board
to be defended in public
on Friday 8 March 2013
at 11 a.m. in the Aula.
Linda Gijsbers
In vitro reporter gene assays for assessment of PPAR- and 
Nrf2-mediated health effects of tomato and its bioactive 
constituents
PhD thesis, Wageningen University, Wageningen, NL (2013)
With references, with summaries in Dutch and English
ISBN 978-94-6173-509-6
TAbLe of coNTeNTs
chapter 1 Introduction 7
chapter 2 Induction of electrophile-responsive element (EpRE)-mediated 
gene expression by tomato extracts in vitro  31
chapter 3 Stable reporter cell lines for peroxisome proliferator-activated 
receptor γ (PPARγ)-mediated modulation of gene expression 49
chapter 4 Induction of peroxisome proliferator-activated receptor γ 
(PPARγ)-mediated gene expression by tomato (Solanum 
lycopersicum L.) extracts 67
chapter 5 Induction of peroxisome proliferator-activated receptor α 
(PPARα)-mediated gene expression by extracts of tomato 87
chapter 6 Identification via metabolomics screening of tomato compounds 
responsible for inducing electrophile-responsive element 
(EpRE)-mediated gene transcription 105
chapter 7 Discussion 123
chapter 8 Summary 139
chapter 9 Samenvatting 145
Appendix Dankwoord 153
Curriculum Vitae 155
List of publications and abstracts 157
Overview of completed training activities 159

iNTRoducTioN
1

IN
TRo
D
U
CTIo
N
1
fuNcTioNAL foods ANd bioAcTive comPouNds
In the last years, the number of functional foods on the market, such as margarines with 
plant sterols, fruit juice enriched with calcium and cereals with (soluble) fibre, has been 
growing steadily (1-3). The world health organisation (WHO) defines a functional food as 
“any food claiming to have a health-promoting or disease-preventing property beyond the 
basic function of supplying nutrients”. Using this definition, not only processed food items, 
but also natural products can be considered as functional foods. Fruits and vegetables 
are an example of natural foods with additional health-promoting properties; their 
consumption has been related to many health-promoting effects, including decreased risk 
for cardiovascular diseases and diabetes mellitus (4-6). Therefore, fruits and vegetables 
can be considered as functional foods (1, 7).
The health-promoting effects of functional foods may be (partly) due to the presence 
of bioactive compounds (8, 9). Several definitions of bioactive compounds have been 
adopted, all sharing the main notion that bioactive compounds are food components 
that have a beneficial effect on human health (10, 11). Many authors exclude nutrients 
from the definition of bioactive compounds (11-13), but some include macronutrients 
and micronutrients (10). As fatty acids and their derivatives also have been related to 
beneficial health effects (14), we choose here to use the more general definition that 
includes nutrients as possible bioactive compounds. The number of food products with 
possible additional health benefits, including functional foods, has increased over the 
past years. In January 2007, the new EU regulation 1924/2006 became effective, stating 
that nutrition and health claims for functional foods are not allowed unless the claim is 
approved by the European Commission, based on advice given by the European Food 
Safety Authority (EFSA)(15, 16). In this regulation, two categories of claims are identified: 
nutrition claims and health claims. A nutrition claim states that a food has a specific 
beneficial nutritional property, for example that the food is containing calcium or that 
it is low in sugar. Health claims are defined as “any claim that states, suggests or implies 
that a relationship exists between a food category, a food or one of its constituents and 
health” (15, 16). Nowadays, the market for functional foods is rapidly growing and given 
the EU requirements, there is a major interest of food industry to scientifically support 
beneficial effects of functional foods and their bioactive ingredients. To achieve this, fast 
and low-cost tools for identification of bio-functional characteristics of food items and 
food compounds are essential. Until now, research on the health-beneficial effects of 
food products and food compounds has been mainly based on animal studies, human 
intervention studies or epidemiologic studies, which are all laborious and expensive. 
Reporter gene assays are a fast and low-cost alternative to investigate bio-functional 
characteristics of food compounds and food items. As the activity of various transcription 
factors has been strongly related to beneficial health effects (17, 18), reporter gene assays 
for such health-related transcription factors may provide first-level support in a tiered 
approach to support nutrition and health claims for bioactive ingredients.
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Aims of The Thesis
The aims of this thesis were:
1. To develop and validate stable reporter cell lines to facilitate high-throughput screening 
of natural and synthetic compounds for several health-related functions.
2. To show that reporter gene assays provide a tool to link fruits and vegetables to 
specific health-beneficial pathways, by assessing the activity of tomato extracts in 
these reporter gene assays. 
3. To verify that reporter gene assays are useful tools in selecting health-beneficial traits 
of crop varieties, again using tomato fruit as a model.
To achieve these aims, three health-related gene expression pathways were chosen; Nrf2/
EpRE-mediated gene expression, PPARγ-mediated gene expression and PPARα-mediated 
gene expression. 
Selected health-related gene expreSSion pathwayS
Nrf2/epRe
The nuclear factor E2-related factor (Nrf2) is a transcription factor able to regulate 
expression of several genes. Normally, Nrf2 is present in the cytoplasm of cells in its 
inactive form: bound to Kelch-like ECH-associated protein 1 (Keap1). Once the cell is 
exposed to Nrf2-activating compounds, this leads to the release of Nrf2 from Keap1. 
once released from Keap1, Nrf2 migrates into the nucleus where it forms a complex 
Nrf2 Small
Maf
Target genes incl. 
phase II enzymes

Keap1 Nrf2
-SH
-SHKeap1
-S
-S
EpRE
Nrf2
figure 1. In the presence of Nrf2-activating compounds, Nrf2 is released from Keap1 and moves into 
the nucleus. In the nucleus, it forms a complex with Small Maf proteins and this complex binds to the 
EpRE, thereby enhancing transcription of the target genes. 
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with Small Maf proteins and subsequently binds to the electrophile-responsive element 
(EpRE) in the regulatory domains of the Nrf2 target genes (figure 1). The expression 
of these target genes is thereby enhanced. Genes regulated by Nrf2/EpRE include 
phase II detoxifying enzymes, which catalyse reduction or conjugation of reactive 
electrophiles. As a result, metabolites are formed which are less toxic and more easily 
excreted from the body (17, 19). In this way, phase II enzymes are able to detoxify 
harmful (e.g. carcinogenic) metabolites. Therefore, EpRE-mediated gene expression 
is chosen as one of the health-beneficial endpoints for this thesis. In this thesis, the 
EpRE-LUX reporter assay, which was earlier described by Boerboom and colleagues, was 
used to measure Nrf2/EpRE-mediated effects on gene expression (20). Nrf2-activating 
compounds include for example flavonoids such asquercetin and kaempferol (20-22) 
and isothiocyanates (23).
PPARs
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription 
factors belonging to the nuclear receptor superfamily (24). Ligands for PPARs include for 
example fatty acids and their derivatives, but also synthetic ligands have been produced, 
mainly for pharmaceutical applications (25). Once activated by ligands, PPARs form a 
complex with retinoid X receptor (RXR) and bind to the peroxisome proliferator-responsive 
element (PPRE) in the regulatory regions of their target genes (26). In this way, activation 
of PPARs influences the expression of these target genes (figure 2). 
Target genes

PPRE
PPA
R
R
XR
PPA
R
R
XR
figure 2. PPAR forms a heterodimer with RXR. Upon activation of the PPAR-RXR complex, it binds to 
the PPRE and enhances transcription of the target genes.
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Three PPAR isoforms are known: PPARα (NR1C1), PPARβ/δ (NR1C2) and PPARγ 
(NR1C3). These isoforms differ in their tissue distribution and their response to certain 
ligands. Furthermore, the three isoforms have their own set of target genes, which 
partially overlap (27). By enhancing the transcription of their target genes, PPARs play 
key roles in important physiological processes. For example, PPARα is known for its role 
in lipid metabolism (28, 29) and PPARγ is essential for adipogenesis (30, 31). PPARβ/δ has 
more pleiotropic effects and plays a role in various processes, for example in lipid and 
lipoprotein metatolism (32, 33), inflammation (34), and wound healing (35, 36). In the 
next sections, PPARα and PPARγ, for which reporter gene assays were developed in the 
present thesis, will be discussed in some more detail. 
pparα
PPARα was the first PPAR isoform discovered and is mainly present in liver, skeletal 
muscle and brown adipose tissue (37). Several fatty acids and their derivatives, including 
arachidonic acid, linolenic acid, linoleic acid and eicosanoids, function as endogenous 
ligands for PPARα, while fibrates are a potent class of exogenous ligands (25, 38). Fibrates 
are a class of lipid-lowering drugs including gemfibrozil, clofibrate, fenofibrate, bezafibrate 
and ciprofibrate. 
PPARα is an important factor in lipid metabolism (28, 29) and its target genes include 
many genes involved in uptake and oxidation of fatty acids (28, 39, 40). Activation of 
PPARα by fibrates results in decreased plasma levels of triglycerides and LDL cholesterol, 
and in increased HDL cholesterol levels (41-43). As high levels of triglycerides and LDL 
cholesterol and low levels of HDL cholesterol are risk factors for atherosclerosis and other 
cardiovascular diseases (CVDs), fibrates in this way may decrease the risk for developing 
atherosclerosis or CVDs. Indeed, several authors report a decreased risk for CVDs after 
treatment with fibrates (44-46). Besides its protective role in CVDs, PPARα-mediated gene 
expression has also been related to improved insulin sensitivity (42, 47). An overview of 
possible health-beneficial effects of PPARα-activation is given in table 1. 
pparγ
PPARγ is mainly expressed in adipose tissue, but is also present in for example colon, 
liver and kidney (48). PPARγ is activated by both endogenous and synthetic ligands. 
Endogenous ligands include fatty acids and their derivatives, such as 15-deoxy-Δ12,14-
prostaglandin J2 (15d-PGJ2), docosahexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA)(25). Thiazolidinediones (TZDs) are the most well-known synthetic PPARγ agonists 
and include, amongst others, rosiglitazone, troglitazone and pioglitazone. In humans, 
PPARγ is present in two isotypes: PPARγ1 and PPARγ2, generated from the same gene by 
alternative promoter usage and mRNA splicing (48, 69). PPARγ1 and PPARγ2 differ in the 
N-terminus of the protein; PPARγ2 contains 28 extra amino acids at this site. There is also 
a difference in expression pattern between the isoforms; PPARγ1 is expressed broadly 
and is present in adipose tissue, spleen, liver, skeletal muscle, heart, large intestine and 
kidney. PPARγ2 is mainly expressed in adipose tissue and in lower amounts in liver and 
skeletal muscle (48, 70, 71). It is not completely clear to what extent the two subtypes 
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display functional differences. Some studies indicate that PPARγ2 is more important in 
adipogenesis and insulin sensitivity than PPARγ1 (72-74).
PPARγ was initially known for its crucial role in adipocyte differentiation and 
adipogenesis (30, 31). Later, it was discovered that insulin-sensitizing drugs from the class 
of TZDs function as PPARγ agonists (24). Several lines of evidence suggest that TZDs exert 
their insulin-sensitizing effects via PPARγ (24). Besides improvements in insulin sensitivity, 
PPARγ has been related to several other possible beneficial health effects, which are 
summarized in table 2. PPARγ agonists have been related to decreased risk of developing 
prostate, breast and colon cancer (75, 76). It is, however, not yet known to what extent 
these anticancer effects are mediated by PPARγ (77-79). In addition, activation of PPARγ 
is considered to have a protective effect on the risk for atherosclerosis and to lower blood 
pressure (84, 85, 102, 103). 
TZDs, the best known synthetic PPARγ agonists, are well-known anti-diabetic drugs. 
Presently, however, pioglitazone is the only TZD still prescribed as insulin-sensitizing drug 
to patients suffering from type 2 diabetes mellitus (104, 105). Troglitazone was taken from 
the market because of its liver toxicity (106), while rosiglitazone is no longer prescribed 
because of concerns about its cardiovascular safety (107). Although TZDs are known 
for their clinical effects on insulin sensitivity and hyperglycemia, there are also adverse 
effects known for these drugs, including edema, fluid retention and weight gain (108, 
109). Selective PPARγ modulators, SPPARMs, may have the same therapeutic effectiveness 
as TZDs without causing the adverse effects (110, 111). Currently known SPPARMs include 
Table 1. Overview of beneficial health effects mediated by PPARα agonists and corresponding literature 
references.
Physiological process or disease References
Cardiovascular diseases (CVD)
Reduced risk for cardiovascular events
Decreased levels of plasma triglycerides
Decreased levels of total cholesterol
Decreased levels of non-HDL cholesterol
Increased levels of HDL cholesterol
Reduced blood pressure
(44-46)
(42, 49, 50)
(41, 42, 49)
(42, 49)
(41, 49, 50)
(41, 51)
Atherosclerosis
Reduced progression of atherosclerosis
Regression of aortic plaques
(52)
(53-56)
(57)
Inflammation and inflammatory diseases
Reduced cytokine release
Decreased inflammatory markers
(58)
(59-61)
(59, 61, 62)
Insulin sensitivity
Decreased fasting insulin levels
Improved glucose tolerance 
Improved insulin sensitivity
(63)
(49)
(64)
(41, 49, 64)
Diabetic nephropathy
Reduced progression of albuminuria 
Improved glomular filtration rate
(65, 66)
(67)
(68)
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for example GW0072, halofenate, linoleic acid and 15d-prostaglandin J2, and the search 
for new SPPARMs is continuing (110, 112). 
reporter gene aSSayS
The aim of this thesis was to develop and validate stable reporter cell lines to facilitate 
high-throughput screening of bioactive food compounds for several health-related effects 
on gene expression level. The concept of reporter gene assays is explained in some more 
detail here. 
A reporter gene assay is a cell-based tool which enables measuring gene transcription 
through a specific signalling pathway. Reporter gene assays make use of cells which are 
genetically engineered with a reporter construct. This reporter construct contains a 
reporter gene under transcriptional control of a response element for the transcription 
factor of interest. When the stimulus is present, the transcription factor binds to its 
response element, thereby enhancing the transcription of the reporter gene (figure 3). 
The reporter gene is generally a gene encoding a protein with an enzymatic activity that 
can be measured easily. In that way, the enzyme activity is ‘reporting’ transcriptional 
activation and expression of the reporter gene (113). One of the most frequently used 
reporter genes is the luciferase gene. Transcription of this gene results in the production 
of the luciferase enzyme, which catalyses the oxidation of luciferin (figure 3). During this 
Table 2. Overview of beneficial health effects mediated by PPARγ agonists and corresponding literature 
references.
Physiological process or disease References
Adipogenesis
Stimulation of adipocyte differentiation
Increased storage of fatty acids in adipocytes
Reduced serum levels of free fatty acids
(31, 80)
(81, 82)
(82, 83)
Diabetes Mellitus type 2
Improved insulin sensitivity
Improved glucose tolerance
Lowered fasting insulin levels
Lowered fasting blood glucose levels
(84, 85)
(84)
(50, 86)
(50, 86)
Cardiovascular diseases (CVD)
Lowered blood pressure
Increased HDL cholesterol
Slower progression of atherosclerosis
(87, 88)
(84, 85)
(86, 89)
(50, 90)
Inflammation and inflammatory diseases
Anti-inflammatory effects
Clinical improvement of asthma
Clinical improvement of inflammatory bowel disease
(91, 92)
(91, 92)
(93, 94)
(95, 96)
Cancer
Prostate cancer: inhibition of tumor growth
Liposarcoma: induction of terminal differentiation
Lung cancer: reduced risk / inhibition of growth
(75, 76)
(97, 98)
(99)
(100, 101)
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oxidation reaction, light is produced. This light signal can be measured and indicates the 
presence of a stimulus capable to induce effects on gene transcription mediated by the 
regulatory sequence inserted upstream of the reporter gene (113).
Reporter gene assays are used to measure potencies of both agonists and antagonists 
to induce and inhibit transcription factor-mediated expression (114). Reporter cell lines, 
however, contain only one cell type, and therefore miss the context with other cell types 
as is found in tissues, organs and organ systems when performing in vivo studies. This 
means that results from reporter gene assays cannot be directly translated into in vivo 
effects (115, 116). On the other hand, reporter gene assays have the advantage that they 
are easy to handle, rapid and allowing for many compounds to be screened for their effects 
on expression mediated by a specific receptor, in a short time frame and at a relatively 
low cost (114). 
TomATo
The present thesis aims at providing proof-of-principle that reporter gene assays can be 
applied to investigate the effect of (compounds found in) fruits and vegetables on several 
transcription factor-mediated endpoints. Tomato was chosen as the model fruit, because 
of its health-beneficial effects (114), and because tomato is one of the most consumed 
vegetables in the world (117). In 2009, the average tomato consumption was 20.5 kg per 
person per year worldwide and 30.6 kg per person per year in Europe (117).
The consumption of tomato and tomato products has been related to several 
beneficial health effects. Epidemiological studies suggest a relation between tomato 
responsive
element
Transcription
factor
luciferase
gene




 
figure 3. General principle of luciferase-based reporter gene assays. 
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consumption and reduced risk of certain forms of cancer, including prostate cancer, lung 
cancer and colorectal cancer (118-120). High intake of tomato has also been related to 
lower risk of atherosclerosis and cardiovascular diseases (CVDs)(121, 122). Furthermore, 
tomato consumption improves risk factors for CVDs: it leads to increased HDL cholesterol, 
decreased LDL cholesterol and decreased triglyceride plasma levels (123). In addition, 
treatment with tomato extract induced a decrease in blood pressure in patients suffering 
from hypertension (124, 125). Finally, carotenoids and naringenin, phytochemicals known 
to be present in tomato, have been shown to improve insulin sensitivity and blood glucose 
levels (126, 127). The beneficial health effects related to tomato consumption may thus be 
due to the presence of several bioactive phytochemicals present in tomato fruit (118, 128), 
including polyphenols (such as quercetin, kaempferol and naringenin) and carotenoids 
(such as lycopene and β-carotene)(129-132). 
Tomato breeding programmes are currently not only focussing on yield, resistance to 
plant diseases, and taste, but also on nutritional value and the amounts of phytochemicals 
present in tomato fruits (133, 134). For example, high pigment mutants of tomato contain 
more phytochemicals including lycopene, β-carotene, α-tocopherol, vitamin C, rutin 
and quercetin (129, 135), and purple tomato fruits enriched with anthocyanins were 
developed as well (136, 137). Due to their higher content of phytochemicals, the high 
pigment tomatoes and purple tomatoes may provide stronger beneficial health effects 
than wild type tomatoes, but this remains to be investigated. 
phytochemicalS
Many plants and plant-based food products contain bioactive phytochemicals, such as 
carotenoids and flavonoids, which are in particular found in fruits and vegetables (128). 
Bioactive phytochemicals are mainly secondary metabolites formed by plants for several 
functions, such as protection against bacteria and fungi, protection against UV damage, 
attraction of pollinating insects, etcetera. When (parts of these) plants are eaten by 
humans, certain bioactive phytochemicals may have beneficial effects on human health 
(138, 139). 
In this thesis, we focus mainly on phytochemicals known to be present in tomato 
fruit, including flavonoids and carotenoids. Many of these compounds are not specific 
for tomato, and are also present in other fruits and vegetables. Lycopene, for example, 
is present in tomato, but also in watermelon and pink grapefruit and β-carotene is found 
in carrots and apricots (140). Quercetin is known to be present in onion and apple, while 
naringenin is found in citrus fruits (141).
carotenoids
Carotenoids are a family of fat-soluble, colorful pigments mainly found in plants. 
Carotenoids are responsible for the yellow, orange and red colors occurring in plants. 
Furthermore, carotenoid-chlorophyll complexes give rise to the green colors of leafy 
vegetables (7). Humans are not able to synthesize carotenoids and rely on dietary intake. 
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In the human diet, fruits and vegetables are the main source of carotenoids (142). For 
example, the main sources of lycopene are tomato and water melon, while carrots and 
apricots are good sources of β-carotene (140). Carotenoids have an isoprenoid structure 
and consist of a long skeleton containing 40 carbon atoms, as can be clearly recognized 
in the structure of lycopene (figure 4A). The skeleton is synthesized by tail-to-tail linkage 
of two C20 geranyl-geranyldiphosphate molecules. The long tail of carotenoids consists 
of alternating single and double bonds (143, 144). There are some variations on the long 
basic skeleton. For example, some carotenoids have a hydrocarbon ring on one or both 
ends of the molecule (such as β-carotene, figure 4B). Carotenoids are divided into two 
subgroups: carotenes and xanthophylls. Carotenes contain only carbon and hydrogen 
atoms, while xanthophylls, such as violaxanthin (figure 4C), also contain oxygen atoms 
(143, 144).
The major dietary carotenoids are lycopene, β-carotene, α-carotene, cryptoxanthin, 
and lutein, which are especially present in deeply pigmented fruits and vegetables such as 
apricots, tomato fruits and carrots, and in green leafy vegetables such as spinach and kale 
(145). Carotenoids have been related to several health-promoting properties. First of all, 
some carotenoids, including β-carotene, function as precursors of vitamin A (144). These 
carotenoids can be metabolized in the enterocytes into retinoids by cleaving the carotenoid 
C40 molecule into two C20 retinal molecules. Retinal is then further metabolized into 
retinoic acid and into retinol, the active form of vitamin A (146, 147). Vitamin A is known 
to play an important role in vision, and carotenoid intake has been related to protection 
from cataract and from oxidative damage of the retina (148, 149). In addition, it has been 
suggested that dietary intake of carotenoids is related to reduced risk of chronic diseases 
including cardiovascular diseases and certain forms of cancer (145, 150). 
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flavonoids
Flavonoids belong to the group of polyphenols and are found in many fruits and 
vegetables, but also in plant-derived products such as tea and chocolate (151, 152). 
Important food sources of flavonoids include natural food products such as soy, citrus 
fruits, grapes, berries and onions, but also plant-derived food products such as red wine, 
tea and chocolate (153, 154). Flavonoids consist of 15 carbon atoms arranged in three 
aromatic rings (C6 – C3 – C6) and can be divided into many subclasses, including flavonols 
(figure 5A), flavones (figure 5B), isoflavones (figure 5C) and anthocyanidins (figure 5D)
(151, 152, 155).
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Many flavonoids have been related to various beneficial health effects. For example, 
flavonoids have been linked to reduced overall risk of atherosclerosis and other 
cardiovascular diseases (156), and have been shown to improve specific risk factors for 
cardiovascular diseases, such as hypertension and high levels of LDL cholesterol (157). In 
addition, i take of flavonoids has bee  r lated to protective effects gainst cancer (158). 
Several in vitro experiments have shown that flavonoids have antioxidant properties (152). 
Although it was previously thought that the health-beneficial effects of flavonoids were 
due to their antioxidant properties, nowadays the relevance of the antioxidant properties 
of flavonoids in vivo is questioned and beneficial effects of flavonoids may rather be due 
to their effects on transcriptional gene regulation (159, 160). 
figure 5. Basic structures of subclasses of flavonoids. A) flavonols; B) flavones; C) isoflavones; 
D) anthocyanidins. 
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ouTLiNe of The Thesis
In order to scientifically support and facilitate the development of nutrition and health 
claims for functional foods or their bioactive ingredients, reporter gene assays may be 
fast and useful tools. Therefore, the aim of this thesis was to develop and validate stable 
reporter cell lines to facilitate high-throughput screening of bioactive food compounds for 
several health-related functions. chapter 1, the present chapter, defines the aim of the 
studies and provides some background information on the topics of the thesis and the 
three health-beneficial endpoints addressed in this thesis. 
In order to test whole fruits or vegetables for their effects on transcription factor-
mediated expression, methods are needed to prepare extracts of fruits and vegetables 
which can be tested in reporter gene assays. chapter 2 describes methods for the 
preparation of extracts, using tomato fruit as a model for fruits and vegetables. These 
tomato extracts, as well as individual tomato constituents, were tested for their potency 
to enhance EpRE-mediated gene expression using the EpRE-LUX reporter cells. 
In chapters 3, 4 and 5, new reporter gene assays for additional health-related 
functions were developed and subsequently used to investigate the capacity of individual 
tomato compounds and tomato extracts to influence the related gene expression 
pathways. Newly developed reporter gene assays for PPARγ1- and PPARγ2-mediated gene 
expression are presented in chapter 3. The two new cell lines, named PPARγ1 CALUX and 
PPARγ2 CALUX, provide in vitro tools to test known PPARγ ligands, chemicals, and food 
compounds for their potency to activate PPARγ-mediated gene expression. In chapter 4, 
the PPARγ2 CALUX cell line was used to investigate the capacity of tomato extracts and 
individual tomato components, including polyphenols, isoprenoids and fatty acids, to 
activate PPARγ-mediated gene expression. The development and validation of a stable 
reporter gene assay for PPARα-mediated gene expression, called the PPARα CALUX assay, 
was described in chapter 5. Furthermore, capacity of individual tomato compounds and 
tomato extracts to influence PPARα-mediated gene expression, was characterized using 
this newly developed reporter gene assay.
In chapter 6, it was verified that reporter gene assays are useful tools in measuring 
differences between tomato varieties regarding their capacity to induce EpRE-mediated 
gene expression and in selecting varieties which show the highest potency. To that end, 
extracts of 97 different tomato accessions were prepared and screened for their capacity 
to induce EPRE-mediated expression using the EpRE-LUX reporter cells. Next, metabolomic 
profiles of these extracts were generated in order to identify phytochemicals responsible 
for the differences in potency of the 97 tomato varieties to induce EpRE-mediated 
expression. This study provided a proof of principle of how to identify specific ingredients 
contributing to the activity of the whole tomato extracts using metabolic profiling. 
The thesis concludes with an overall discussion and future perspectives in chapter 7. 
In the future perspectives it is discussed, for example, if and how reporter gene assays can 
be useful in a tiered approach to support nutrition and health claims for functional foods. 
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The market for food products with additional health benefits is increasing rapidly and tools 
for identification of bio-functional characteristics of food items are essential. To facilitate 
the detection of beneficial effects of tomato on gene expression, methods to prepare 
tomato extracts suitable to test in the EpRE-LUX assay and other cell-based reporter 
gene assays for health-related bioactivity mechanisms, were developed. An isoprenoid-
containing chloroform extract of tomato fruit and most individual isoprenoids did not 
induce electrophile-responsive element (EpRE)-mediated gene expression. A semi-polar 
extract of tomato fruits, enzymatically hydrolyzed to remove the glycosyl residues from 
the phenolic ingredients, was able to induce EpRE-mediated luciferase expression at 
both mRNA and protein level, which might be partly due to the presence of quercetin, 
kaempferol, naringenin and naringenin chalcone. It was concluded that induction of EpRE-
regulated genes, such as detoxifying phase II and antioxidant enzymes, may contribute to 
the beneficial health effects of tomato. 
Key wordS
Tomato, Solanum lycopersicum, extracts, electrophile-responsive element (EpRE), 
phenolic compounds, isoprenoids. 
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Recently, there has been increased interest to obtain scientific support for possible 
beneficial health effects of phytochemicals and other bioactive food compounds. For 
example, both flavonoids (1, 2) and carotenoids (3) have been proposed to protect against 
cancer and cardiovascular diseases (CVD). 
Epidemiological studies indicate that a diet rich in tomato or tomato products reduces 
the risk of certain chronic diseases, including coronary heart disease and certain forms 
of cancer (4-6). Although the cancer-protective properties of tomato and its products 
are often related to lycopene, the most abundant carotenoid present in these fruits (7), 
tomatoes contain many other potentially health-beneficial phytochemicals (8). These 
include for example considerable levels of phenolic compounds like naringenin chalcone, 
quercetin and kaempferol (9, 10), which have also been related to anti-carcinogenic 
effects (11, 12). Some of the beneficial effects of these bioactive phytochemicals have 
been attributed to their capacity to activate Nrf2 and EpRE-mediated changes in gene 
expression (13). 
The nuclear factor E
2-related factor 2 (Nrf2) is a transcription factor that can form a 
complex with Small Maf proteins and subsequently bind to the electrophile-responsive 
element (EpRE) in the regulatory region of its target genes, thereby enhancing the expression 
of these genes (14). The target genes of Nrf2 include phase II detoxifying enzymes, such 
as NAD(P)H:quinone oxidoreductase 1 (NQO1) and glutathione S-transferases (GSTs)(14). 
Phase II detoxifying enzymes are able to catalyze reduction or conjugation of reactive 
electrophiles, resulting in metabolites that are less toxic and more easily excreted from 
the body (15). Phytochemicals able to induce this EpRE-mediated gene expression include 
the phenolic compounds quercetin and kaempferol (16, 17) which are present in tomato 
fruit (10). 
In the last years, reporter gene assays were developed with the goal to link bioactive 
compounds found in food products to beneficial health effects (16, 18, 19). So far these 
assays have been mainly used to screen isolated pure compounds, but the assays have not 
yet been used to test extracts from fruits and vegetables to get an integral view of their 
potential effects on gene regulatory pathways. A method to test fruits and vegetables in 
reporter gene assays would provide a tool to link certain fruits or vegetables to specific 
health-beneficial pathways. It would also provide a tool to test different varieties from 
breeding programs and/or different preparation technologies in food processing practice, 
in order to select the variety or processing strategy that results in the largest possible 
content of active ingredients producing a selected beneficial biological effect. Such an 
in vitro assay would also minimize the need for animal testing at early stages of breeding 
programs or processing strategies. Therefore, the aim of the present study was to develop 
a method to test extracts of fruits and vegetables in reporter gene assays. The present 
study will focus on tomato fruit as a model for fruit and vegetables and on the EpRE-LUX 
reporter cell line (16) as a model reporter gene assay. 
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chemicals and reagents
Kaempferol, kaempferol-3-O-rutinoside, delphinidin chloride, cyanidin chloride, and lutein 
were purchased from Extrasynthese (Genay, France). Trifluoroacetic acid (TFA), β-carotene, 
lycopene, α-tocopherol, (+)-δ-tocopherol, (+)-γ-tocopherol, quercetin, chlorogenic 
acid, caffeic acid, ascorbic acid, tert-butylhydroquinone (tBHQ), tetrahydrofuran (THF) 
containing 0.025% butylated hydroxytoluene (BHT), β-glucuronidase from Helix pomatia 
(H. pomatia) type HP2 and Viscozyme L were purchased from Sigma-Aldrich (St. Louis, 
USA). Phytoene, phytofluene, neoxanthin, violaxanthin, neurosporene, δ-carotene and 
γ-carotene were obtained from CaroteNature GmbH (Lupsingen, Switzerland). Naringenin 
and a second preparation of β-carotene (which was stored for several years at -20°C) 
were obtained from ICN Biomedicals Inc. (Aurora, USA). Dimethyl sulfoxide (DMSO) and 
rutin were obtained from Acros Organics (Geel, Belgium). Methanol and chloroform were 
purchased from Biosolve (Valkenswaard, The Netherlands). 
Minimum Essential Medium alpha (further referred to as α-MEM), Minimum Essential 
Medium alpha without phenol red, the 1:1 mixture of Dulbecco’s modified Eagle’s medium 
and Ham’s F12 medium (further referred to as DMEM/F12), DMEM/F12 without phenol 
red, fetal calf serum (FCS), Hank’s balanced salt solution (HBSS), trypsin, nonessential 
amino acids (further referred to as NEAA), gentamicin, penicillin/streptomycin and G418 
were purchased from Invitrogen Corporation (Breda, The Netherlands). Dextran-coated 
charcoal-stripped FCS (DCC-FCS) was purchased from Thermo Scientific (Waltham, USA).
Naringenin chalcone was not commercially available as a pure compound. Naringenin 
chalcone was obtained from Apin Chemicals (Abingdon, UK) as a mixture with naringenin 
and the percentage of naringenin chalcone in the mixture was determined to be 
approximately 40% by HPLC analysis. 
Tomato samples
The model tomato sample was described earlier (20). In short, the sample was prepared 
by pooling fruits from several genotypes of beef, cherry, and round tomatoes in fully red 
stage of ripening. The fruit material was snap frozen in liquid nitrogen and ground in an 
analytical mill. The tomato powder was stored at -80°C until further use, and in this article 
will be further referred to as: tomato mix. 
Another tomato sample was prepared from roma tomatoes that were purchased at a 
local supermarket in Wageningen (The Netherlands). These fruits were also pooled and 
snap frozen in liquid nitrogen and ground in an analytical mill. The tomato powder was 
stored at -80°C until further use, and in this article will be further referred to as: roma 
tomato mix. 
preparation of tomato extracts containing semi-polar metabolites
Semi-polar metabolites such as flavonoids and phenolic acids and their glycosides, 
were extracted using methods described earlier (21). Briefly, nonhydrolyzed tomato 
extracts containing phenolic compounds were prepared by adding 3.4 ml of methanol 
34
EpR
E-M
ED
IATED
 G
EN
E EXPR
ESSIO
N
 &
 TO
M
ATO
2
to 0.6 g of tomato mix followed by sonication for 10 minutes and centrifugation at 
1000 g for 10-15 minutes. The supernatant of the samples was filtered using 0.2 μm 
polytetrafluoroethylene (PTFE)-filters (M-filter, Tiel, The Netherlands) and freeze-dried. 
Prior to analysis in the EpRE-LUX assay these tomato extracts, further referred to as 
nonhydrolyzed tomato extracts, were redissolved in DMSO:α-MEM (1:2 v/v). 
preparation of enzymatically hydrolyzed tomato extracts containing semi-polar 
metabolites
Enzymatically hydrolyzed tomato extracts containing phenolic compounds were 
prepared by adding 300 μl of 0.1 M sodium acetate (pH 4.8) and 100 μl of Viscozyme L 
or β-glucuronidase from H. pomatia type HP2 to 0.6 g tomato mix, followed by 1 hour 
incubation in a water bath at 37°C. Then, samples were put on ice and 3.0 ml of methanol 
were added, followed by 10 minutes sonication and 15 minutes centrifugation at 1000 g. 
The supernatant was filtered (0.2 μm PTFE-filters) and 2.0 ml of filtered methanol 
supernatant were dried under a stream of nitrogen. The remaining solution was finally 
freeze-dried and stored at -80°C until further analysis. Prior to analysis in the EpRE-LUX 
assay these extracts, further referred to as enzymatically hydrolyzed tomato extracts, 
were redissolved in DMSO:α-MEM (1:4 v/v).
preparation of tomato extracts containing isoprenoid derivatives
Isoprenoids such as carotenoids and tocopherols, were extracted using methods 
described earlier (21). In short, 4.5 ml of methanol/chloroform (2.5/2.0 v/v) was added 
to 0.5 g roma tomato mix, and the sample was mixed and put on ice for 10 minutes. 
Subsequently, to each sample 2.5 ml of cold 50 mM Tris-HCl buffer (pH 7.4) were added, 
samples were mixed and then centrifuged for 10 minutes at 1000 g. The chloroform phase 
was transferred to a new tube. The methanol/Tris sample was re-extracted twice by 
adding 1 ml of chloroform, mixing and centrifugation of the tubes. The three chloroform 
extraction fractions were combined and dried under a stream of nitrogen. Prior to analysis 
in the EpRE-LUX assay these extracts, further referred to as isoprenoid-containing tomato 
extracts, were redissolved in THF:α-MEM (1:1 v/v). 
Separation and detection of semi-polar metabolites by hplc-pda
The separation, detection and quantification of semi-polar metabolites such as flavonoids 
and phenolic acids was performed using high-performance liquid chromatography with 
photodiode array detection (HPLC-PDA) according to a modified method described 
before (21). Briefly, the freeze-dried samples were dissolved in 2 ml methanol and 
analyzed using a Waters e2695 separation module (Waters, Milford, USA) connected 
to a Waters 996 photodiode array detector. The system was equipped with a Luna C18 
(3 μm, 150 mm x 4.60 mm)(Phenomenex, Torrance, USA) column coupled to a C18 guard 
column (Phenomenex, Torrance, USA). Column temperature was maintained at 40°C by 
a Pharmacia oven. Separation was performed using a 5 - 35% acetonitrile linear gradient 
in 0.1% TFA for 45 minutes, followed by 35% - 75% acetonitrile linear gradient in 0.1% 
TFA for 2 minutes. Hereafter, the column was washed for 5 minutes at 75% acetonitrile 
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in 0.1% TFA and in 2 minutes brought back to initial concentrations and equilibrated for 
15 minutes before the next injection. This was all performed at a flow rate of 1 ml/min. The 
samples were monitored continuously from 200 to 600 nm by the Waters 996 photodiode 
array detector. Data were collected and analyzed using Waters Empower 2 software. HPLC 
chromatograms were recorded at 360 nm.
cell culture
The EpRE-LUX cells, which are Hepa-1c1c7 mouse hepatoma cells stably transfected with 
a reporter construct carrying a luciferase reporter gene under transcriptional control of 
an EpRE enhancer element in conjunction with a minimal promoter and an initiator (16), 
were cultured in α-MEM medium supplemented with 10% fetal calf serum (FCS), 50 μg/mL 
gentamicin and 0.5 mg/mL G418. The cells were maintained at 37°C in a humidified 
atmosphere with 5% Co2. 
The Cytotox CALUX cells are human osteosarcoma U2oS cells stably transfected with 
a reporter construct carrying a luciferase reporter gene under transcriptional control of a 
constitutive promoter. The reporter construct was generated by inserting the luciferase 
gene into the multiple cloning site of the pSG5-neo vector (22). These cells have an 
invariant luciferase expression and were originally designed to discover cytotoxicity (23). 
The Cytotox CALUX cells were cultured in DMEM/F12 supplemented with 7.5% FCS, NEAA, 
and penicillin/streptomycin (final concentrations 10 U/ml and 10 μg/ml, respectively). 
Once per week, 200 μg/ml G418 was added to the culture medium in order to keep the 
selection pressure.
epre-lux assay
The ability of tomato extracts and individual tomato compounds to induce EpRE-mediated 
luciferase expression at protein level was tested by measuring luciferase activity in the 
EpRE-LUX reporter cells. EpRE-LUX cells were seeded in the 60 inner wells of a white 
96-wells view plate at a density of 20,000 cells per well in 100 μL culture medium. In the 
outer wells 100 μl Hanks’ Balanced Salt Solution (HBSS) was added to maintain physical 
homogeneity throughout the plate. The seeded cells were incubated for 24 hours to allow 
them to attach and form a confluent monolayer. Subsequently, the cells were exposed 
for 24 hours to α-MEM without FCS and antibiotics containing individual compounds or 
tomato extracts. The freeze-dried extracts were dissolved in DMSO: α-MEM (1:2 v/v), 
DMSO:α-MEM (1:4 v/v) or THF:α-MEM (1:1 v/v) as described above. The pure phenolic 
compounds were dissolved in DMSo and the pure isoprenoids were dissolved in THF. 
The final concentration of solvent in the exposure medium was 0.5% for studies with all 
individual compounds, 1.5% for studies with enzymatically hydrolyzed tomato extract, and 
1.0% for studies with isoprenoid-containing tomato extract. On each plate, 30 μM tBHQ, 
a well-known inducer of EpRE-controlled gene transcription (16, 24, 25), was included 
as a positive control. Experiments with isoprenoids were conducted under reduced light 
conditions (exclusion of light with a wavelength <550nm). 
After 24 hours of exposure, medium was removed, cells were lysed by adding low salt 
lysis buffer (16) and incubated overnight at -80°C. Luciferase activity in the lysate was 
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measured using a luminometer (Luminoscan Ascent, Thermo Scientific, Waltham, USA) 
and flash mix (16). Luciferase activity per well was measured in relative light units (RLU). 
Compounds giving less than twofold induction at the maximum concentration (100 μM 
or the highest concentration that could be tested without cytotoxicity) were considered 
unable to induce EpRE-mediated luciferase expression at protein level. A viable cell 
count using trypan blue exclusion was performed as described elsewhere (26) in order to 
ascertain that the individual compounds and the various tomato extracts did not cause 
cytotoxicity at the concentrations used (data not shown). 
Quantitative pcr
The ability of the enzymatically hydrolyzed tomato extract and individual tomato 
compounds to induce EpRE-mediated luciferase expression at mRNA level was tested 
by measuring luciferase mRNA in EpRE-LUX cells by quantitative PCR. Since exposure 
time curves with tBHQ showed that 6 hour exposure is optimal for luciferase mRNA 
induction (data not shown), the exposure time for qPCR experiments was 6 hours 
compared to 24 hour exposure in luciferase activity experiments. EpRE-LUX cells were 
plated in 6-well plates. The next day, the EpRE-LUX cells were exposed for 6 hours to 
the individual compounds or to the enzymatically hydrolyzed tomato extract and then 
total RNA was extracted using a RNeasy kit (Qiagen, Hilden, Germany). The extracted 
RNA was reverse transcribed into cDNA using iScript RT supermix (Biorad, Hercules, USA). 
Quantitative PCR was performed using SYBR Green (Biorad, Hercules, USA), an iCycler Real 
Time PCR machine (Biorad, Hercules, USA), and specific primers for luciferase (forward 
5’-CGGGCGCGGTCGGTAAAGTT-3’; reverse 5’-AAGGCGTTGGTCGCTTCCGG-3’) and for 
mouse succinate dehydrogenase complex, subunit A (Sdha) as a reference gene (forward 
5’-CTTGAATGAGGCTGACTGTG -3’; reverse 5’- ATCACATAAGCTGGTCCTGT-3’). 
cytotox calux assay
The Cytotox CALUX cells have an invariant luciferase expression and were originally 
designed to discover cytotoxicity (23). These cells, however, can also be used to 
investigate whether stabilization of the luciferase enzyme is occurring during the exposure 
to compounds or extracts, a phenomenon that would result in increased luciferase activity 
without underlying increased expression of the gene (27). The Cytotox CALUX cells were 
seeded in the 60 inner wells of a white 96-well view plate at a density of 10,000 cells per 
well in 100 μl assay medium: phenol red-free DMEM/F12 medium supplemented with 
5% dextran-coated charcoal-stripped FCS (DCC-FCS), NEAA and penicillin/streptomycin 
(final concentrations 10 U/ml and 10 μg/ml, respectively). The outer wells were filled with 
HBSS. The next day, the cells were exposed to assay medium (200 μl per well) containing 
the test compounds. After 24 hours of exposure, the cells were lysed by adding low 
salt lysis buffer (16) and overnight incubation at -80°C. Luciferase activity in the lysate 
was measured using a luminometer and flash mix (16). Luciferase activity per well was 
measured in relative light units (RLU). 
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data processing and statistical analysis
For each experiment, at least 2 independent repetitions were performed, of which one 
representative curve is presented. Data were analyzed using GraphPad Prism version 5.04 
and Microsoft Excel 2010. Data are expressed as fold induction over the solvent control 
and are presented as mean values ± standard error of the mean (SEM). Each data point was 
measured (at least) in triplicate. Statistical significance was assessed using the one-sided 
Student’s t-test and a cut-off value of p≤0.05. 
ResuLTs
induction of epre-mediated luciferase expression at protein level by isoprenoid-
containing tomato extracts
The EpRE-LUX assay was used to determine whether tomato extracts are capable of inducing 
EpRE-mediated luciferase expression at the protein level. A chloroform extract containing 
isoprenoids was prepared from the roma tomato mix. After 24 hours of exposure, the 
isoprenoid-containing tomato extract was not able to induce EpRE-mediated luciferase 
protein expression at concentrations up to 100 gram fresh weight per liter (g FW/L)(data 
not shown). This is in line with our findings that of the individual isoprenoids lycopene, 
lutein, α-tocopherol, δ-tocopherol, γ-tocopherol, β-carotene, δ-carotene, γ-carotene, 
phytoene, phytofluene, neoxanthin, violaxanthin and neurosporene, only the latter was 
able to induce EpRE-mediated luciferase protein expression at concentrations higher than 
20 μM (figure 1).
Altogether, these results indicate that isoprenoids, either as individual compounds or as 
a constituent in tomato, do not play an important role as inducers of EpRE-regulated genes. 
figure 1. Luciferase activity induced in the EpRE-LUX reporter cells by 24 hour exposure to 
neurosporene. Luciferase activity is expressed as fold induction compared to solvent control and 
data are presented as mean ± SEM of six replicates.
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induction of epre-mediated luciferase expression at protein level by tomato extracts 
containing phenolic compounds
In order to determine whether phenolic compounds in tomato extracts are capable of 
activating EpRE-mediated luciferase protein expression, a nonhydrolyzed methanol 
extract containing phenolic compounds was prepared from the tomato mix. This extract, 
tested in the EpRE-LUX cells in concentrations up to 15 g FW/L, was unable to induce 
EpRE-mediated luciferase protein expression after 24 hours of exposure (data not shown). 
Qualitative HPLC analysis showed that quercetin and kaempferol were only present in 
these extracts in the form of glycosides, mainly quercetin-rutinoside and kaempferol-
rutinoside (figure 2A). Unlike flavonoid aglycones (16, 17, 24), flavonoid glycosides were 
not able to activate EpRE-mediated luciferase protein expression (table 1). In order to 
deglycosylate these flavonoids, a method for hydrolysis of the extract containing phenolic 
compounds had to be developed. To avoid generation of non-natural by-products of the 
hydrolysis reaction, enzymatic hydrolysis was used instead of acid hydrolysis. 
Table 1. Capacity of individual compounds known to be present in ripe tomato, to induce EpRE-mediated 
luciferase expression. In order to rank the compounds, the fold inductions at 20 μM and at the highest 
concentration that could be tested without cytotoxicity, were compared. Fold inductions are given as the 
average value of at least three independent experiments ± SEM.
compound fold induction at 20 μm
maximum fold induction at the concentration 
indicated between parentheses
Quercetin 4.2 ± 0.3 4.9 ± 0.4 (30 μM)
Kaempferol 3.8 ± 0.4 3.5 ± 0.4 (20 μM)
Naringenin 0.9 ± 0.1 2.5 ± 0.4 (100 μM)
Naringenin Chalcone 1.0 ± 0.1 3.2 ± 0.3 (100 μM)
Isoquercetin inactive inactive
Rutin inactive inactive
Kaempferol-3O-rutinoside inactive inactive
Chlorogenic acid inactive inactive
Caffeic acid inactive inactive
Ferulic acid inactive inactive
Cyanidin chloride inactive inactive
Delphinidin chloride inactive inactive
induction of epre-mediated luciferase expression at protein and mrna level by 
enzymatically hydrolyzed tomato extracts
To enzymatically hydrolyze flavonoid glycosides present in tomato mix, two commercially 
available enzyme preparations were used; Viscozyme L and H. pomatia type-2 
β-glucuronidase. The optimal incubation time was determined by following the hydrolysis 
of rutin and kaempferol-3-O-rutinoside into their corresponding aglycones in time using 
HPLC. Even after 15 hours of incubation with H. pomatia type-2 β-glucuronidase, the 
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rutin present in the tomato mix was not completely hydrolyzed (figure 2B). After only 
one hour incubation with Viscozyme L, neither rutin nor kaempferol-3-O-rutinoside could 
be detected anymore and a corresponding increase in the concentrations of quercetin 
and kaempferol was observed (figure 2C), indicating that hydrolysis of the glycosides was 
complete. In subsequent experiments it was demonstrated that tomato extract generated 
with this method, further referred to as enzymatically hydrolyzed tomato extract, was 
able to significantly induce EpRE-mediated luciferase expression in a dose dependent 
manner, both at protein level (figure 3) and at mRNA level (figure 4). In addition, it was 
shown that exposure to the enzymatically hydrolyzed tomato extract had hardly any 
effect on the luciferase activity measured in the Cytotox CALUX cells (figure 3), indicating 
that stabilization of the luciferase enzyme is not playing a major role in the induction of 
luciferase activity. 
A
U
 
0.000 
0.002 
0.004 
0.006 
0.008 
retention time (minutes) 
0.000 
0.002 
0.004 
0.006 
0.008 
0.000 
0.002 
0.004 
0.006 
0.008 
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 
A
U
 
A
U
 
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 
A 
C 
B 
1 2 3 4 
5 
7 
8 
6 
7 
5 
7 
8 
9 
2 
figure 2. HPLC chromatograms of tomato extracts recorded at 360 nm. A) nonhydrolyzed tomato 
extract; B) tomato extract hydrolyzed for 15 hours with H. pomatia type-2 β-glucuronidase; and 
C) tomato extract hydrolyzed for 1 hour with Viscozyme L. 1: chlorogenic acid; 2: caffeic acid; 3: ferulic 
acid; 4: quercetin-3-O-glycoside 5: rutin; 6: kaempferol-3-O-rutinoside; 7: quercetin; 8: naringenin 
chalcone; 9: kaempferol. 
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figure 3. Luciferase activity induced in EpRE-LUX reporter cells (grey bars) and in Cytotox CALUX cells 
(white bars) by 24 hour exposure to enzymatically hydrolyzed tomato extract. Concentrations of 
the extract are expressed as gram fresh weight per liter (g FW/L). Luciferase activity is expressed as 
fold induction compared to solvent control and data are presented as mean ± SEM of six replicates. 
Asterisks indicate a significant difference from the corresponding solvent control: * p < 0.05; 
** p < 0.01; *** p < 0.0001. 
figure 4. Luciferase gene expression measured as luciferase mRNA levels in EpRE-LUX cells after 
6 hour exposure to enzymatically hydrolyzed tomato extract (45 g FW/L) or to individual phenolic 
compounds. Luciferase mRNA levels were measured by qPCR and are expressed as fold induction 
compared to solvent control. Data are presented as mean ± SEM of three (tomato extract) or four 
replicates (individual compounds). Asterisks indicate a significant difference from the solvent control: 
* p < 0.05; ** p < 0.01; *** p < 0.0001. 
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activation of epre-mediated luciferase expression by individual compounds present 
in enzymatically hydrolyzed tomato extracts
The induction of EpRE-mediated luciferase expression found after exposure of EpRE-LUX 
cells to the enzymatically hydrolyzed tomato extract raises the question which compounds 
in this extract are responsible for this effect. In order to investigate this, EpRE-LUX 
reporter cells were exposed for 24 hours to increasing concentrations of the following 
compounds, known to be important phenolic ingredients in tomato fruits (9, 10, 28): 
quercetin, isoquercetin, rutin, naringenin, naringenin chalcone, kaempferol, kaempferol-
3-O-rutinoside, chlorogenic acid, ferulic acid, caffeic acid, delphinidin chloride, and 
cyanidin chloride. Quercetin, kaempferol, naringenin and naringenin chalcone were 
able to induce EpRE-mediated luciferase protein expression in EpRE-LUX cells in a dose-
dependent manner (figure 5), while all other compounds tested were not able to induce 
EpRE-mediated protein expression in concentrations up to 100 μM (data not shown). 
Quercetin was slightly more potent than kaempferol. Naringenin and naringenin chalcone 
were equally potent, but both were less potent than quercetin and kaempferol (table 1 / 
figure 5). Quercetin, kaempferol and naringenin were also able to induce EpRE-mediated 
expression at the mRNA level, although naringenin chalcone was not (figure 4). 
figure 5. Luciferase activity induced in the EpRE-LUX reporter cells by 24 hour exposure to individual 
phenolic compounds; kaempferol (), quercetin (), naringenin (), and naringenin chalcone (). 
Luciferase activity is expressed as fold induction compared to solvent control and data are presented 
as mean ± SEM of six replicates.
discussioN
In this study, a robust method was developed to prepare crude extracts of ripe tomato 
fruits that are compatible with cell-physiological and cell culture conditions and thus 
enable testing of these extracts in the cell-based EpRE-LUX reporter assay and other cell-
based assays. This method may also be used to test other fruits and vegetables for their 
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EpRE-mediated effects on gene expression and to test fruit and vegetable extracts in other 
cell-based bioassays. It may also provide a tool to test different varieties and/or food 
processing strategies, in order to select the variety or processing strategy resulting in the 
most optimal content of bioactive compounds producing the selected beneficial biological 
effect. The method developed might therefore provide a tool to link fruits or vegetables to 
beneficial gene expression profiles without the need for animal testing. 
An isoprenoid-containing tomato extract was prepared by chloroform extraction and 
an enzymatically hydrolyzed tomato extract containing flavonoid aglycones was prepared 
by enzymatic hydrolysis for 1 hour with Viscozyme L followed by methanol extraction. 
Both the isoprenoid-containing tomato extract and the enzymatically hydrolyzed tomato 
extract were shown to be biocompatible with the EpRE-LUX reporter cells. It is shown that 
the isoprenoid-containing tomato extract was not able to induce EpRE-mediated luciferase 
protein expression, while the enzymatically hydrolyzed tomato extract was able to induce 
a dose-dependent induction of EpRE-mediated luciferase expression as detected both at 
the protein and the mRNA level. 
In line with our findings that the isoprenoid-containing tomato extract was not able 
to induce EpRE-mediated luciferase, most individual isoprenoids also showed no EpRE-
mediated luciferase induction. Most isoprenoids lack an electrophilic moiety and are 
therefore unable to react with thiol-groups of Keap1 and to facilitate release of Nrf2 from 
the Keap1-Nrf2 complex, which is necessary to activate EpRE-mediated expression (25). 
Previously, however, Linnewiel and coworkers showed that not the carotenoid parent 
compounds, but rather their oxidation products are activators of EpRE-mediated gene 
expression (25). This is in line with our observation that an old and partially discolored 
batch of β-carotene was able to induce luciferase activity in the EpRE-LUX cells (data not 
shown), whereas the newly purchased batch of β-carotene was not. 
The nonhydrolyzed tomato extract and the flavonoid glycosides rutin and kaempferol-3-
O-rutinoside were not able to induce EpRE-mediated luciferase protein expression. This 
lack response is likely due to the fact that these glycosides are not able to enter the 
cells. The tomato mix was therefore enzymatically hydrolyzed in order to convert the 
flavonoid glycosides into their aglycones. This enzymatic hydrolysis of flavonoid glycosides 
also occurs in humans in the small intestine before uptake (29, 30). The enzymatically 
hydrolyzed tomato extract made of ripe tomato fruit was able to induce EpRE-mediated 
luciferase expression at the mRNA level and at the protein level. These results indicate 
that phytochemicals present in tomato may induce transcription of phase II detoxifying 
enzymes, which are often under control of an EpRE. Induction of EpRE-mediated gene 
expression has frequently been suggested to play a role in the protection against cancer 
(14, 15). Quercetin, kaempferol, naringenin and naringenin chalcone are present in 
enzymatically hydrolyzed tomato fruit extracts (9, 10) and were able to activate EpRE-
mediated gene expression when tested as pure compounds. These findings are in line 
with previous in vitro studies showing that quercetin and kaempferol are able to induce 
EpRE-mediated gene expression (16, 17, 24). It is likely that these four compounds are 
at least partly responsible for the induction of EpRE-mediated luciferase expression by 
enzymatically hydrolyzed tomato extracts. 
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It is important to note that some chemicals can bind to and stabilize the luciferase 
enzyme produced in the reporter gene cells, resulting in high bioluminescence values 
reflecting luciferase stabilization rather than increased expression of the luciferase gene 
(27). In the present study, exposure to enzymatically hydrolyzed tomato extract (45 g 
FW/L) induced luciferase expression at both protein level and at mRNA level in the 
same order of magnitude. This indicates that stabilization of the luciferase enzyme is 
not playing an important role when testing tomato extracts in the EpRE-LUX assay. This 
was corroborated by the observation that exposure to enzymatically hydrolyzed tomato 
extract had hardly any effect on the luciferase activity in the Cytotox CALUX cells. In case 
the enzymatically hydrolyzed tomato extract would lead to stabilization of the luciferase 
enzyme, a dose-dependent increase in luciferase activity in the Cytotox CALUX cells would 
be expected. This was clearly not observed. Thus, based on the mRNA data and the results 
of the Cytotox CALUX assay it was firmly established that the luciferase induction by the 
tomato constituents and the enzymatically hydrolyzed tomato extract was not due to an 
effect on the luciferase enzyme itself.
Although the results of the present study indicate that tomato may increase EpRE-
mediated expression of phase II enzymes and other EpRE-regulated genes, this result 
needs to be confirmed and validated in in vivo studies. From in vivo studies it is known 
that in mice, a combination of tomato and garlic leads to increased activity of the phase II 
enzyme GST and to reduced frequencies of chemically-induced genotoxicity (31). 
In conclusion, the current study has developed an extraction and enzymatic 
deglycosylation method that enables testing of fruits and vegetables in in vitro bioassays 
for beneficial health effects. The developed method may allow the selection of optimal 
breeding and processing technologies and the definition of specific health claims without 
the need for animal testing. The utility of the developed method for these purposes 
should be further explored. The results obtained show that enzymatically hydrolyzed 
tomato extracts and phytochemicals present in these tomato extracts are able to induce 
EpRE-mediated changes in gene expression and may thereby increase the levels of phase 
II detoxifying enzymes, which may play a role in protection against cancer. 
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AbsTRAcT 
Activation of peroxisome proliferator-activated receptor γ (PPARγ) by ligands is associated 
with beneficial health effects including anti-inflammatory and insulin-sensitizing effects. 
The aim of the present study was to develop luciferase reporter gene assays to enable fast 
and low-cost measurement of PPARγ agonist and antagonist activity. 
Two reporter gene assays, PPARγ1 CALUX and PPARγ2 CALUX, were developed by 
stable transfection of U2OS cells with an expression vector for PPARγ1 or PPARγ2, and a 
pGL3-3xPPRE-tata-luc or pGL4-3xPPRE-tata-luc reporter construct, respectively. PPARγ1 
CALUX and PPARγ2 CALUX cells showed similar concentration-dependent luciferase 
induction upon exposure to the PPARγ agonists rosiglitazone, troglitazone, pioglitazone, 
ciglitazone, netoglitazone and 15-deoxy-Δ12,14-prostaglandin J2. The potency to induce 
luciferase decreased in the following order: rosiglitazone > troglitazone = pioglitazone > 
netoglitazone > ciglitazone. A concentration-dependent decrease in the response to 50 nM 
rosiglitazone was observed upon addition of PPARγ antagonist GW9662 or T0070907, both 
in PPARγ1 CALUX and PPARγ2 CALUX cells. The PPARα agonists WY14643 and fenofibrate 
failed to induce luciferase activity, confirming the specificity of these cell lines for PPARγ 
agonists.
In conclusion, PPARγ1 CALUX and PPARγ2 CALUX cells provide a reliable and useful 
tool to screen (bio-)chemicals for PPARγ agonist or antagonist activity. 
Keywords: peroxisome proliferator-activated receptor γ (PPARγ), peroxisome proliferator-
responsive element (PPRE), stable luciferase reporter cell line, human U2OS cells, 
thiazolidinediones (TZDs)
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iNTRoducTioN
Peroxisome proliferator-activated receptors (PPARs) are transcription factors which are 
activated by ligands (1). Ligand-activated PPARs can bind to a peroxisome proliferator-
responsive element (PPRE) in the regulatory region of target genes and thereby influence 
the expression of those genes. At present, three PPAR isoforms are known: PPARα 
(NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3). Each isoform has its own set of target 
genes, which partially overlap, and the isoforms show differential activation levels in 
response to certain ligands (2). The target genes include genes considered to play a role 
in health preservation and health promotion. Especially PPARγ has been associated with 
several beneficial health effects. 
PPARγ was initially known for its role in adipogenesis (3-5) and lipid metabolism in 
adipose tissue (6). Nowadays, PPARγ agonists are especially renowned for their function 
in the regulation of insulin sensitivity: thiazolidinediones (TZDs) are a group of synthetic 
PPARγ agonists showing insulin-sensitizing activity in animal models (7, 8). Of the TZDs, 
pioglitazone is presently used as insulin-sensitizing drug in patients suffering from type 2 
diabetes mellitus (9-11). PPARγ-mediated gene expression also results in anti-inflammatory 
effects (12-15). Therefore, ligands for PPARγ are assumed to exert health-promoting effects 
on several inflammation-related diseases, including atherosclerosis (16, 17), inflammatory 
bowel disease (17), Alzheimer’s disease (16, 18) and airway inflammation (including 
asthma)(17, 19). Furthermore, activation of PPARγ has been reported to promote health 
by lowering blood pressure (20-23) and by inhibiting the development of certain cancers 
(24-27).
PPARγ is present in humans in two isotypes: PPARγ1 and PPARγ2. The two isoforms 
are generated from the same gene by alternative promoter usage. Human PPARγ2 has 28 
extra amino acids at the N-terminus of the protein (28, 29) and is found mainly in adipose 
tissue and in lower amounts in liver and skeletal muscle (29-31). PPARγ1 is expressed 
more broadly and is found in adipose tissue, spleen, liver, skeletal muscle, heart, large 
intestine and kidney (29-31). The functional differences between PPARγ1 and PPARγ2 
are not completely clarified yet. There are some indications that PPARγ2 plays a more 
important role than PPARγ1 in adipogenesis (32, 33), insulin sensitivity (34) and in the 
response to nutritional conditions (30, 34). 
Given the possible beneficial health effects mediated by PPARγ activation, the aim 
of the present study was to develop and validate stable luciferase reporter cell lines to 
facilitate high-throughput screening of bioactive food compounds for PPARγ agonist and 
antagonist activity. In order to achieve this, a DNA construct containing multiple PPREs 
and a minimal promoter controlling the transcription of a luciferase reporter gene was 
created and co-transfected into U2oS cells together with an expression plasmid for human 
PPARγ1 or human PPARγ2 respectively. Since U2OS cells have very low endogenous PPAR 
levels (35, 36), the co-transfection of the human PPARγ1 or human PPARγ2 receptor will 
make the system specific for detecting PPARγ1-mediated or PPARγ2-mediated effects on 
gene expression. 
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mATeRiAL ANd meThods
chemicals
Rosiglitazone (CAS no: 122320-73-4), 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2; CAS no: 
89886-60-2), netoglitazone (also known as MCC-555, CAS no: 161600-01-7), GW9662 
(CAS no: 22978-25-2), T0070907 (CAS no: 313516-66-4), ciglitazone (CAS no: 74772-77-3), 
pioglitazone (CAS no: 111025-46-8), troglitazone (CAS no: 97322-87-7) and GW501516 (CAS 
no: 317318-70-0) were all obtained from Cayman Chemical (Ann Arbor, USA). All chemicals 
were dissolved in dimethylsulphoxide (DMSO, 99.9%)(Acros, Geel, Belgium) and stored at 
-20°C. G418-disulfate (CAS no: 108321-42-2) was purchased from Duchefa Biochemie 
(Haarlem, The Netherlands).
dNA constructs
Expression vectors
A 2 kb NotI fragment from pCMV6-hPPARγ1 and a 1.6 kb NotI fragment from pCMV6-hPPARγ2 
(both purchased from Origene, Rockville, USA) were inserted into the unique NotI site in the 
multiple cloning site of pSG5-neo (37) containing the neomycin resistance gene. This resulted 
in the expression plasmids pSG5-neo-PPARγ1 and pSG5-neo-PPARγ2, respectively. 
Reporter constructs
To generate the reporter construct, a DNA fragment containing three copies of the 
PPRE (consisting of the nucleotide sequence 5'-GTCGACAGGGGACCAGGACAAAGGTCA 
CGTTCGGGAGTCGAC-3' repeated three times in tandem, consensus PPRE underlined 
(38)) was designed and synthesized at GeneArt (Regensburg, Germany), and cloned in 
vector pMA (GeneArt, Regensburg, Germany). The KpnI/XbaI fragment of pMA-3xPPRE 
was ligated into a TATA box-containing pGL3 vector partially digested with KpnI/XbaI to 
generate pGL3-3xPPRE-tata-luc. The pGL4-3xPPRE-tata-luc was generated by cloning the 
3xPPRE-tata containing DNA fragment from pGL3-3xPPRE-tata-luc into a pGL4.10[luc] 
vector (Promega, Madison, USA).
cell culture
Human osteoblastic osteosarcoma U2OS cells (American Type Culture Collection, ATCC) 
were cultured as described before in a 1:1 mixture of Dulbecco’s modified Eagle’s medium 
and Ham’s F12 medium (DF)(Invitrogen, Breda, The Netherlands) supplemented with 
7.5% fetal calf serum (FCS)(Invitrogen), non-essential amino acids (NEAA)(Invitrogen) 
and penicillin/streptomycin (Invitrogen)(final concentrations 10 U/ml and 10 μg/ml, 
respectively)(39). Stably transfected PPARγ1 CALUX cells and PPARγ2 CALUX cells were 
cultured in DF medium supplemented with 7.5% FCS, NEAA, and penicillin/streptomycin. 
Once per week 200 μg/ml G418 was added to the culture medium. 
generation of stable cell lines
Stable transfectants were generated essentially as described before (39). U2OS cells were 
plated in 12-well tissue culture plates. After culturing for one day, cells were transfected 
with reporter plasmid (pGL3-3xPPRE-tata-luc to generate PPARγ1 CALUX, and pGL4-
3xPPRE-tata-luc for PPARγ2 CALUX), and an expression plasmid for PPARγ (pSG5-neo-
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PPARγ1 or pSG5-neo-PPARγ2, respectively), using a calcium phosphate co-precipitation 
method (40). G418-resistant clones were tested for their response to 1 μM rosiglitazone, 
fifteen responsive clones were selected and tested to generate full dose-response curves. 
From these, the clone repeatedly showing the best response was selected based on the 
obtained fold induction and the level of luciferase expression. 
Reporter gene assays
Assays were performed as described before (39). In short, PPARγ1 CALUX cells and PPARγ2 
CALUX cells were plated in 96-well plates with phenol red-free DF medium supplemented 
with 5% dextran-coated charcoal-stripped FCS (DCC-FCS). The next day, the cells were 
incubated in triplicate wells with the test compounds added to the culture medium from 
a 1000 times concentrated stock solution in DMSO. After 24 hours, the cells were checked 
visually for cytotoxicity, the medium was removed and the cells were lysed. Luciferase 
activity in the lysate was measured using a luminometer (Anthos, Eugendorf, Austria) and 
100 μl of Glow Mix (20 mM Tricine, 1.07 mM (MgCO
3)4Mg(OH)2, 2.67 mM MgSo4, 0.1 mM 
EDTA, 33.3 mM dithiothreitol, 270 μM Co-enzyme A, 470 μM D-Luciferine, 530 μM ATP) 
or 100 μl flash mix (20 mM Tricine, 1.07 mM (MgCO3)4Mg(OH)2, 2.67 mM MgSo4, 0.1 mM 
EDTA, 2.0 mM dithiothreitol, 470 μM D-luciferine, 5.0 mM ATP) per well. Luciferase 
activity per well was measured as relative light units (RLUs). For each test compound, at 
least three independent experiments were performed, of which one representative curve 
is presented. Data are presented as mean values ± standard error of the mean (SEM) with 
each experimental point measured in triplicate.
data analysis
Dose-response curves were fitted to the equation of a sigmoidal curve y = a0 + a1/(1 + 
exp(-(x-a2)/a3)) using GraphPad Prism (version 4.00 for Windows, GraphPad Software, San 
Diego, CA), which determines the fitting coefficients by an iterative process minimizing the 
c2 merit function (least squares criterion).
ResuLTs
construction of the pparγ1 calux and pparγ2 calux reporter cell lines 
Responsiveness of the luciferase constructs to the PPARγ agonist rosiglitazone was 
confirmed by transient transfection experiments in U2OS cells. U2OS cells were co-
transfected with pGL3-3xPPRE-tata-luc and with one of three pSG5-neo vectors: a 
pSG5-neo vector without any PPARγ-encoding sequence, a pSG5-neo-PPARγ1 vector 
containing a constitutive human PPARγ1 expression cassette, or a pSG5-neo-PPARγ2 
vector containing a constitutive human PPARγ2 expression cassette. U2OS cells co-
transfected with pSG5-neo-PPARγ1 or pSG5-neo-PPARγ2 showed induction of luciferase 
activity up to 27-fold when exposed to rosiglitazone (figure 1). In cells co-transfected with 
pSG5-neo (figure 1), only a 2-fold induction in luciferase activity was seen after 24 hours 
of exposure to a high (1000 nM) concentration of rosiglitazone, indicating that luciferase 
expression due to endogenous PPARγ in U2OS cells is relatively low. From these results it 
can be concluded that co-transfection with pSG5-neo-PPARγ1 or pSG5-neo-PPARγ2 largely 
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increased the level of the corresponding PPARγ subtype in U2OS cells, leading to much 
higher fold inductions of the luciferase activity upon exposure to rosiglitazone. 
In the next step, two stably transfected cell lines were created. The first cell line was 
generated by co-transfecting pGL3-3xPPRE-tata-luc and pSG5-neo-PPARγ1 into U2OS 
cells. From the transfected cell population, single cell clones were isolated and tested for 
responsiveness to rosiglitazone. Clone 141 was selected for its high luciferase values and 
fold inductions upon exposure to rosiglitazone. This clone was designated PPARγ1 CALUX. 
The second cell line was created by co-transfecting pGL4-3xPPRE-tata-luc and pSG5-
neo-PPARγ2 into U2OS cells and cloning of the transfected cell population. Clone 54 was 
selected for its high luciferase values and fold inductions after exposure to rosiglitazone 
and was designated PPARγ2 CALUX. 
characterization of pparγ1 calux and pparγ2 calux reporter cell lines
PPARγ1 CALUX reporter cells and PPARγ2 CALUX reporter cells were exposed to increasing 
concentrations of six known PPARγ agonists (rosiglitazone, troglitazone, pioglitazone, 
ciglitazone, netoglitazone (MCC-555) and 15d-PGJ2 (41-43)) and of two PPARγ antagonists 
(GW9662 (44) and T0070907 (45)) in the presence of rosiglitazone. Upon exposure to 
rosiglitazone, troglitazone, pioglitazone, ciglitazone, netoglitazone and 15d-PGJ2, both 
PPARγ1 CALUX and PPARγ2 CALUX cells showed a concentration-dependent luciferase 
induction (figure 2A-F). The level of luciferase induction differs greatly among the 
various agonists tested. In the concentration range that could be tested without inducing 
cytotoxicity, most agonists (including troglitazone and ciglitazone) did not reach their 
maximum induction level; dose-response curves of these agonists were not yet leveling 
off at the highest concentration that could be tested. EC
50 values could therefore not be 
figure 1. Luciferase induction in U2OS cells that were transiently co-transfected with pGL3-3xPPRE-
tata-luc construct and a pSG5-neo vector (pSG5-neo (white bars); pSG5-neo-PPARγ1 (light grey bars); 
or pSG5-neo-PPARγ2 (dark grey bars)) and subsequently exposed for 24 hours to three concentrations 
of rosiglitazone or solvent control (SC). Fold induction of luciferase activity was calculated from 
measured RLUs. Data are expressed as mean ± SEM. An asterisk (*) indicates a significant (p<0.05) 
difference compared to solvent control. 
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figure 2. Luciferase activity induced in the two PPARγ CALUX cell lines. PPARγ1 CALUX cells 
(continuous lines) and PPARγ2 CALUX cells (dotted lines) were exposed to agonists (A-F) or antagonists 
(G and H), the latter in the presence of 50 nM rosiglitazone. Luciferase activity is expressed as 
percentage of the maximum rosiglitazone response. Data are corrected for solvent control luciferase 
values and are expressed as mean ± SEM (n=3). A: rosiglitazone. B: troglitazone. C: pioglitazone. 
D: ciglitazone. E: netoglitazone. F: 15d-PGJ2. G: GW9662. H: T0070907.  
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determined reliably for these agonists. Consequently, we chose to determine the relative 
potency of all compounds based on the concentration that induced 10% and 50% of the 
maximum response level attained with rosiglitazone (table 1). This analysis showed that in 
both PPARγ1 CALUX and PPARγ2 CALUX cells rosiglitazone is the most potent TZD followed 
by troglitazone/pioglitazone, netoglitazone and ciglitazone. Troglitazone and pioglitazone 
showed comparable potencies. Since 15d-PGJ2 could not be tested in concentrations higher 
than 1 μM, there is not enough information to include 15d-PGJ2 in this potency ranking. 
For testing antagonist activity, the PPARγ1 CALUX cells and PPARγ2 CALUX cells 
were exposed to increasing concentrations of the antagonist in the presence of 50 nM 
rosiglitazone. Upon exposure of PPARγ1 CALUX cells and PPARγ2 CALUX cells to both 
PPARγ antagonists, the luciferase induction by 50 nM rosiglitazone was inhibited in 
a concentration-dependent manner (figure 2G and H). The observed IC
50 values are 
presented in table 2. 
In order to facilitate their comparison, the responses in the PPARγ1 and PPARγ2 CALUX 
cells were plotted in the same graph (figure 2). Comparison of the dose-response curves 
reveals that PPARγ1 CALUX cells and PPARγ2 CALUX cells respond in the same way to each 
of the tested agonists: induction of the luciferase activity starts at the same concentration 
in both PPARγ1 CALUX cells and PPARγ2 CALUX cells and increases with comparable dose-
Table 1. Concentrations (in μM) of PPARγ agonists inducing 10% or 50% of the maximum response level 
attained with rosiglitazone, both for PPARγ1 CALUX cells and for PPARγ2 CALUX cells. 
compound
pparγ1
10% (μm)
pparγ2
10% (μm)
pparγ1
50% (μm)
pparγ2
50% (μm) ec50 (μm) in literature
rosiglitazone 0.01 0.01 0.11 0.07 0.04
0.06
0.09
0.21
0.30
(52) 
(43)
(49) 
(50)
(51)
troglitazone 0.23 0.28 0.95 0.47 0.54
0.55 
(49) 
(52)
pioglitazone 0.14 0.11 0.95 0.60 0.10 
0.26
0.58
0.59
0.69
0.90
(65) 
(48)
(52) 
(49)
(43)
(51)
ciglitazone 1.55 2.34 7.76 Xa 3.0
4.0 
23
(43) 
(65)
(49)
netoglitazone 
(MCC-555)
0.30 0.37 1.41 1.62 0.76 
8.0 
(63) 
(41)
15d-PGJ2 0.20 0.34 Xa Xa 0.82
2.0
3.0
20
(67)
(68) 
(65) 
(69)
aX indicates that the 50% of the maximum response level attained with rosiglitazone was not reached. 
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Table 2. IC50 values of PPARγ antagonists found in PPARγ1 CALUX cells, PPARγ2 CALUX cells and in literature.
compound
ic50 (nm)
a
pparγ1 calux
ic50 (nm)
a
pparγ2 calux ic50 (nm) in literature
GW9662  9.1 ± 5.3  1.2 ± 0.3 3.8 
7.6 
(48) 
(44)
T0070907 3.2 ± 0.8  0.9 ± 0.3 nM range
4100 
(45) 
(66)
aMean IC50 values from three independent experiments ± SEM.
figure 3. Luciferase activity of PPARγ1 CALUX cells (A) and PPARγ2 CALUX cells (B) upon exposure to 
agonists for PPARα (fenofibrate (dotted line) and WY14643 (dashed line)) and PPARβ/δ (GW501516, 
continuous line), expressed as percentage of the maximum rosiglitazone response. Data are 
corrected for solvent control values and are expressed as mean ± SEM (n=3). 
dependency. For the two antagonists, GW9662 and T0070907, PPARγ2 CALUX cells seem 
to be somewhat more sensitive than PPARγ1 CALUX cells (figure 2G-H), although the 
differences were not statistically significant (p>0.05). 
In order to test specificity of the PPARγ CALUX cells for PPARγ agonists, the response to 
one PPARβ/δ agonist and two PPARα agonists was investigated as well. Exposure of PPARγ1 
CALUX cells and PPARγ2 CALUX cells to the PPARα agonists WY14643 (46) and fenofibrate 
(47) showed no increase in luciferase activity (figure 3), indicating that both PPARγ1 
CALUX cells and PPARγ2 CALUX cells do not respond to agonists for PPARα. GW501516 is 
known as PPARβ/δ agonist, but can also activate PPARγ at high concentrations (48). Both 
PPARγ1 CALUX cells and PPARγ2 CALUX cells showed an increase in luciferase activity upon 
exposure to PPARβ/δ agonist GW501516, but only at concentrations of 1 μM or higher 
(figure 3). 
discussioN
In the present study, two stable human luciferase reporter cell lines specifically 
responding to PPARγ1 or PPARγ2 agonist and antagonist activity were developed and 
designated PPARγ1 CALUX and PPARγ2 CALUX. The PPARγ1 CALUX and PPARγ2 CALUX 
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cell lines enable high-throughput in vitro screening of chemicals for their potential PPARγ 
activating capacity, and they are faster and less costly than the conventional in vivo test 
methods. The PPARγ CALUX cell lines can contribute to the 3Rs (Replacement, Refinement 
and Reduction) of in vivo experimental animal testing, since these in vitro tools provide 
an alternative for animal testing in the initial stages of compound screening. The PPARγ 
CALUX cell lines provide a first level support to health claims of functional food ingredients 
in which activation of PPARγ-mediated gene expression is known to play a role. In addition, 
the cell lines may provide an important tool to identify endogenous ligands for PPARγ. 
Finally, these cell lines express the complete human PPARγ receptor, potentially allowing 
more faithful translation to effects in humans than the presently available systems based 
on a chimeric PPARγ-GAL4 receptor (43, 49-52). 
To generate highly PPARγ-selective CALUX reporter cell lines reliably reflecting the 
PPARγ-mediated activation of gene expression in humans, a cell line of human origin 
with low background levels of other PPAR isotypes was preferred. The U2oS cell line 
fulfills these criteria, is relatively easy to transfect and was therefore selected. Besides 
low levels of PPARα and PPARβ/δ, the selected cell line has also low endogenous PPARγ 
expression. This allowed generation of PPARγ1- and PPARγ2-specific reporter gene assays 
by co-transfecting an expression plasmid for the PPARγ1 gene or the PPARγ2 gene into the 
U2OS cells. Specificity to PPARγ agonists was confirmed by exposing PPARγ1 CALUX cells 
and PPARγ2 CALUX cells to the PPARα agonists WY14643 and fenofibrate, which failed to 
induce luciferase activity. In addition, upon exposure of PPARγ1 CALUX and PPARγ2 CALUX 
cells to the PPARβ/δ agonist GW501516, luciferase induction in both PPARγ1 CALUX and 
PPARγ2 CALUX cells was only seen at concentrations of 1 μM and higher. The EC50 value 
of GW501516 for activation of human PPARβ/δ is around 1-2 nM (53-56), while luciferase 
induction in PPARγ CALUX cells is only seen at concentrations higher than 1 μM. This is 
consistent with earlier findings showing that GW501516 is 1000-fold selective for PPARβ/δ 
over the other subtypes (48, 53, 55). It was therefore concluded that both PPARγ1 CALUX 
cells and PPARγ2 CALUX cells specifically respond to PPARγ agonists and not to agonists 
for other PPAR isotypes. 
A large difference in absolute RLU levels between the PPARγ1 CALUX and PPARγ2 
CALUX cell lines was observed. The PPARγ2 CALUX cell line, which is transfected with pGL4-
3xPPRE-tata-luc, showed the highest absolute luciferase levels. This reporter construct 
was based on the pGL4 vector containing Luc2 as the reporter gene, while the pGL3-
3xPPRE-tata-luc construct present in the PPARγ1 CALUX cells was based on the pGL3 vector 
containing Luc+ as the reporter gene. According to the manufacturer the pGL4 vector 
shows increased reporter gene expression compared to the pGL3 vector (57). This may 
partially explain the higher absolute luciferase activity levels found in the PPARγ2 CALUX 
cell line compared to the PPARγ1 CALUX cell line. The difference in absolute luciferase 
activity levels may also be due to a difference in the integration site or a difference in 
the number of copies integrated in the genome. Although absolute RLU levels differed 
greatly between the PPARγ1 CALUX and PPARγ2 CALUX cell lines, the relative response to 
all PPARγ agonists tested was similar. 
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Compared with PPARγ1, PPARγ2 contains 28 additional amino acids at the N-terminus 
of the protein (28, 29). These additional amino acids are part of the A/B domain, which 
comprises an activation function called AF-1 (58-60). The observation that AF-1 acts as 
ligand-independent activation domain (61), suggests that the extra amino acid stretch in 
PPARγ2 would not affect the ligand-dependent transcription activation by this receptor. 
Results of the present research indicate that this may indeed be the case; human PPARγ1 
and PPARγ2 are activated with similar dose-dependency by all PPARγ agonists tested 
sofar. This is in line with results found by Elbrecht and colleagues who report similar 
binding affinities and EC
50 values for rosiglitazone and troglitazone for both isoforms of 
human PPARγ (28). In addition, Lehmann et al. found that troglitazone, pioglitazone and 
ciglitazone showed no differences in potency for murine PPARγ1 and PPARγ2 (62). They 
report, however, that rosiglitazone is a more potent activator for murine PPARγ1 than for 
murine PPARγ2 (62), which may indicate a difference between the human and the murine 
transcription factor.
Since EC
50 values for most PPARγ agonists tested could not be determined reliably, 
the concentrations inducing 10% and, if possible, 50% of the maximum response level 
attained by rosiglitazone were determined for each agonist. Although this approach differs 
from the conventional method to determine EC50 values, the absolute concentrations of 
rosiglitazone, troglitazone, pioglitazone and netoglitazone inducing 50% of the maximum 
rosiglitazone response level are comparable to the conventional EC50 values for PPARγ-
mediated reporter activity for these compounds reported in literature (table 1). 
Based on the concentrations of PPARγ agonists inducing 10% and 50% of the maximum 
response level attained with rosiglitazone, the potency of each PPARγ agonist was 
determined. The PPARγ agonists were ranked based on their potency to induce PPARγ-
mediated luciferase activity: rosiglitazone > troglitazone = pioglitazone > netoglitazone 
> ciglitazone. This ranking is in line with results found by Willson et al. (52), Lehmann et 
al. (62), Giaginis et al. (63) and Henke et al. (49), but differs from the results found by 
Young et al. (64) and Awais et al. (65) who report that troglitazone is less potent than 
pioglitazone and ciglitazone. 
Based on IC
50 values, T0070907 was shown to be slightly more potent as an antagonist 
than GW9662. This is in line with results reported by Burton et al. who found lower IC50 
values for T0070907 than for GW9662 for antiproliferative effects in several cancer cell 
lines (66).
In conclusion, the present study describes the development, characterization and 
validation of the stable reporter gene cell lines PPARγ1 CALUX and PPARγ2 CALUX. These 
new assays provide in vitro tools to test (mixtures of) chemicals, endogenous ligands and 
(food) compounds for their ability to activate PPARγ1-mediated and PPARγ2-mediated 
gene expression. 
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AbsTRAcT
Since beneficial effects related to tomato consumption partially overlap with those related 
to PPARγ activation, our aim was to test tomato components (including polyphenols and 
isoprenoids) and extracts of tomato fruits and for their capacity to activate PPARγ. Thirty 
tomato compounds were tested, of which seven carotenoids and three polyphenols 
were able to induce PPARγ2-mediated gene expression. Two extracts of tomato fruit, 
one containing deglycosylated phenolic compounds and one containing isoprenoids, 
also induced PPARγ2-mediated expression at physiologically relevant concentrations. 
Furthermore, enzymatically hydrolyzed extracts of seven tomato varieties were all able to 
induce PPARγ-mediated expression, with a 1.6 fold difference between the least potent 
and the most potent variety. The two most potent varieties had high flavonoid content, 
while the twoleast potent varieties had low flavonoid content. These data indicate that 
tomato fruits are able to induce PPARγ-mediated gene expression, and that some tomato 
varieties are more potent than others. 
KeywordS 
Peroxisome proliferator-activated receptor gamma (PPARγ); tomato extracts; polyphenols; 
carotenoids; fatty acids; luciferase reporter gene assay; mixture effects.
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iNTRoducTioN
Peroxisome proliferator-activated receptor γ (PPARγ, NR1C3) belongs to the nuclear 
receptor superfamily. Upon activation by agonists, PPARγ forms a heterodimer with retinoid 
X receptor (RXR) and binds to a peroxisome proliferator-responsive element (PPRE) in 
the regulatory domain of target genes, thereby affecting their expression (1, 2). PPARγ is 
known to be an important stimulator of adipogenesis (2, 3). In addition, thiazolidinediones 
(TZDs) are a group of PPARγ agonists shown to improve insulin sensitivity (4, 5). Other 
beneficial health effects that have been related to PPARγ activation include, for example, 
anti-inflammatory activity (6, 7), effects on cholesterol levels (8, 9) and reduced risk of 
atherosclerosis (10, 11). Furthermore, PPARγ agonists have been related to inhibition 
of the development of prostate, breast and colon cancer (12, 13), although it is not yet 
clearly established to what extent the anticancer effects are PPARγ-mediated (14-16). 
Tomato is one of the most consumed vegetables in the Western world and is a major 
component of the healthy Mediterranean diet (17, 18). The consumption of tomato has 
been related to reduced risk of prostate cancer and several other cancer types (17, 19). 
High intake of tomato is believed to modify lipid profiles towards a healthier pattern 
(20, 21) and to lower the risk of atherosclerosis and cardiovascular diseases (22, 23). 
In addition, some phytochemicals present in tomato have been related to improved 
glucose and insulin levels (24, 25). Tomato fruits contain many bioactive phytochemicals, 
for example flavonoids including quercetin, kaempferol and naringenin chalcone, and 
carotenoids including β-carotene and lycopene (26-30).
Given the overlap between the beneficial health effects associated with PPARγ-
activation and those associated with tomato consumption, we hypothesized that bioactive 
components of tomato fruit may be able to activate PPARγ. Therefore, the aim of the 
present study was to investigate whether tomato components, including polyphenols, 
isoprenoids and fatty acids, as well as tomato extracts are able to activate PPARγ-mediated 
gene expression. To that end, the recently developed PPARγ2 CALUX reporter cell line (31) 
was used to investigate whether flavonoid-rich and isoprenoid-rich tomato extracts as 
well as individual compounds known to be present in tomato fruits are able to induce 
PPARγ-mediated gene expression.
mATeRiALs ANd meThods
chemicals
Rosiglitazone and palmitic acid were obtained from Cayman Chemical (Ann Arbor, USA). 
α-Linolenic acid (ALA), oleic acid (OA), linoleic acid (LA), stearic acid (SA), myristic acid 
(MA), quercetin dihydrate, ferulic acid, chlorogenic acid, β-carotene, α-tocopherol, 
γ-tocopherol, and δ-tocopherolwere purchased from Sigma Aldrich (St. Louis, USA). 
Kaempferol, kaempferol-3-O-rutinoside, cyanidin chloride, delphinidin chloride, lycopene 
and lutein were obtained from Extrasynthase (Genay, France). Caffeic acid and rutin were 
obtained from Acros (Geel, Belgium). Naringenin was obtained from ICN Biomedicals 
(Ohio, USA). Naringenin chalcone as a mixture with naringenin was purchased from Apin 
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Chemicals (Oxon, UK), since the pure compound was not commercially available. Phytoene, 
phytofluene, neoxanthin, violaxanthin, neurosporene, γ-carotene and α-carotene were 
obtained from Carotenature (Lupsingen, Switzerland). 
Rosiglitazone and all phenolic compounds and tocopherols were dissolved in 
dimethylsulphoxide (DMSO, 99.9%, Acros, Geel, Belgium). The fatty acids were dissolved 
in ethanol (Merck KGaA, Darmstadt, Germany) and the carotenoids were dissolved in 
tetrahydrofuran (THF; Acros, Geel, Belgium). 
extraction of tomato samples
Tomato extracts containing semi-polar compounds
The model tomato sample “tomato mix” was previously described (32). In short, ripe beef, 
cherry and round tomatoes were pooled and snap frozen in liquid nitrogen. Then, the frozen 
tomatoes were ground to powder using an analytical mill (type A11 basic, IKA, Staufen, 
Germany). The powder was stored at -80°C until further use. A glycosidase-treated tomato 
extract which contains enzymatically hydrolyzed phenolic compounds was prepared from the 
tomato mix. To this end 300 μl of 0.1 M sodium acetate (pH 4.8) and 100 μl of Viscozyme L 
(Sigma Aldrich, St. Louis, USA) were added to 0.6 gram of tomato mixand incubated at 37°C for 
1 hour. Then, 3 ml methanol was added and the Viscozyme-treatedtomato mix was put in an 
ultrasonic bath for 10 minutes and centrifuged at 1000x g for 10-15 minutes. The supernatant 
was filtered using 0.2 μm polytetrafluoroethylene filters (M-filter, Tiel, The Netherlands) and 
dried under a nitrogen stream and stored at -80°C. The Viscozyme-treated extract, referred to 
as enzymatically hydrolyzed tomato extract (containing hydrolyzed phenolic compounds) was 
dissolved in DMSO:assay medium (1:4 v/v) just before analysis in the PPARγ2 CALUX cells. 
In addition to the tomato mix, nine different tomato varieties, which were kindly 
provided by Syngenta (Enkhuizen), were investigated. These nine tomato varieties vary 
in their polyphenolic content and included two high pigment tomato varieties (varieties 
G and H). Enzymatically hydrolyzed extracts of the nine tomato varieties were prepared 
using the method described above. These extracts were tested in the PPARγ2 CALUX cell 
line for their potency to induce PPARγ-mediated gene expression. In addition, chemical 
analyses of the seven extracts that appeared active in the PPARγ2 CALUX assay without 
showing cytotoxicity (varieties A-H) were performed using LC-MS.
Tomato extract containing isoprenoids
Roma tomatoes were purchased at a local supermarket and were pooled, snap frozen in 
liquid nitrogen and subsequently ground in an analytical mill. The powder, which will be 
further referred to as Roma tomato mix, was stored at -80°C until further use. A chloroform 
extract containing isoprenoids was prepared from the Roma tomato mix as described before 
(26). In short, 0.5 g Roma tomato mix was dissolved in 4.5 ml of methanol:chloroform 
(2.5:2.0 v/v) and put on ice for 10 minutes. Then, 2.5 ml of pre-cooled Tris-HCl (50 mM, 
pH 7.4) was added and the sample was mixed. After centrifugation for 10 minutes at 1000x g, 
the chloroform phase was transferred to a new tube. Extraction was repeated twice by 
adding fresh chloroform to the remaining methanol/Tris phase, mixing and centrifugation 
of the tubes. The three chloroform fractions were combined and dried under a stream of 
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nitrogen and stored at -80°C. Prior to analysis in the PPARγ2 CALUX cells, the isoprenoid-
containing tomato extract was dissolved in THF: assay medium (1:1 v/v).
cell culture
The construction and validation of the PPARγ2 CALUX cell line (BioDetection Systems, 
Amsterdam, The Netherlands) was described before (31). In short, human U2OS 
osteosarcoma cells were stably transfected with an expression vector for PPARγ2 
and a pGL4–3xPPRE–tata–luc reporter construct. PPARγ2 CALUX cells were grown in 
culture medium: DMEM/F12 glutamax medium (Invitrogen, Breda, The Netherlands) 
supplemented with 7.5% fetal calf serum (Invitrogen), non-essential amino acids 
(Invitrogen) and penicillin/streptomycin (Invitrogen)(final concentrations 10 U/ml and 
10 μg/ml, respectively). Once per week 200 μg/ml G418 (Duchefa Biochemie, Haarlem, 
The Netherlands) was added to the culture medium in order to maintain selection 
pressure. Cells were cultured at 37°C and 5% CO
2 in a humid atmosphere. 
Reporter gene assays
The ability of tomato extracts or individual compounds to induce PPARγ2-mediated 
luciferase expression was tested by measuring luciferase activity in the PPARγ2 CALUX 
reporter cells. To this end, PPARγ2 CALUX cells were seeded in 96-well plates (Corning 
Incorporated, Cambridge, USA) at a density of 10,000 cells per well in 100 μL assay medium: 
DMEM/F12 without phenol red (Invitrogen) supplemented with 5% fetal calf serum 
treated with dextran-coated charcoal (Thermo Scientific, Waltham, USA), non-essential 
amino acids (Invitrogen) and penicillin/streptomycin (Invitrogen)(final concentrations 
10 U/ml and 10 μg/ml, respectively). Before exposure to the fatty acids, the plated cells 
were treated with vitamin E by adding 20 μl of a 50 mM vitamin E solution (mixed isomers of 
(+)-α-tocopherol, CAS 59-02-9; Sigma Aldrich, St. Louis, USA) to 20 ml assay medium (final 
concentration 50 μM vitamin E). Vitamin E serves as an antioxidant to prevent oxidation 
of the unsaturated fatty acids. After 24 hours, when the cells formed a monolayer, 100 μL 
fresh assay medium supplemented with the test compounds was added to the wells. When 
testing the individual compounds, the percentage of solvent in the exposure medium was 
kept at or below 0.5%. Only for testing the highest concentrations of 100 μM, 1% of solvent 
had to be used. On each plate, 1 μM of rosiglitazone was included as a positive control. 
Although rosiglitazone is no longer used as an insulin-sensitizing drug in humans, it is still 
generally used as reference compound for PPARγ-activation (33, 34). During the exposure 
to fatty acids, the cells were co-exposed to 50 μM freshly added vitamin E (mixed isomers 
of (+)-α-tocopherol; Sigma Aldrich, St. Louis, USA) and 0.1% BSA (Sigma Aldrich, St. Louis, 
USA). BSA facilitates the solubility and cellular availability of the fatty acids. After 24 hours 
of exposure, the medium was removed and low salt buffer (30 μl per well) was added. The 
plates were subsequently frozen overnight at -80°C in order to lyse the cells. Luciferase 
activity was measured using a luminometer (Luminoscan Ascent, Thermo Scientific, 
Waltham, USA) by adding 100 μl flash mix (20 mM Tricine, 1.07 mM (MgCO
3)4Mg(OH)2, 
2.67 mM MgSo4, 0.1 mM EDTA, 2.0 mM dithiothreitol, 470 μM luciferine, 5.0 mM ATP) per 
well and measuring the light production as relative light units (RLU). 
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All individual tomato compounds were tested for cytotoxicity using the Cytotox CALUX 
cell line as described by Van der Linden et al. (35). These Cytotox CALUX cells are U2OS 
cells with an invariant luciferase expression and respond to cytotoxicity with a decreased 
luciferase activity compared to the solvent control. Only non-cytotoxic concentrations of 
the individual tomato compounds were used for testing in the PPARγ2 CALUX cell line.
chemical analysis using Lc-PdA-QTof-ms
Using LC-PDA-QTOF-MS, semi-polar compounds in the sample can be separated using liquid 
chromatography (LC) and detected using photodiode array (PDA). In the next step, the 
compounds are ionized and masses are detected using quadrupole time of flight (QTOF) in 
combination with mass spectrometry (MS). This LC-PDA-QTOF-MS method provides insight 
in the semi-polar compounds present in the (tomato) sample since individual compounds 
can be identified based on their retention time and mass. LC-PDA-QTOF-MS analysis was 
performed as described before by De Vos and colleagues (36) in order to detect semi-polar 
compounds present in the enzymatically hydrolyzed extracts of the seven non-cytotoxic 
tomato varieties. In short, 5µl of the re-dissolved and filtered enzymatically hydrolyzed 
tomato extracts were injected onto a C18 column. Chromatographic separation was 
performed using ultrapure water (eluent A) and acetonitrile (eluent B), both acidified 
with 0.1% formic acid, using a linear gradient starting at 5% eluent B up to 35% eluent B 
in 45 minutes with a flow rate of 0.190 ml/min. Hereafter, the column was washed an 
equilibrated for 15 minutes, before the next injection. After separation and detection of 
the semi-polar compounds by LC-PDA, ionization was performed using an electrospray 
ionization source and masses were detected in positive mode (ESI+) using quadrupole 
time of flight high-resolution mass spectrometry QTOF-MS. Ion chromatograms obtained 
from LC-PDA-QTOF-MS were analyzed using MassLynx 4.1 (Waters) software.
data analysis
Each test compound or extract was tested in at least two independent experiments, 
and one representative curve is presented (unless stated otherwise). In each of the 
independent experiments, all data points were performed in triplicate. The RLU data were 
converted into percentages of the positive control (1 μM rosiglitazone) and presented 
as mean values ± standard error (SE). Fold inductions were calculated by dividing the 
luciferase activity of the sample by the luciferase activity of the solvent control sample. 
Statistical significance was assessed using the one-sided Student’s t-test and a cut off 
value of p≤0.05.
ResuLTs ANd discussioN
pparγ-activation by individual phytochemicals
In order to investigate whether compounds which are known to be present in tomato have 
the capacity to function as PPARγ agonists, PPARγ2 CALUX reporter cells were exposed 
for 24 hours to increasing concentrations of thirty individual compounds. These thirty 
compounds were selected based on their presence in tomato fruit (table 1) and include 
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eleven polyphenols, ten carotenoids, three tocopherols and six fatty acids. Of all thirty 
compounds tested, the phenolic compounds kaempferol, naringenin and naringenin 
chalcone and the carotenoids violaxanthin, phytofluene, neurosporene, lycopene, 
Table 1. overview of tomato compounds selected to be tested and summary of the results obtained in the 
PPARγ2 CALUX reporter cell line.
compound reference(s) for presence in tomato fold induction at 10 μm
Polyphenolic compounds
kaempferol (28, 30) 3.8
kaempferol-3-O-rutinoside (28) inactive
quercetin (26, 30) inactive
rutin (26, 28) inactive
naringenin (28, 30, 37) 5.3
naringenin chalcone (26, 28) 2.6
delphinidina (38) inactive
cyanidina (39) inactive
chlorogenic acid (28, 37) inactive
ferulic acid (37, 40) inactive
caffeic acid (37, 40) inactive
Carotenoids
lutein (26, 27) inactive
neoxanthin (26, 27) inactive
violaxanthin (26, 27) 1.6 (fold at 100 μM: 2.6)
phytoene (27, 29) inactive
phytofluene (27, 29) 1.5
neurosporene (27, 29) 1.5
lycopene (27, 29) 1.5 (fold at 100 μM: 2.5)
β-carotene (26, 27) 2.3
γ-carotene (27) 3.8
δ-carotenea (41, 42) 2.3
Tocopherols 
α-tocopherol (26, 43) inactive
β-tocopherol (43, 44) inactive
δ-tocopherol (26, 43) inactive
Fatty acids
α-linolenic acid (ALA; C18:3n3) (45, 46) 2.7b
oleic acid (OA; C18:1n9) (45, 46) 3.8b
linoleic acid (LA; C18:2n6) (45, 46) 2.8b
palmitic acid (PA; C16:0) (45, 46) inactive
stearic acid (SA; C18:0) (45, 46) inactive
myristic acid (MA; C14:0) (45) inactive
aAlthough not found in conventional tomato, these compounds are found in special varieties like purple 
tomato (delphinidin and cyanidin) and Delta tomato (δ-carotene)(38, 41, 42). 
bFor fatty acids, the fold induction at 100 μM is presented. 
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β-carotene, γ-carotene and δ-carotene were able to induce PPARγ2-mediated expression 
of luciferase (table 1). The other phenolic compounds and carotenoids as well as the three 
tocopherols were not able to activate PPARγ2-mediated luciferase expression (table 1). 
Induction of PPARγ by β-carotene, lycopene, kaempferol, naringenin and naringenin 
chalcone is in line with findings in literature reporting that these compounds can bind to 
PPARγ when tested in receptor binding assays (47-49). These earlier findings, however, 
indicate binding to the PPARγ receptor, which does not automatically lead to activation 
of PPARγ and to subsequent changes in PPARγ-mediated gene expression patterns. For 
example, although quercetin was reported to bind to PPARγ (47, 49), it was not able to 
stimulate PPARγ-mediated gene expression in PPARγ2 CALUX cells. To our best knowledge, 
of the polyphenols and isoprenoids tested in the current research, only naringenin and 
naringenin chalcone have been shown to influence PPARγ-mediated gene expression 
before (50, 51). It is of interest to note that none of the flavonoid glycosides was able 
to induce PPARγ2-mediated expression, whereas some of the corresponding aglycones 
are active agonists (table 1). For example, the aglycone kaempferol was able to induce 
PPARγ2-mediated expression, while its glycoside kaempferol-3-O-rutinoside was not. 
Of the six fatty acids tested for their ability to activate PPARγ2, α-linolenic acid (ALA), 
oleic acid (OA), and linoleic acid (LA) were found to act as PPARγ2 agonists, while palmitic 
acid, stearic acid and myristic acid were not functioning as PPARγ2 agonists (table 1). 
These findings are in line with data reported by Chou et al. showing that ALA, oA and LA 
function as PPARγ agonists and that palmitic acid and stearic acid do not activate PPARγ 
(52). Chou and colleagues, however, report that myristic acid also functions as PPARγ 
agonist, while our data did not show PPARγ agonism for this compound. Of all tested 
compounds, naringenin, kaempferol and γ-carotene were the most active inducers of 
PPARγ2-mediated luciferase gene expression: these compounds induce PPARγ2-mediated 
luciferase expression at concentrations of 1 µM or higher and showed the highest fold 
induction at a concentration of 10 µM (table 1). 
pparγ-activation by extracts of tomato fruit
To investigate the potential of tomato fruit to induce PPARγ2-mediated luciferase gene 
expression, two different types of tomato extracts were tested: one extract containing 
isoprenoids (which was obtained by chloroform extraction and is further referred to 
as isoprenoid-containing extract) and one extract containing semi-polar compounds, 
including flavonoids and other phenolic compounds. As the results with the individual 
compounds indicated that only the aglycones (and not the glycosides) were able to 
activate PPARγ, the tomato homogenate was treated with Viscozyme L before extraction 
with methanol in order to remove the glycosyl residues from the bioactive phenolic 
components and will be further referred to as enzymatically hydrolyzed tomato extract. 
After 24 hours of exposure, the isoprenoid-containing tomato extract was able to induce 
PPARγ2-mediated luciferase in a dose-dependent manner (figure 1). The PPARγ2-activating 
effect of the isoprenoid-containing tomato extract may be due to the presence of the 
carotenoids violaxanthin, phytofluene, neurosporene, lycopene, β-carotene, γ-carotene 
and δ-carotene, which were all found to function as PPARγ2-agonists (table 1) and are 
74
PPA
R
γ-M
ED
IATED
 G
EN
E EXPR
ESSIO
N
 &
 TO
M
ATO
4
known to be present in tomato fruits (26, 27, 29, 42). In addition, also the enzymatically 
hydrolyzed tomato extract was able to induce PPARγ2-mediated luciferase in a dose-
dependent manner (figure 1). In the enzymatically hydrolyzed tomato extract, kaempferol, 
naringenin and naringenin chalcone may contribute to the activity since these compounds 
were able to activate PPARγ2 when tested as pure compounds. Previous studies have 
reported the presence of these compounds in tomato fruit (28, 30). In humans, enzymatic 
hydrolysis of flavonoid glycosides also occurs in the intestine before uptake (53, 54). 
figure 1. Enzymatically hydrolyzed tomato extract (grey bars) and isoprenoid-containing tomato 
extract (white bars) induce dose-dependent PPARγ2-mediated luciferase expression in the PPARγ2 
CALUX cells. The amount of tomato extract is expressed as gram fresh weight per liter (g FW/L). 
Luciferase activity is expressed as percentage of the positive control (1 μM rosiglitazone). Data are 
corrected for background luciferase activity and are expressed as mean ± SEM (n=3). Asterisks indicate 
the level of significance compared to the solvent control: * p<0.05; ** p<0.01 and *** p<0.001.
figure 2. Enzymatically hydrolyzed extracts of seven tomato varieties induce PPARγ2-mediated 
luciferase expression in the PPARγ2 CALUX cells. The extracts were tested at 45 g FW/L. The solvent 
control (0) is included. Luciferase activity is expressed as percentage of the positive control (1 μM 
rosiglitazone). Data are corrected for background luciferase activity and are expressed as mean 
± SEM of three independent experiments. Asterisks indicate the level of significance compared to 
the solvent control: * p<0.05; ** p<0.01; and *** p<0.001.
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pparγ-activation by seven different tomato varieties
In addition to the mixture of beef, cherry and round tomatoes, enzymatically hydrolyzed 
extracts of nine tomato varieties, designated A-I, were tested for their potency to induce 
PPARγ-mediated gene expression. These nine tomato varieties included two high pigment 
tomato varieties (G and H). Two tomato varieties, H and I, showed cytotoxicity at 45 g FW/L 
and were therefore not included in further analysis. The other seven varieties were all 
able to significantly induce PPARγ-mediated gene expression at 45 g FW/L (figure 2). There 
was a 1.6 fold difference in the induction found with the least potent variety (variety A) 
and the most potent variety (variety G)(figure 2).
Time
-0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
%
0
100
Q N Kglycosides
Variety G
Variety F
Q N K
glycosides
Time
-0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
%
0
100
figure 3. Chromatograms of enzymatically hydrolyzed extracts of the most potent tomato varieties 
(F and G), representing the total ion signal of selected masses: 273.075 (naringenin); 287.055 
(kaempferol); 303.050 (quercetin). Maximal intensity (100%) of 15000. Indicated with arrows are: 
N = naringenin; K = kaempferol; Q = Quercetin; glycosides = flavonoid glycosides. For complete 
chromatograms, see supplemental data.
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The extracts of the seven tomato varieties not showing cytotoxicity, were chemically 
analyzed using LC-MS, and chromatograms representing the total ion signal of each 
variety are presented in the supplemental data. Chromatograms showing selected masses 
of flavonoid aglycones indicated that considerable amounts of kaempferol, naringenin 
and quercetin were present in the most potent tomato varieties F and G (figure 3). In 
addition, levels of kaempferol and naringenin, both found to function as PPARγ2-agonists 
when tested individually, were quantified in the enzymatically hydrolyzed extracts of the 
seven tomato varieties (table 2). It is interesting to note that the least potent varieties, 
A and B, had the lowest content of kaempferol and naringenin, while the two most potent 
varieties, F and G, had the highest content of kaempferol and naringenin. These results 
suggest that the differences in potency to induce PPARγ-mediated gene expression may 
be partly explained by the differences in levels of kaempferol and naringenin and/or other 
flavonoids. 
Table 2. Levels of kaempferol and naringenin found in enzymatically hydrolyzed extracts of seven tomato 
varieties. 
Tomato variety Kaempferol (μm)a naringenin (μm)a
A 0.07 0.59
B 0.04 0.04
C 1.13 7.76
D 0.03 1.30
E 0.02 1.59
F 0.31 13.19
Gb 1.33 10.56
aKaempferol and naringenin are presented as μM present in extract dissolved and diluted to 45 g FW/L, 
which is the concentration at which the extracts were tested in the PPARγ2 CALUX cell line. 
bHigh pigment variety.
pparγ-activation by phytochemical mixtures
Most of the individual compounds induced PPARγ2-mediated luciferase expression at 
concentrations of 1 µM and higher. These concentrations seem relatively high, since 
the concentrations of these compounds in human plasma normally do not exceed 1 μM 
(55, 56). After tomato consumption, plasma concentrations of several phytochemicals, 
including β-carotene, lycopene and naringenin increase, but still stay below 1 μM (21, 
37, 55). The total concentration of phytochemicals, however, is higher than 1 μM (57, 58) 
and may be high enough to activate PPARγ and lead to PPARγ-mediated changes in gene 
expression. To investigate whether an additive effect of different tomato compounds on 
PPARγ2 activation can be expected, induction of PPARγ2-mediated gene expression by 
combinations of kaempferol, naringenin and β-carotene was investigated. This reveals that 
upon combining different compounds at concentrations of 1 μM, which individually do 
not induce PPARγ2-mediated gene expression, induction of PPARγ2-mediated expression 
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can be obtained (figure 4). The effect was most striking for the combination of β-carotene 
with either kaempferol or naringenin: the individual compounds were not able to induce 
PPARγ2-mediated expression at 1 μM, but the combination of 1 μM β-carotene with 
either 1 μM kaempferol or 1 μM naringenin resulted in a significant induction. Our results 
suggest an additive effect when combining individual phytochemicals. Additive effects 
between phytochemicals have been reported before (59). This additive effect might be 
achieved by the fact that these phytochemicals all act by binding to the same receptor 
and therefore their concentrations can be added up. Another explanation could be that 
the mixtures of phytochemicals are also able to activate RXR, which is the dimerization 
partner for PPARγ, leading to an additive effect in activation of the PPARγ-RXR complex. 
Furthermore, phytochemicals are not only present in plasma, but also in tissues. In 
tissues the total carotenoid level has been reported to reach concentrations of 5.1, 9.4 
and 7.6 nmol/gram wet tissue (equal to 5.1, 9.4 and 7.6 μM, assuming that 1 kg of wet 
tissue corresponds to 1 liter) in liver, adrenal glands and testes, respectively (60). Based 
on the results of the present paper it can be concluded that these levels are high enough 
to induce PPARγ-mediated gene expression. To substantiate functional effects of the food 
compounds and extracts in vivo, however, additional data are needed, in particular for 
polyphenols that do not occur as aglycones in plasma. 
The beneficial effects of tomato consumption have often been linked to lycopene (61). 
our data indicate that many other phytochemicals present in tomato may be involved in 
possible PPARγ-mediated beneficial health effects of tomato fruits.
figure 4. PPARγ2-mediated luciferase expression in the PPARγ2 CALUX cells induced by individual 
phytochemicals and combinations of phytochemicals at 1 μM each. Luciferase activity is expressed as 
percentage of the positive control (1 μM rosiglitazone). Data are corrected for background luciferase 
activity and for luciferase activity observed with the solvent control. Data are expressed as mean 
± SEM of five independent experiments. Asterisks indicate the level of significance compared to the 
solvent control: * p<0.05; and ** p<0.01. 
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tomato, pparγ and health
Induction of PPARγ-mediated gene expression has frequently been suggested to play a 
role in insulin-sensitization (62), protection against prostate, breast and colon cancer (12, 
13) and protection against atherosclerosis (10, 11). Although our data indicate that tomato 
extracts are able to induce PPARγ-mediated changes in gene expression, additional data 
are needed to confirm that tomato consumption in vivo leads to PPARγ-mediated gene 
expression and to PPARγ-related beneficial health effects. Several in vivo studies provide 
a link between tomato consumption and beneficial effects on lipid peroxidation rate (63), 
lipid profile (19) and blood pressure (64, 65). A role for PPARγ-mediated gene expression 
in endpoints like serum levels of free fatty acids and HDL cholesterol, blood pressure and 
glucose tolerance has been reported (4, 8, 66) and activation of PPARγ may thus provide a 
potential mode of action of several of the beneficial health effects of tomato consumption. 
Using reporter gene assays, it was previously demonstrated that PPARγ1 and PPARγ2 
are activated by PPARγ agonists in a similar way (31, 67). This suggests that tomato 
compounds and tomato extracts which are able to activate PPARγ2, may be able to also 
activate PPARγ1. 
In conclusion, our data show that isolated tomato compounds as well as the enzymatically 
hydrolyzed tomato extract containing phenolic compounds and the isoprenoid-containing 
tomato extract were able to induce PPARγ2-mediated gene expression. Taking into account 
concentrations at which PPARγ activation was detected and reported physiological levels 
of PPARγ-activating compounds in plasma and various tissues, our results indicate that 
beneficial health effects associated with tomato consumption may be (partly) mediated 
by PPARγ2-mediated induction of gene transcription. 
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figure s1. Chromatograms of enzymatically hydrolyzed extracts of tomato varieties, representing the 
total ion signal obtained from QTOF-MS analysis (with max intensity = 100% of 35000). 
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In the present study, a stable reporter gene assay for detection of PPARα activation 
was developed and characterized. This assay, designated PPARα CALUX assay, showed 
a concentration-dependent increase of PPARα-mediated luciferase expression upon 
exposure to the PPARα agonists GW7647, GW9578, WY14643 and bezafibrate. The PPARα 
CALUX assay was further used to test extracts of tomato fruit and phytochemicals present 
in tomato for their ability to induce PPARα-mediated gene expression. An isoprenoid-
containing extract of tomato was able to induce PPARα-mediated gene expression, which 
is consistent with our findings that β-carotene, γ-carotene and lycopene also induce 
PPARα-mediated gene expression. In addition, it was shown that an extract of tomato 
containing semi-polar compounds is only a weak inducer of PPARα-mediated gene 
expression, but enzymatic hydrolysis of the tomato homogenate before extraction greatly 
increases this capacity. This is in line with our findings that all tested flavonoid glycosides 
failed to induce PPARα-mediated gene expression, but that the aglycones kaempferol 
and naringenin were able to induce PPARα-mediated gene expression. Furthermore, 
nine tomato varieties were tested for their capacity to induce PPARα-mediated gene 
expression, and the varieties showing the highest capacity were the ones containing the 
highest amounts of kaempferol and naringenin. Although this suggests that naringenin and 
kaempferol contribute to the induction of PPARα-mediated gene expression found with 
the enzymatically hydrolyzed tomato extracts, kaempferol and naringenin cannot fully 
explain the high (up to 12-fold) induction found with these tomato varieties. Presumably 
there are more, yet unidentified PPARα-activating compounds present in tomato. Taken 
together the data presented indicate that the beneficial effects associated with tomato 
consumption may partly be explained by induction of PPARα-mediated transcription by 
tomato compounds.
KeywordS 
Peroxisome proliferator-activated receptor alpha (PPARα); polyphenols; isoprenoids; 
tomato; stable reporter gene assay. 
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iNTRoducTioN
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription 
factors belonging to the nuclear receptor family (1, 2). Three PPAR isoforms are known: 
PPARα (NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3)(3). Once activated by ligands, PPARs 
influence the expression of their target genes, thereby influencing important physiological 
processes. For example, PPARγ is well-known for its role in adipogenesis (4, 5) while PPARβ/δ 
has more pleiotropic effects and is involved in for example lipid metabolism, inflammation 
and wound healing (6-10). PPARα is known for its role in lipid metabolism (11, 12): it 
modulates the expression of genes involved in cellular uptake and β-oxidation of fatty acids 
(11, 13, 14). PPARα is mainly expressed in liver, skeletal muscle and brown adipose tissue (2) 
and is activated by both endogenous and exogenous ligands. Endogenous ligands include 
several fatty acids and their derivatives, like for example arachidonic acid, docosahexaenoic 
acid (DHA), eicosapentaenoic acid (EPA), linolenic acid, linoleic acid and eicosanoids (15, 
16). Exogenous ligands for PPARα are for example fibrates, a class of lipid-lowering drugs 
including gemfibrozil, clofibrate, fenofibrate, bezafibrate, and ciprofibrate (16). 
Activation of PPARα by its ligands has been related to several beneficial health 
effects. Fibrates, which are potent PPARα agonists, are known to improve risk factors 
for cardiovascular disease (CVD): fibrates decrease plasma levels of triglycerides and 
LDL cholesterol, and increase HDL cholesterol (17, 18). In addition, PPARα activation has 
been related to a decreased risk on development of atherosclerosis by improving risk 
factors (17-20). Furthermore, activation of PPARα has been related to slower progression 
of atherosclerosis by inhibition of leukocyte infiltration, reduction of foam cells formation 
and enhanced plaque stability (21, 22). PPARα activation has also been related to improved 
insulin sensitivity (18, 23, 24). 
Beneficial health effects related to PPARα activation partially overlap with those 
related to the consumption of tomato; epidemiological studies indicate that consumption 
of tomato or tomato products is related to a reduced risk of several chronic diseases, 
including CVD, prostate cancer and several other cancer types (25-28). It is of interest to 
know whether PPARα activation by tomato extracts and tomato constituents could have 
a role in explaining these beneficial effects. Therefore, the aim of the present study was 
to investigate whether tomato extracts and tomato constituents, including flavonoids and 
carotenoids, are able to induce PPARα-mediated gene expression. In order to test this, a 
luciferase reporter gene assay to measure PPARα agonism was developed and validated. 
This cell-based assay was then used to test tomato constituents and extracts of tomato 
fruit for their ability to activate PPARα-mediated gene expression. 
mATeRiALs ANd meThods
materials
GW7647 (CAS no: 265129-71-3) was obtained from Sigma Aldrich (St. Louis, USA), bezafibrate 
(CAS no: 41859-67-0), WY14643 (CAS no: 50892-23-4), GW9578 (CAS no: 247923-29-1), 
rosiglitazone (CAS no: 122320-73-4), pioglitazone (CAS no: 111025-46-8), L165041 (CAS no: 
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79558-091) and GW501516 (CAS no: 317318-70-0) were purchased from Cayman Chemical 
(Ann Arbor, USA). Lycopene, lutein, kaempferol, kaempferol-3-O-rutinoside, cyanidin 
chloride and delphinidin chloride were purchased from Extrasynthase (Genay, France). 
Phytoene, phytofluene, neoxanthin, violaxanthin, neurosporene, γ-carotene and α-carotene 
were obtained from Carotenature (Lupsingen, Switzerland). Quercetin, chlorogenic acid, 
ferulic acid, β-carotene, α-tocopherol, γ-tocopherol, and δ-tocopherol were obtained from 
Sigma Aldrich (St. Louis, USA). Caffeic acid and rutin were purchased from Acros (Geel, 
Belgium) and naringenin from ICN Biomedicals (Irvin, USA). The carotenoids were dissolved 
in tetrahydrofuran (THF; VWR Prolabo, Radnor, USA), all other compounds were dissolved in 
dimethylsulphoxide (DMSO, 99.9%, Acros, Geel, Belgium). 
development of the pparα calux cell line
Human U2OS osteosarcoma cells (obtained from the American Type Culture Collection 
(ATCC), Manassas, USA) were stably transfected as described before (29), using reporter 
construct 3xPPRE-tata-luc (30) and expression vector pSG5-neo-PPARα expressing 
human PPARα. The PPARα gene was excised from pCMV6-XL4-PPARα (purchased from 
Origene, Rockville, USA) and inserted into the unique NOTI site in the multiple cloning 
site of pSG5-neo, which contains the neomycin resistance gene (29). Stable transfection 
was carried out using a calcium phosphate co-precipitation method, as described before 
(31). In short, after transfection G418-disulfate (CAS no: 108321-42-2, DuchefaBiochemie, 
Haarlem, The Netherlands) was added to the culture medium (final concentration 
150 μg/ml) to maintain selection pressure and all G418-resistant clones were tested for 
their responsiveness to the well-known PPARα agonist GW7674 (32). The responsive 
clones were tested to generate full dose-response curves and the clone showing the best 
response was selected and used for further validation. 
cell culture
Stably transfected PPARα CALUX cells were cultured in culture medium: DMEM/F12 
glutamax medium (Invitrogen, Breda, The Netherlands) supplemented with 7.5% fetal 
calf serum (FCS, Invitrogen), non-essential amino acids (NEAA, Invitrogen) and penicillin/
streptomycin (Invitrogen)(final concentrations 10 U/ml and 10 μg/ml, respectively). Once 
per week 200 μg/ml G418 was added to the culture medium, in order to maintain the 
selection pressure. Cells were cultured at 37°C and 5% CO2 in a humid atmosphere.
Tomato extracts
Roma tomatoes, cherry tomatoes and cocktail tomatoes were purchased at a local 
supermarket in Wageningen (The Netherlands). For each variety, several tomato fruits 
were snap-frozen in liquid nitrogen. Next, the frozen tomato was ground to powder using 
an analytical mill (IKA, Staufen, Germany) and stored at -80°C until further use. Prior 
to extract preparation, the frozen powders were pooled in order to get a mix of roma 
tomatoes, cherry tomatoes and cocktail tomatoes, further referred to as tomato mix. 
Three different extracts were generated from this tomato mix: one extract containing 
isoprenoids and two extracts containing semi-polar compounds. 
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Isoprenoids, including carotenoids and tocopherols, were extracted from the tomato 
mix by a chloroform extraction method described before (33). This resulted in an extract 
further referred to as isoprenoid-containing tomato extract.
The two extracts containing semi-polar compounds were generated. The first extract 
containing semi-polar compounds was prepared by methanol extraction using a method 
described before (33). This extract contains for example flavonoid glycosides and other 
polyphenols, and is further referred to as nonhydrolyzed tomato extract. For the second 
extract containing semi-polar compounds, tomato mix was treated with Viscozyme L for 
two hours prior to the methanol extraction. The Viscozyme L treatment was performed 
in order to remove glycosyl groups from glycosylated ingredients. Viscozyme L treatment 
and subsequent methanol extraction were performed as previously described (33). The 
resulting extract contains for example flavonoid aglycones and is further referred to as 
enzymatically hydrolyzed tomato extract.
In addition to the tomato mix, nine different tomato varieties were tested for their 
capacity to induce PPARα-mediated gene expression. These varieties include two high 
pigment tomato varieties (varieties 7 and 8) and were kindly provided by Syngenta 
(Enkhuizen, The Netherlands). Enzymatically hydrolyzed extracts of these nine tomato 
varieties were prepared using the method described above. Furthermore, chemical 
analysis of these extracts was performed using LC-MS as described below.
chemical analysis using Lc-PdA-QTof-ms
The LC-PDA-QTOF-MS method combines four techniques: liquid chromatography (LC), 
photodiode array (PDA), quadrupole time of flight (QTOF) and mass spectrometry (MS). 
Semi-polar compounds in the sample can be separated with LC and detected with 
PDA. Then, the compounds are ionized and masses are detected using QTOF and MS. 
As individual compounds can be identified based on their retention time and mass, the 
LC-PDA-QTOF-MS method provides insight in the semi-polar compounds present in the 
sample. LC-PDA-QTOF-MS analysis was performed as described before by De Vos and 
colleagues (34). In short, 5 µl of enzymatically hydrolyzed tomato extracts were injected 
onto a C18 column. Separation was performed using ultrapure water (eluent A) and 
acetonitrile (eluent B), both acidified with 0.1 % formic acid, and a flow rate of 190 µl/min. 
A linear gradient was applied increasing eluent B from 5% to 35% in 45 minutes. Before the 
next injection, the column was washed and equilibrated for 15 minutes. After separation 
and detection of the semipolar compounds by LC-PDA, positive electrospray ionization 
was applied and masses were detected using QTOF-MS. Chromatograms obtained in this 
way were analyzed using MassLynx 4.1 (Waters) software.
exposure experiments
PPARα CALUX cells were plated in 96-well plates at a density of 10,000 cells per well using 
100 μl assay medium: phenol red-free DMEM/F12 medium (Invitrogen) supplemented 
with 5% dextran-coated charcoal-stripped FCS, NEAA and penicillin/streptomycin (final 
concentrations 10 U/ml and 10 μg/ml, respectively). The next day, the medium was 
replaced by 200 μl fresh assay medium supplemented with the test compounds or 
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tomato extracts. The percentage of solvent in the exposure medium was kept at 0.5% 
for experiments with individual compounds and at or below 1.0% for experiments with 
tomato extracts. After 24 hours, the exposure medium was removed and the cells were 
lysed. Luciferase activity in the lysate was measured using a luminometer (Berthold LB941, 
Bad Widbad, Germany), as described before (29). Experiments with isoprenoids and the 
isoprenoid-containing tomato extract were performed in the dark. 
All extracts of tomato and all individual compounds were tested for cytotoxicity using 
the Cytotox CALUX cell line as described before (35). The Cytotox CALUX cells show an 
invariant luciferase expression and a decrease in luciferase activity therefore indicates 
a cytotoxic effect. Moreover, an increase in luciferase activity in the Cytotox CALUX 
cells may indicate stabilization of the luciferase enzyme and possible false positives 
for gene expression in the PPARα CALUX assay (33). All individual tomato compounds 
and tomato extracts were tested for cytotoxicity using the Cytotox CALUX cells and 
only non-cytotoxic concentrations were used for testing in the PPARα CALUX cell line. 
Furthermore, the Cytotox CALUX cells were used to investigate whether stabilization 
of the luciferase enzyme was occurring during the exposure to tomato compounds and 
tomato extracts. 
data analysis
Luciferase activity per well was measured as relative light units (RLUs). Induction factors 
were calculated using the following formula: RLU for exposed well / average RLU of the 
solvent control. For each test compound, at least two independent experiments were 
performed. Data are presented as mean values ± standard error of the mean (SEM). 
Statistical significance was assessed using the one-sided Student’s t-test and a cut-off 
value of p≤0.05.
ResuLTs
characterization and validation of the pparα calux cell line
PPARα CALUX cells were exposed to four known PPARα agonists: GW7647, GW9578, 
WY14643, and bezafibrate. Upon exposure to these compounds, PPARα-mediated 
luciferase expression was induced (figure 1A). GW7647 had an EC50 value of 4.3 nM and 
GW9578 had an EC50 of 0.23 μM. For WY14643 and bezafibrate, no complete dose-response 
curves were generated in the concentration range that could be tested without causing 
cytotoxicity, and therefore EC50 values could not be determined. The concentrations at 
which the tested agonists start to induce PPARα-mediated luciferase expression and EC50 
values found for GW7647 and GW9578, are in line with data from other reporter gene 
assays reported in literature (32, 36, 37). GW7647 was the most potent of the tested 
agonists asreflected by the lowest EC50 value, followed by GW9578, and then by WY14643 
and bezafibrate which have comparable potencies. This potency ranking is consistent with 
rankings reported in literature (32, 38). 
In order to verify that the PPARα CALUX cells specifically respond to PPARα 
activation and not to activation via PPARβ/δ or PPARγ, the PPARα CALUX cells were 
92
PPA
R
α
-M
ED
IATED
 G
EN
E EXPR
ESSIO
N
 &
 TO
M
ATO
5
exposed to two agonists selective for PPARγ (rosiglitazone and pioglitazone (39)) and 
to two agonists selective for PPARβ/δ (L165041 and GW501516 (40)). PPARα CALUX 
cells showed increased luciferase expression upon exposure to the PPARγ agonists 
rosiglitazone and pioglitazone, but only in concentrations higher than 1 μM (figure 1B). 
This is higher than their concentrations needed for PPARγ agonist activity (two orders 
of magnitude for rosiglitazone and one order of magnitude for pioglitazone), which 
underlines that these responses cannot be mediated by PPARγ. It has been shown before 
that rosiglitazone and pioglitazone activate PPARα at relatively high concentrations 
(>1μM)(16, 40, 41). Luciferase induction in the PPARα CALUX cells was also found 
upon exposure to the PPARβ/δ agonists L165041 and GW501516 (figure 1B). This is 
consistent with data in literature showing that L165041 and GW501516 activate PPARα 
at concentrations of 1 μM and higher (40, 42), which is higher than their concentrations 
needed for PPARβ/δ agonist activity (two orders of magnitude for L165041 and three 
orders of magnitude for GW501516), which underlines that these responses cannot be 
mediated by PPARβ/δ.
induction of pparα-mediated gene expression by tomato extracts
Next, extracts of tomato fruit were tested for their ability to induce PPARα-mediated gene 
expression. To this end, PPARα CALUX cells were exposed for 24 hours to the isoprenoid-
containing tomato extract, the nonhydrolyzed tomato extract and the enzymatically 
hydrolyzed tomato extract. The isoprenoid-containing tomato extract showed an 
induction in PPARα-mediated luciferase expression up to 2.1 fold at 45 g FW/L (figure 2). 
The nonhydrolyzed tomato extract, containing semi-polar compounds including flavonoid 
glycosides, only showed significant induction (1.4 fold) of PPARα-mediated luciferase 
at the highest concentration tested (figure 2). The enzymatically hydrolyzed extract, in 
which flavonoid glycosides were hydrolyzed into flavonoid aglycones, showed significant 
induction of PPARα-mediated luciferase even at 5 g FW/L (2.4 fold) and reached an 
induction of 9.3 fold at 45 g FW/L (figure 2). 
figure 1. Luciferase activity is induced in the PPARα CALUX assay upon exposure to A) PPARα agonists 
GW7647 (), GW9578 (), WY14643 () and bezafibrate (); and B) PPARβ/δ agonists GW501516 
() and L165041 (), and PPARγ agonists rosiglitazone () and pioglitazone ().
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The PPARα-mediated luciferase induction found with the enzymatically hydrolyzed 
tomato extract at 45 g FW/L (9.3-fold) is much higher than with the isoprenoid-containing 
tomato extract (2.1-fold). This may suggest that in tomato, semi-polar compounds 
including polyphenols are more important than isoprenoids in activating PPARα. 
induction of pparα-mediated gene expression by tomato compounds
To assess which tomato constituents may contribute to the induction of PPARα-mediated 
gene expression by tomato extracts, 23 compounds known to be present in tomato 
(table 1) were tested for their capacity to induce PPARα-mediated gene expression. Of 
the 10 polyphenols tested, only naringenin and kaempferol were able to induce PPARα-
mediated gene expression (table 1), but only at concentrations higher than 1 μM (data not 
shown). Our results are in line with data reported in literature showing that naringenin is 
able to activate PPARα at concentrations in the micromolar range (43, 44). 
Of the 10 carotenoids investigated, lycopene, β-carotene and γ-carotene were able 
to induce PPARα-mediated gene expression, while the three tested tocopherols were not 
able to do so (table 1). These data indicate that lycopene, β-carotene and γ-carotene 
might contribute to the induction of PPARα-mediated gene expression by the isoprenoid-
containing tomato extract. 
The induction of PPARα-mediated luciferase expression with kaempferol, naringenin, 
lycopene, β-carotene and γ-carotene at a concentration of 17 μM is comparable with the 
induction found with 1 μM bezafibrate.
induction of pparα-mediated gene expression by various tomato varieties
Besides extracts of a mix of roma, cherry and cocktail tomatoes, enzymatically hydrolyzed 
extracts of nine tomato varieties, designated 1-9, were tested for their potency to induce 
PPARα-mediated gene expression using the PPARα CALUX cells. These nine varieties include 
figure 2. Luciferase activity induced in the PPARα CALUX assay upon exposure to tomato extracts: 
isoprenoid-containing extract (white bars), nonhydrolyzed tomato extract (light grey bars) and 
enzymatically hydrolyzed extract (dark grey bars). The concentration of tomato extract is given as 
gram fresh weight (FW) per liter. Asterisks indicate the level of significance compared to the solvent 
control: * p<0.05; ** p<0.01; and *** p<0.001.
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two high pigment varieties (7 and 8). Enzymatically hydrolyzed extracts of these nine 
tomato varieties were prepared and tested for their potency to induce PPARα-mediated 
gene expression using the PPARα CALUX cells. Varieties 8 and 9 showed cytotoxicity at 
45 g FW/L and these varieties were therefore not included in further analysis. The seven 
varieties not showing cytotoxicity at this concentration were all able to significantly 
induce PPARα-mediated gene expression at 45 g FW/L and fold induction ranged from 
7.5-fold (variety 1) to 12.8-fold (variety 7)(figure 3A). This means that there was a 1.7-fold 
difference in induction between the least potent variety and the most potent variety. 
Using the Cytotox CALUX cell line, it was shown that the tomato varieties had hardly any 
effect on the luciferase activity measured in those cells (figure 3B). This indicates that the 
induction of luciferase activity upon exposure of the PPARα CALUX cells to tomato extracts 
is not due to stabilization of the luciferase enzyme. 
Table 1. Luciferase expression induced by tomato compounds in the PPARα CALUX assay.
compound reference(s) for presence in tomato fold induction at 17 μm
Polyphenolic compounds
naringenin (45-47) 1.3
kaempferol (45, 46) 1.5
kaempferol-3-O-rutinoside (45) inactive
quercetin (46, 48) inactive
rutin (45, 48) inactive
delphinidina (49) inactive
cyanidina (50) inactive
chlorogenic acid (45, 47) inactive
ferulic acid (47, 51) inactive
caffeic acid (47, 51) inactive
Carotenoids
lutein (48, 52) inactive
neoxanthin (48, 52) inactive
violaxanthin (48, 52) inactive
phytoene (52, 53) inactive
phytofluene (52, 53) inactive
neurosporene (52, 53) inactive
lycopene (52, 53) 1.6
β-carotene (48, 52) 1.7
γ-carotene (52) 1.8
δ-carotene* (54, 55) Inactive
Tocopherols
α-tocopherol (48, 56) inactive
β-tocopherol (56, 57) inactive
δ-tocopherol (48, 56) inactive
aAlthough these compounds are not found in conventional tomato, they are found in special varieties 
like purple tomato (delphinidin and cyanidin) and Delta tomato (δ-carotene)(49, 50, 54, 55).
95
PPA
R
α
-M
ED
IATED
 G
EN
E EXPR
ESSIO
N
 &
 TO
M
ATO
5
figure 3. Luciferase activity is induced in the PPARα CALUX assay (A) but not in the Cytotox CALUX 
assay (B) upon exposure to enzymatically hydrolyzed extracts of seven tomato varieties at 45 g FW/L. 
Variety 7 is a high-pigment tomato variety. Asterisks indicate the level of significance compared to 
the solvent control: * p<0.05; ** p<0.01; and *** p<0.001.
The extracts of tomato varieties 1-7 were analyzed using LC-PDA-QTOF-MS and the 
levels of kaempferol and naringenin in these extracts were quantified (table 2). It is 
interesting to note that the most potent varieties (5, 6 and 7) had the highest content of 
kaempferol and naringenin. Altogether, these data suggest that kaempferol and naringenin 
present in tomato may contribute to potency differences between the tomato varieties. 
Table 2. Levels of kaempferol and naringenin found in enzymatically hydrolyzed extracts of seven tomato 
varieties. 
Tomato variety Kaempferol (μm)a naringenin (μm)a
1 0.02 1.59
2 0.07 0.59
3 0.03 1.30
4 0.04 0.004
5 0.31 13.19
6 1.13 7.76
7b 1.33 10.56
aKaempferol and naringenin present in tomato extract diluted to 45 g FW/L, which is the concentration 
at which the extracts were tested in the PPARα CALUX assay.
bHigh pigment variety.
discussioN
In the present study, a stable reporter gene assay for activation of PPARα was developed 
and characterized. This PPARα CALUX assay enables fast and low-cost screening of 
synthetic and natural compounds for their potency to induce PPARα-mediated gene 
expression. This reporter gene assay was based on the U2oS cell line, a cell line of human 
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origin with low endogenous expression of the three PPAR subtypes (58, 59). By stably 
transfecting the U2OS cells with an expression vector for human PPARα, a cell line was 
generated which is specific for PPARα-mediated gene expression. This was supported 
by the results obtained with GW7647, GW9578, WY14643 and bezafibrate: induction of 
PPARα-mediated luciferase expression was seen with all four PPARα agonists. In order to 
verify that the PPARα CALUX cells specifically respond to PPARα agonism, the PPARα CALUX 
cells were exposed to rosiglitazone and pioglitazone (PPARγ agonists) and to L165041 
and GW501516 (PPARβ/δ agonists). The PPARα CALUX cells showed increased luciferase 
expression upon exposure to the PPARγ agonists as well, but only at concentrations much 
higher than needed for PPARγ activation. This underlines that these responses cannot 
be mediated by PPARγ. The same holds for the response to the PPARβ/δ agonists: they 
induce luciferase expression at concentrations much higher than their concentrations 
needed for PPARβ/δ agonist activity, which underlines that the responses observed in the 
PPARα CALUX cells cannot be mediated by PPARβ/δ.
The present results indicate that tomato is able to induce PPARα-mediated gene 
expression. This is in line with an earlier report in which a tomato extract was fractionated 
using HPLC, with several of the generated fractions being able to induce PPARα-mediated 
gene expression (60). Recent studies towards PPARα-activating effects of tomato and of 
food compounds mainly used chimera systems combining the ligand binding domain of 
PPARα with the DNA binding domain of GAL4 (43, 60, 61). These chimera systems therefore 
mainly reflect binding to the ligand binding domain of PPARα, which does not necessarily 
lead to activation of PPARα and subsequent PPARα-mediated effects on gene expression. 
The PPARα CALUX cells express the complete human PPARα receptor and detect PARα-
mediated gene expression, and may therefore be closer to physiological effects on gene 
expression.
The newly developed PPARα CALUX cell line was applied to test extracts of tomato 
fruit and phytochemicals present in tomato for their ability to induce PPARα. It was 
shown that both tomato extracts and phytochemicals present in tomato are able to 
induce PPARα-mediated changes in gene expression. Our data indicate that an isoprenoid-
containing extract of tomato is able to induce PPARα-mediated gene expression, which is 
consistent with our findings that β-carotene, γ-carotene and lycopene are able to induce 
PPARα-mediated gene expression as well. To our knowledge, this is the first time that 
these carotenoids are reported to activate PPARα, but it is consistent with the recently 
reported finding that another carotenoid, astaxanthin, which is present in for example sea 
food, is able to activate PPARα (62). Besides activating PPARα, β-carotene, γ-carotene and 
lycopene were also able to activate PPARγ-mediated gene expression (63). It would be of 
interest to see whether these compounds also activate PPARβ/δ and/or the dimerization 
partner of PPARs, RXR. 
In addition, it was shown that an extract of tomato containing semi-polar compounds 
is only a weak inducer of PPARα-mediated gene expression, but that enzymatic hydrolysis 
of the tomato sample before extraction greatly increases this capacity. This is in line with 
our findings that none of the flavonoid glycosides was able to induce PPARα-mediated 
gene expression, but that the aglycones kaempferol and naringenin were. Furthermore, 
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of the seven tomato varieties tested for their capacity to induce PPARα-mediated gene 
expression without showing cytotoxicity, the varieties showing the highest potency 
are also the ones containing the highest amounts of kaempferol and naringenin. These 
results together suggest that kaempferol and naringenin contribute to the induction 
of PPARα-mediated gene expression found with the enzymatically hydrolyzed tomato 
extracts, and that differences in the levels of kaempferol and naringenin may contribute 
to the differences in PPARα-activating capacity of the tomato varieties. The amounts 
of kaempferol and naringenin, however, cannot fully explain the high induction found 
with the enzymatically hydrolyzed tomato extracts: variety 7 contains approximately 
1.5 μM kaempferol and 10 μM naringenin (table 2). When these phytochemicals were 
tested individually, these concentrations gave about 1.1-fold induction each, while the 
enzymatically hydrolyzed extract of tomato variety 7 gave an induction of 12.8 fold 
(figure 3). This might point at an additive or even synergistic effect. Additive effects in 
mixtures of phytochemicals have been reported before (64). It also might point to other 
phytochemicals present in enzymatically hydrolyzed extracts of tomato fruit which may 
be able to induce PPARα-mediated gene expression. For example, it has been shown 
before that fatty acids and fatty acid derivatives like eicosanoids, which are also present 
in tomato fruits, are able to induce PPARα-mediated gene expression (15, 16, 60, 61). 
Furthermore, it was recently shown that 9-oxo-10(E),12(E)-octadecadienoic acid (9-oxo-
ODA) from tomato and 13-oxo-9,11-octadecadienoic acid (13-oxo-ODA) from tomato juice 
are potent PPARα activators (60, 61). In addition, the tomato extracts may also contain 
agonists for RXR – the dimerization partner for PPARγ – which may lead to an additive or 
even synergistic effect in activation of the PPARα-RXR complex. 
It was shown here that PPARα CALUX cells can be used to investigate differences in 
PPARα-activating capacity between tomato varieties. This implies that the PPARα CALUX 
cells can be used to select tomato varieties showing the highest capacity to induce 
PPARα-mediated gene expression. Although the present results indicate that tomato and 
phytochemicals present in tomato are able to induce PPARα-mediated gene expression, 
in vivo experiments are needed to confirm that PPARα-activation by tomato and its 
phytochemicals also leads to beneficial health effects in vivo. In vivo data from literature 
indicate that tomato consumption leads to decreased blood pressure, decreased total 
cholesterol and LDL cholesterol levels and decreased myocardial lesions after myocardial 
infarctions (65-68), but it remains to be elucidated to what extent these effects induced 
by tomato are PPARα-dependent. 
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AbsTRAcT
Reporter gene assays may be fast and useful tools for breeders and food industry to select 
for health-beneficial traits of crops or food processing methods that lead to an improved 
level and range of health-beneficial compounds. In this study, the ability of extracts of 
tomato fruit from different accessions to induce EpRE-mediated luciferase expression 
was measured using the EpRE-LUX reporter cells. By combining data from reporter gene 
assays obtained with tomato extracts with metabolic profiles from the same extracts, 
using multivariate analysis, it was possible to identify the flavonoid aglycone quercetin as 
one of the main compounds responsible for the ability of tomato extracts to induce EpRE-
mediated gene expression. It seems likely that also other, yet unidentified compounds 
contribute to EpRE-mediated gene expression induced by tomato extracts. The results 
indicate that combining reporter gene assays with metabolomics of tomatoes provides a 
powerful tool towards the identification of health beneficial constituents of foods.
Key wordS
Tomato, Solanum lycopersicum, electrophile-responsive element (EpRE), phenolic 
compounds, LC–MS, metabolomics, reporter gene assay, multivariate analysis.
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iNTRoducTioN
Tomato fruit (Solanum lycopersicum) is one of the most important vegetables consumed 
worldwide. It is used both as fresh and as processed food. The annual production 
of tomatoes worldwide was >145 million metric tons in 2010 according to FAOSTAT 
(http://faostat.fao.org). Tomato breeding programmes have mainly focussed on producer 
traits such as disease resistance, yield and shelf life. However, consumer traits relating to 
taste, nutritional value and health have become more importantduring the last decade 
(1). A number of epidemiological and intervention studies show that a diet rich in tomato 
results in a decreased incidence of certain cancers and coronary heart diseases (2-4). In 
these studies, the major carotenoid in tomato, lycopene, has gained much attention as 
health beneficial phytochemical. However, in addition to carotenoids, tomatoes contain 
many other potentially health beneficial phytochemicals such as flavonoids, chlorogenic 
acid and vitamin C (5). Flavonoids are able to induce the transcription of enzymes such as 
the quinone-reducing enzyme NAD(P)H: quinone oxidoreductase (NQO1) and glutathione 
S-transferases (GSTs)(6-8). Induction of these enzymes has been linked to reduced toxicity 
of chemical carcinogens due to efficient detoxification and an enhanced redox status to 
sustain optimal physiologic conditions in the body (7, 9, 10). Transcription of many of these 
detoxification enzymes, or phase II enzymes, is under control of the Antioxidant-Responsive 
Element (ARE) also called Electrophile-Responsive Element (EpRE, which will be used here). 
The EpRE mainly controls expression through the Kelch-like ECH associated protein 1 / 
nuclear factor-E2-related factor 2 (Keap1/Nrf2) system; oxidation of cysteines in Keap1 
releases the transcription factor Nrf2, which will translocate to the nucleus and activate 
EpRE-mediated gene expression (11). In our previous study, a method was developed to 
prepare tomato extracts in order to test them for potential health effects in cell-based 
reporter gene assays. Furthermore, induction of EpRE-controlled gene expression by 
tomato extracts was monitored in such a cell system using the EpRE-LUX reporter cell 
line (6). It was shown that neither chloroform extracts nor methanol extracts of the 
tomato fruits induced EpRE-controlled luciferase expression. It is known that many plant 
polyphenols are present as sugar conjugates in plants and have to be hydrolyzed to their 
aglycones before uptake (12, 13). Deglycosylation of polyphenols normally occurs in the 
small intestine by the membrane-bound lactase-phlorizin hydrolase (LPH) and putatively 
by the cytosolic β-glucosidase (CBG)(14, 15). When deglycosylation was mimicked using 
fungal glycosidases, methanol extracts did activate EpRE-mediated luciferase expression.
The present study describes the use of the previously developed method, to screen 
a collection of 97 different tomato accessions for their ability to induce EpRE-mediated 
gene expression. The metabolic variation between the different accessions appeared to 
influence their potency to induce EpRE-mediated gene expression. In order to identify 
metabolites putatively involved in the induction of EpRE-mediated gene expression, the 
reporter gene-assay data were linked to metabolomic profiles of the same extracts and a 
regression analysis was performed using various methods. The regression analysis yielded 
candidate metabolites (mostly flavonoids) for the EpRE-LUX induction. These results were 
validated using a transgenic tomato line accumulating high levels of flavonoids. 
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mATeRiALs ANd meThods
chemicals and Reagents 
Quercetin dihydrate, rutin, quercetin 3-glucoside, kaempferol, tert-butylhydroquinone 
(tBHQ), acetic acid, sodium acetate and Viscozyme L were purchased from Sigma-Aldrich 
(St. Louis, USA). Dimethyl sulfoxide (DMSO) and naringenin were obtained from Acros 
Organics (Geel, Belgium). Methanol and acetonitrile were purchased from Biosolve 
(Valkenswaard, The Netherlands). Minimum Essential Medium alpha (further referred to as 
α-MEM), Minimum Essential Medium alpha without phenol red, Dulbecco’s modified fetal 
calf serum (FCS), Hank’s balanced salt solution (HBSS), trypsin, gentamicin and G418 were 
purchased from Invitrogen Corporation (Breda, The Netherlands). HLB solid phase extraction 
(SPE) cartridges (3cc) were obtained from OASIS, Waters, (Etten-Leur, The Netherlands). 
Formic acid was obtained from Merck Millipore (Amsterdam, The Netherlands). Kaempferol-
3-rutinoside was purchased from Apin Chemicals (Abingdon, UK). 
Tomato material 
A diverse set of 97 different tomato (Solanum lycopersicon) accessions was selected and 
provided by Syngenta (Enkhuizen, The Netherlands). Six plants per accession were grown 
in Morocco in the summer of 2009. Preferably at least one fruit per plant was harvested 
by picking the fruit next to the ripest on the truss. In this way, at least six fruits were 
harvested for each accession. The picked fruits were stored in bags overnight to facilitate 
further ripening. The next day fruits were pooled and blended using a Whring blender for 
30 sec at maximal speed. Juice obtained this way was aliquoted into cryovials, snap-frozen 
in liquid nitrogen and stored at -20°C until transportation on dry ice to The Netherlands. 
Samples were finally stored at -80°C until further use. Additionally, a reference sample 
was prepared by blending frozen fruit juice of one cryovial of each of the 97 different 
accessions.
A commercial tomato accession was purchased at a local supermarket. These tomatoes 
were peeled. Peel and flesh samples were separated, snap frozen in liquid nitrogen and 
subsequently ground in an analytical mill. The powder, was stored at -80°C until further 
use. Furthermore, tomato peel samples were prepared from wild type (wt) and flavonoid 
enriched tomato, which is overexpressing the petunia chalcone isomerase1 (CHI1) gene 
and the Gerbera flavone synthase II (FNSII) gene as described previously (16, 17).
enzymatic hydrolysis and extraction of semi-polar metabolites
Tomato samples were enzymatically hydrolyzed using a method that has previously 
been described by (6). In short, enzymatically deglycosylated tomato methanolextracts 
were prepared by adding 500 μl of 0.1M sodium acetate buffer (pH 4.8) and 167 μl of 
Viscozyme L per gram tomato juice, followed by incubation in a waterbath at 37°C. After 
two hours of incubation, samples were put on ice and extracts were prepared by adding 
3 ml methanol per ml of deglycosylated tomato sample, followed by 10 minutes sonication 
and 15 minutes centrifugation at 1000 g. The supernatant was aliquoted in portions 
of 1.5 ml in eppendorf tubes. Methanol was evaporated under a nitrogen atmosphere 
and the remaining residue was dried using a centrifugal vacuum concentrator. The dried 
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extracts were stored at -80°C until further analysis. Prior to analysis, the dried extracts 
were re-dissolved in 375 µL DMSO:α-MEM without phenol red (1:4) and filtered through a 
Captiva 96-well 0.45µm polypropylene filter plate, (Agilent Technologies Netherlands B.V., 
Amstelveen). Samples were split to be used for either EpRE-mediated gene expression 
measurements or metabolomic analysis using LC-MS.
The freeze dried wt and flavonoid enriched tomato peel samples were first re-dissolved 
in water to give a final concentration of 60 mg dried sample/ml. Immediately thereafter, 
enzymatic hydrolysis and extraction were performed as described above. 
cell culture
Hepa-1c1c7 mouse liver hepatoma cells containing a stably transfected luciferase reporter 
gene under transcriptional control of an EpRE, as described by Boerboom et al. (18) and in 
this article further referred to as: EpRE-LUX cells, were cultivated in α-MEM, supplemented 
with FCS and 0.5 mg/ml G418 and 50 µg/ml gentamicin, under a humidified atmosphere 
with 5% Co2 at 37°C.
epre-lux assay
The EpRE-LUX cells were used to test the ability of deglycosylated tomato extracts to 
induce EpRE-mediated gene expression. Cells were plated onto 96-wells view plates by 
adding 100 μl EpRE-LUX cell suspension (2*105 cells/ml) to the inner 60 wells of the plate. 
In the outer wells 100 μl HBSS was added to maintain physical homogeneity throughout 
the plate. To allow the cells to attach to the bottom and to form a confluent monolayer, 
the 96-wells view plate was incubated for 24 hours. 
Exposure medium was prepared by adding 60 µl of the re-dissolved and filtered 
deglycosylated tomato extracts to 740 µl of α-MEM without addition of FCS and antibiotics, 
resulting in a final concentration of the tomato extracts tested in the EpRE-LUX assay of 
45 g FW/L. The final concentration of DMSO was kept at 1.5% (a concentration tested not 
to be toxic to the cells). As a positive control, each plate contained six wells with tBHQ, a 
well-known inducer of EpRE-mediated gene expression, at a final concentration of 15 μM. 
Furthermore, on each plate an additional six wells were used for the solvent control (1.5 % 
DMSO) and six wells for an extract of enzymatically hydrolyzed reference tomato sample.
After exposure of the EpRE-LUX cells to the tomato extracts for 24 hours under a 
humidified atmosphere with 5% CO
2 at 37°C, absence of cytotoxicity was checked visually 
using a microscope. Exposure medium was removed, cells were lysed using a low salt lysis 
buffer and at least overnight incubated at -80°C. Upon addition of flash mix, the luciferase 
activity (in relative light units (RLUs)) of the lysate was measured using a luminometer 
(Luminoscan Ascent, Termo Scientific, Waltham USA)(18).
Lc-ms machinery and methods
Semi-polar compounds present in the enzymatically deglycosylated tomato extracts were 
analysed using C18-reversed-phase liquid chromatography coupled to a photodiode 
array detector and a quadrupole time of flight high-resolution mass spectrometer (LC-
PDA-QTOF-MS) as described by de Vos et al. 2007 (19). In short, 5 µl of the re-dissolved 
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and filtered deglycosylated tomato extracts were injected in the LC-system. Separation 
was performed using degassed solutions of ultrapure water (eluent A) and acetonitrile 
(eluent B), both acidified with 0.1 % formic acid, which were pumped into the LC system 
with a flow rate of 190 µl/min. A linear gradient was applied increasing eluent B from 5% 
to 35% in 45 minutes. Hereafter, the column was washed and equilibrated at the initial 
conditions for 15 minutes before the next injection. After separation and detection of 
the semi-polar compounds by LC-PDA, positive electrospray ionization was applied and 
masses were detected using QTOF-MS.
lc-pda-Qtof-mS data processing and putative identification
The compound profiles obtained from LC-PDA-QTOF-MS were analysed using 
MassLynx (4.1)(Waters) after prepossessing using the MetAlign™ software package 
(http://www.metalign.nl) for baseline correction, noise estimation, and ion-wise mass 
spectral alignment (19). Noise was subtracted and signals that were present in at least 
six tomato accessions were selected for further processing using MS-CLUST software 
(http://www.metalign.nl) as described by Tikunov et al. (20). In short, MS-CLUST clusters 
signals that are derived from the same compound, such as isotopes, adducts and in-source 
fragments based on their signal intensity patterns and retention time over all samples, in 
order to remove data redundancy. This resulted in 313 reconstructed metabolite clusters 
(centrotypes) of which for each cluster the signal of the most unique mass was chosen as 
a representative for the respective cluster and was used for further (statistical) analysis.
For putative identification of the semi-polar compound clusters UV spectra, molecular 
weight and (in source) fragmentation patterns were used in combination with different 
metabolite databases such as the MotoDB (http://appliedbioinformatics.wur.nl/moto), 
Dictionary of Natural Products (http://dnp.chemnetbase.com).
downstream data processing and statistical procedures
For each experiment, at least three independent repetitions were performed. Within 
each experiment at least six technical replicates (six wells with cells were exposed to the 
same sample) were measured. Using Microsoft Excel 2010, EpRE-mediated luciferase 
induction of the different tomato accessions were expressed as the percentage of the 
luciferase induction by the reference sample (mix of all 97 tomato accessions) and the 
least significant difference (lsd) over all tomato accessions at a confidence level of 95% 
was calculated by one way ANOVA using IBM SPSS statistics 19 software package.
EpRE-mediated luciferase induction of the flesh and peel samples of the commercial 
tomato accession as well as the peel samples of the wt tomato and its transgenic high 
flavonoid line were expressed as the percentage of the luciferase induction by the 
reference sample (mix of all 97 tomato accessions) ± standard error of the mean (SEM). 
Statistical significance was assessed using the one-sided Student’s t-test with a significance 
threshold of α=0.01.
For further statistical analysis, intensities of the metabolomic dataset were log-
transformed and mean-centred. The log-normalised metabolomics data for the 7 highest 
and 7 lowest inducing tomato accessions were selected to perform principal components 
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analysis (PCA) using GeneMaths XT version 2.12. Furthermore, statistical significance was 
assessed using a two sided Student’s t-test with a significance threshold of α=0.05.
The log-transformed metabolomics data set was also used for a non-targeted correlative 
approach to find metabolites that show a correlation with the response in the EpRE-LUX 
assay of different tomato accessions. To do so, different statistical algorithms were applied 
using the web-based tool OmicsFusion (http://www.plantbreeding. wur.nl/omicsFusion/). 
This tool combines nine different statistical algorithms, including univariate regression, 
a machine learning algorithm (random forest), and a number of regularized regression 
techniques (principal components regression (PCR), partial least squares (PLS), and ridge 
regression) without variable selection and regularized regression analysis with variable 
selection (lasso regression, elastic net, and sparse PLS), to regress the EpRE-mediated 
luciferase induction on the metabolics dataset.
In order to identify which metabolites show significant correlation with EpRE-mediated 
luciferase induction, the Random Forest (RF) regression approach (21) was combined with 
a permutation test using the Random Forest package in the R statistical software package. 
First, RF was applied 100 times to correlate the metabolomics data with the EpRE-LUX 
response (based on increase in node purity values). Second, the EpRE-LUX luciferase 
levels of the 93 tomato samples were randomised 500 times and for each of these 
500 permutated sets RF was applied. The significance of each individual metabolite, was 
determined by the increase in mean square error after permutation. Significance levels 
were set at a permutation threshold of α=0.05.
ResuLTs ANd discussioN
epre-mediated luciferase induction by tomato lines
Deglycosylated extracts of 97 tomato accessions were tested for their ability to induce EpRE-
mediated gene expression using the EpRE-LUX assay (figure 1). Four of the 97 accessions 
caused cytotoxic effects and for this reason were not used for further analysis and are not 
shown in figure 1. Significant differences (one-way ANOVA, α=0.001) in EpRE-mediated 
luciferase induction between the 93 accessions were found. Induction of EpRE-mediated 
luciferase expression ranged from 52.5% to 151.9% relative to the reference tomato 
sample (a mix of all accessions used)(figure 1). The tomato collection thus showed almost 
three-fold variation in EpRE-controlled luciferase induction. This variation was used to 
link the potency of the tomato accessions to induce EpRE-mediated gene expression with 
their metabolic profiles in order to identify metabolites responsible for this potentially 
health beneficial effect.
metabolic contrasts
Deglycosylated tomato extracts that had been characterised with respect to EpRE-
mediated luciferase induction potential, were subjected to an untargeted metabolic 
profiling using Liquid Chomatography – Mass Spectrometry (LC-MS). MsClust was used to 
reduce redundancy in the LC-MS data, as described by Tikunov et al. (20). This resulted in 
313 unique molecular fragment clusters which each represent a putative compound mass 
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figure 1. Average (of n=3) luciferase induction in EpRE-LUX cells by enzymatically hydrolyzed tomato 
extracts of 93 different tomato accessions (45 g fresh weight/L) after 24 hours of exposure. Induction 
is given relative to the luciferase induction of a reference tomato sample (a mix of all individual 
samples used in this study). Samples are ordered in descending induction activity. The error bar 
represents the Least Significant Difference (LSD).
figure 2. Principal components analysis of the LC-MS data obtained from the 14 tomato accessions 
that showed either highest (dark dots) or lowest (light dots) EpRE-mediated luciferase induction. 
Clustering of these tomato accessions along the first three principal components (PC): PC1, PC2, 
and PC3 describe 42.1%, 19.4%, and 8.3% of the total metabolic variation between the 14 different 
accessions.
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spectrum. The metabolic clusters of the 7 accessions that showed at least 30% increased 
and the 7 accessions that showed at least 15% lower luciferase inductions compared to 
the reference sample were subjected to principal components analysis. A clear separation 
of the accession groups was observed (figure 2). This suggests that the difference in EpRE-
mediated gene expression levels observed in the two groups can be explained based 
on contrasts in metabolic profiles. 64 out of the 313 metabolites were selected to be 
most different between the two groups based on 2 criteria: (1) P<0.01 between the two 
accession groups in a two sided Students t-test and (2) the average intensity within the two 
accession groups needed to be at least 10-fold different. These 64 metabolites included 
most of the putatively annotated flavonoids, among which the aglycones quercetin and 
kaempferol (p = 0.0001 and p = 0.0003 respectively) which have previously been shown to 
be able to induce EpRE-mediated gene expression as pure compounds (6, 8). Interestingly, 
five out of the seven accessions that gave the highest EpRE-mediated luciferase induction 
in the EpRE-LUX assay, are high pigment (HP) ripening mutants. Such mutants are known 
to have elevated levels of carotenoids, flavonoids and vitamin C (5, 22, 23). Moreover, 
two of the seven lowest inducing accessions are white heirloom varieties which are 
generally low in flavonoid and carotenoid levels (23). Together these findings suggest that 
compounds such as flavonoids might play a role in the potential of tomato extracts to 
induce EpRE-mediated gene expression. 
Regression analysis
By using PCA it was possible to visualise clear metabolic contrast between the accessions 
that showed either highest or lowest expression of EpRE-mediated luciferase. In addition 
to this PCA, a non-targeted regression approach was used on all genotypes tested to 
find metabolites that are associated with induction of EpRE-mediated gene expression. 
A number of different regression approaches, each suitable for prediction of a trait from 
a high-dimensional ~omics data set were used. Metabolites were ranked per method 
based on the correlation and these ranks were combined to come to an overall ranking. 
These analyses were performed using the web-based tool omicsFusion. Compounds with 
highest combined ranking over all the methods have been (partly) annotated as flavonoid 
glycosides and flavonoid aglycones (Table 1). In a previous study, flavonoid glycosides 
could not induce EpRE-mediated gene expression (6) and their presence indicates 
that the enzymatic treatment was not sufficient to fully deglycosylate all flavonoid 
glycosides. Not surprisingly, the levels of glycosides show high correlation with the 
flavonoid aglycones, such asquercetin and kaempferol, which were able to induce EpRE-
mediated gene expression (6, 8). High ranking in the regression analysis in combination 
with shown activity make flavonoid aglycones the prime candidate metabolites present 
in the tomato extracts responsible for EpRE-mediated gene expression. The top ranked 
flavonoid aglycones were quercetin (ranking 12) and kaempferol (ranking 35). The 
flavonoid aglycones naringenin and eriodictyol show a weaker relationship and are 
ranked at position 75 and 85 respectively. Moreover, an isomer of chlorogenic acid, 
tri-caffeoylquinic acid, also showed a strong association (rank 8) with EpRE-mediated 
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Table 1. Top 35 metabolites that showed best association with EpRE-mediated gene expression by the 
93 tomato accession according to OmicsFusion and their putative identification.
of Rf incmse rt id mol form
m/z 
theory
m/z 
found 
ppm 
error fragments
1 9 0.002 23.54 Quercetin hexose pentose C26H28o16 597.1450 597.1472 3.6 465.10 – 303.05
2 10 0.006 32.41 Quercetin 3-O-beta-(6’’-O-E-p-coumaroylglucoside)-7-O-beta-blucoside C36H36o19 773.1924 773.1957 4.3 465.10 – 303.05
3 1 0.002 22.31 Quercetin-hexose-deoxyhexose, -pentose C32H38o20 743.2029 743.2046 2.2 611.16 – 465.10 – 303.05
4 3 0.002 31.52 Quercetin hexose C21H20o12 465.1028 465.1042 3.1 303.05
5 4 0.006 44.04 Unknown 1 659.2748
6 15 0.006 25.32 Quercetin 3-O-glucoside C21H20o12 465.1028 465.1042 3.1 303.05
7 2 0.002 41.15 Unknown 2 823.3423
8 8 0.012 39.22 Tri caffeoylquinic acid C34H30o15 679.1657 679.1696 5.7 499.12 – 517.13
9 7 0.002 44.50 Unknown 3 275.2018
10 31 0.040 27.32 Unknown 4 209.1554
11 12 0.050 36.90 Unknown 5 725.3073
12 5 0.002 37.39 Quercetin C15H10o7 303.0499 303.0498 0.5
13 23 0.014 25.00 Unknown 6 525.2372
14 11 0.004 24.57 Kaempferol hexose deoxyhexose pentose C32H38o19 727.2080 727.2113 4.5 595.40 – 449.10 – 287.05
15 26 0.004 30.99 Unknown 7 431.0632
16 25 0.074 26.80 Unknown 8 400.1406
17 18 0.002 20.62 Unknown 9 433.2109
18 27 0.090 30.82 Unknown 10 526.2215
19 30 0.234 42.84 Unknown 11 275.2000
20 20 0.048 41.78 Unknown 12 823.3432
21 37 0.018 24.33 Quercetin 3-O-rutinoside C27H30o16 611.1607 611.1602 0.8 465.10 – 303.05
22 28 0.226 36.44 Unknown 13 693.2795
23 16 0.004 39.73 Unknown 14 481.0793
24 22 0.126 30.32 Unknown 15 693.2784
25 44 0.034 15.94 Unknown 16 335.1351
26 29 0.022 14.82 Unknown 17 378.1679
27 96 0.259 25.75 Unknown 18 443.1900
28 68 0.331 41.99 Unknown 19 425.2536
29 71 0.581 2.26 Unknown 20 381.0792
30 36 0.515 14.44 Unknown 21 381.1175
31 32 0.216 11.84 Unknown 22 288.1913
32 72 0.353 26.63 Unknown 23 319.0523
33 13 0.030 33.12 Unknown 24 677.2855
34 14 0.044 32.90 Naringeninchalcone hexose C21H22o10 435.1311 435.1286 5.8 273.08
35 34 0.040 44.00 Kaempferol C15H10o6 287.0550 287.0555 1.7
Abbreviations: 
oF Rank omicsFusion
RF Rank Random Forest
incMSE Increase in mean square error after permutation (p-value) [Italic = p<0.05]
rt Retention time (minutes)
id Putative identification of the metabolite
mol form Molecular formula of the metabolite
m/z theory Theoretical monoisotopic mass calculated for the ion (M+H)+
m/z found Found m/z- mass detected in the experiment
ppm error Difference between theoretical and found m/z values in ppm
fragments Insource fragments
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Table 1. Top 35 metabolites that showed best association with EpRE-mediated gene expression by the 
93 tomato accession according to OmicsFusion and their putative identification.
of Rf incmse rt id mol form
m/z 
theory
m/z 
found 
ppm 
error fragments
1 9 0.002 23.54 Quercetin hexose pentose C26H28o16 597.1450 597.1472 3.6 465.10 – 303.05
2 10 0.006 32.41 Quercetin 3-O-beta-(6’’-O-E-p-coumaroylglucoside)-7-O-beta-blucoside C36H36o19 773.1924 773.1957 4.3 465.10 – 303.05
3 1 0.002 22.31 Quercetin-hexose-deoxyhexose, -pentose C32H38o20 743.2029 743.2046 2.2 611.16 – 465.10 – 303.05
4 3 0.002 31.52 Quercetin hexose C21H20o12 465.1028 465.1042 3.1 303.05
5 4 0.006 44.04 Unknown 1 659.2748
6 15 0.006 25.32 Quercetin 3-O-glucoside C21H20o12 465.1028 465.1042 3.1 303.05
7 2 0.002 41.15 Unknown 2 823.3423
8 8 0.012 39.22 Tri caffeoylquinic acid C34H30o15 679.1657 679.1696 5.7 499.12 – 517.13
9 7 0.002 44.50 Unknown 3 275.2018
10 31 0.040 27.32 Unknown 4 209.1554
11 12 0.050 36.90 Unknown 5 725.3073
12 5 0.002 37.39 Quercetin C15H10o7 303.0499 303.0498 0.5
13 23 0.014 25.00 Unknown 6 525.2372
14 11 0.004 24.57 Kaempferol hexose deoxyhexose pentose C32H38o19 727.2080 727.2113 4.5 595.40 – 449.10 – 287.05
15 26 0.004 30.99 Unknown 7 431.0632
16 25 0.074 26.80 Unknown 8 400.1406
17 18 0.002 20.62 Unknown 9 433.2109
18 27 0.090 30.82 Unknown 10 526.2215
19 30 0.234 42.84 Unknown 11 275.2000
20 20 0.048 41.78 Unknown 12 823.3432
21 37 0.018 24.33 Quercetin 3-O-rutinoside C27H30o16 611.1607 611.1602 0.8 465.10 – 303.05
22 28 0.226 36.44 Unknown 13 693.2795
23 16 0.004 39.73 Unknown 14 481.0793
24 22 0.126 30.32 Unknown 15 693.2784
25 44 0.034 15.94 Unknown 16 335.1351
26 29 0.022 14.82 Unknown 17 378.1679
27 96 0.259 25.75 Unknown 18 443.1900
28 68 0.331 41.99 Unknown 19 425.2536
29 71 0.581 2.26 Unknown 20 381.0792
30 36 0.515 14.44 Unknown 21 381.1175
31 32 0.216 11.84 Unknown 22 288.1913
32 72 0.353 26.63 Unknown 23 319.0523
33 13 0.030 33.12 Unknown 24 677.2855
34 14 0.044 32.90 Naringeninchalcone hexose C21H22o10 435.1311 435.1286 5.8 273.08
35 34 0.040 44.00 Kaempferol C15H10o6 287.0550 287.0555 1.7
Abbreviations: 
oF Rank omicsFusion
RF Rank Random Forest
incMSE Increase in mean square error after permutation (p-value) [Italic = p<0.05]
rt Retention time (minutes)
id Putative identification of the metabolite
mol form Molecular formula of the metabolite
m/z theory Theoretical monoisotopic mass calculated for the ion (M+H)+
m/z found Found m/z- mass detected in the experiment
ppm error Difference between theoretical and found m/z values in ppm
fragments Insource fragments
115
EpR
E-M
ED
IATED
 G
EN
E EXPR
ESSIO
N
 &
 97 TO
M
ATO
 VA
R
IETIES
6
luciferase induction. Some studies show that chlorogenic acid is able to induce EpRE-
mediated gene expression (24, 25). However, when chlorogenic acid was tested as a 
model compound in our cell assay, it was not shown to induce EpRE-mediated luciferase 
expression (6). Several unidentified metabolites are highly ranked for their correlation 
with the response in the EpRE-LUX (Table 1). It is not unlikely that these compounds 
might also (partially) play a role in the induction of EpRE-mediated gene expression by 
the tomato extracts. Interestingly, most of the high ranked unidentified metabolites have 
a retention time >30 minutes on C18 column, which suggests a more a-polar nature. 
Further identification of these compounds will be a major target of a follow-up study. 
Nevertheless, finding these unidentified metabolites shows that the use of reporter 
gene assays in combination with metabolomics could potentially lead to the discovery of 
“new” metabolites with potential health beneficial properties. 
random forest and permutation test for statistical significance
By combining several statistical algorithms, it was possible to relate the luciferase 
induction level as measured in the EpRE-LUX assay to metabolic profiles and to rank 
the importance of each individual metabolite. However, this approach does not give 
a significance level to individual metabolites. Therefore a Random Forest regression 
approach was performed in combination with a permutation test. This showed that 
24 metabolites have a significant correlation with EpRE-controlled reporter gene 
induction. Nine of these metabolites have been putatively identified and include 
flavonoid glycosides, tri-caffeoylquinic acid and quercetin, which shows to be most 
significant (permutation p-value< 0.002)(Table 1). 
Moreover, this approach also showed that the relationship between metabolites 
and EpRE-induced activity of the tomato accessions is statistically significant, since the 
non-permutated (true) data showed that the variance explained in RF (prediction R2) is 
significantly higher (R2 = 0.46 ± 0.01) than any of the prediction R2 of the permutated data 
sets (R2= -0.19 to 0.13 with an average of -0.05).
flesh vs. peel and wild type vs. genetically engineered high flavonoid tomato
To verify that flavonoid aglycones are a major factor responsible for the EpRE-mediated 
gene expression, extracts of enzymatically deglycosylated peel sample from a transgenic 
high flavonoid tomato and its corresponding wild type tomato (17) were tested in the 
EpRE-LUX assay. This flavonoid-enriched tomato contains significantly increased levels 
of kaempferol-rutinoside (37 fold), quercetin-rutinoside (19 fold), luteolin-glucoside, 
luteolin and quercetin (not detected in wt)(16, 17). These tomatoes were chosen since 
they contain the same genetic background, in contrast to the high and low EpRE-inducing 
accessions, which all have different genetic background and thus a different food matrix 
besides differences in flavonoid levels. Induction of EpRE-mediated luciferase appeared 
to be significantly higher in transgenic (80.1% relative to the reference tomato sample) 
compared to the wt tomato (55.6% relative to the reference tomato sample)(figure 3). 
Therefore it can be concluded that the difference in the potency to induce EpRE-
mediated gene expression is most likely due to the increased flavonoid levels present in 
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the transgenic peel extracts. This suggests that flavonoids present in tomato play a major 
role in the induction of EpRE-mediated expression. In the same experiment also peel and 
flesh sample from a commercial tomato accession have been tested for their ability to 
induce EpRE-mediated-expression. The peel sample showed significantly higher EpRE-
mediated luciferase induction (112.8 percent relative to the reference tomato sample) 
compared to flesh (53.9 percent relative to the reference tomato sample)(figure 3). 
Again, this indicates that flavonoids present in tomato extracts are good candidates 
for the induction of the Keap1/Nrf2/EpRE pathway, since flavonoids are known to be 
mainly present in peel and are hardly detectable in flesh (26). Despite the quantitative 
difference, both peel and flesh sample were able to significantly induce EpRE-mediated 
gene expression, although the levels of quercetin and kaempferol in tomato flesh were 
shown to be low (16, 27, 28). This indicates that in addition to flavonoids, also other 
metabolites may play a role in the induction of EpRE-controlled gene expression by tomato 
extracts. This was also suggested by a quantitative analysis of the levels of quercetin 
and kaempferolin the 93 tomato accessions. Quercetin levels ranged from 0 to almost 
1.1 µmol/gram fresh weight and kaempferol levels ranged from 0 to 0.35 µmol/gram 
fresh weight. For some of the 93 accessions, these levels of quercetin and kaempferol 
were sufficient to fully explain the EpRE-mediated luciferase induction based on the 
inducing activity of pure compounds (6), whereas for several other accessions these 
levels are too low to explain induction. This again indicates that there may be other 
metabolites present in the tomato extracts which are also able to induce EpRE-mediated 
gene expression. 
figure 3. Luciferase activity is induced in the EpRE-LUX reporter cells by 24 hour exposure to 
enzymatically hydrolyzed extracts (27.5 g fresh weight/L) of flesh and peel of a commercial tomato 
accession and of peel samples of a transgenic, high flavonoid tomato and its wild-type. Luciferase 
induction is expressed as induction factor compared to solvent control. Error bars represent the 
± SEM of 12 replicates. Asterisks (*) indicate a significant difference from the solvent control: p < 0.01.
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coNcLusioN
In this study, 97 different tomato accessions were screened for their ability to induce 
EpRE-mediated gene expression. The 93 accessions that did not show cytotoxicity were 
all able to induce EpRE-mediated gene expression, with a three-fold difference between 
the most potent and the least potent accession. The variation in EpRE-mediated gene 
expression between the accessions was combined with the metabolic profiles of the 
tomatoes and showed a significant correlation between the metabolites present and 
EpRE-inducing ability of the tomato accessions. It was shown that the flavonoid aglycone 
quercetin can partly explain the EpRE-inducing ability of the semi-polar extracts of 93 
enzymatically deglycosylated tomato accessions. Yet, it seems that also other metabolites 
present in the extracts play a role in EpRE-mediated gene induction and that activity of the 
complex tomato extracts in the EpRE-LUX assay cannot simply be explained by flavonoid 
aglycones only. Even the semi-polar tomato extracts, that represent only a part of the 
complete tomato metabolome, are complex mixtures of many metabolites that are likely 
to interact with each other and/or cellular components present in the hepatoma cell line. 
Additive, synergistic or even antagonistic effects are likely to play a role (29). Although 
the extraction and detection methods show limitations by only representing the semi-
polair metabolites present in the tomato metabolome, this study shows a clear example 
on how cell-based reporter gene assays, such as the EpRE-LUX assay, might provide useful 
tools for breeders and/or food (processing) industry to make a fast selection of varieties/
processing methods, that result in products with a composition of active ingredients 
optimal for inducing specific health beneficial gene expression pathways. Furthermore, 
it was shown that combining the output of these cell based reporter gene assays with 
metabolome analysis enables putative identification compounds that might be responsible 
for the health beneficial effects. This might also be of interest for the discovery of “new” 
potentially health-beneficial metabolites.
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discussioN 
The use of functional foods, such as margarines with plant sterols, fruit juice enriched 
with calcium and cereals with (soluble) fibre, has increased rapidly during the last years 
(1-3). The world health organisation (WHO) defines a functional food as “any food claiming 
to have a health-promoting or disease-preventing property beyond the basic function of 
supplying nutrients”. The health-promoting effects of functional foods may be (partly) 
due to the presence of bioactive compounds (4, 5). In order to predict health-promoting 
effects of functional foods and to identify bioactive compounds accounting for these 
effects, tools for identification of bio-functional characteristics of food items are essential. 
Reporter gene assays may be fast and useful tools to facilitate detection of effects of food 
products and bioactive compounds present in these foods, on gene expression pathways. 
Therefore, the aim of this thesis was to develop and validate stable reporter cell lines for 
several health-related endpoints and to demonstrate their usefulness by assessing tomato 
extracts and bioactive compounds known to be present in tomato fruits. 
Three health-related endpoints were chosen for this approach; electrophile 
response element (EpRE)-mediated gene expression, peroxisome proliferator-activated 
receptor γ (PPARγ)-mediated gene expression and peroxisome proliferator-activated 
receptor α (PPARα)-mediated gene expression. Genes regulated by EpRE include phase II 
detoxifying enzymes, which stimulate the conversion of reactive electrophiles into less 
toxic metabolites which can be easily excreted from the body (6, 7). In this way, phase II 
enzymes may be able to detoxify carcinogenic metabolites and help in the protection 
against carcinogenesis (6, 8, 9). The second selected endpoint was activation of PPARγ 
and PPARγ-mediated gene expression. PPARγ is an important stimulator of lipogenesis 
and adipogenesis (10, 11) and activation of PPARγ has been related to improved insulin 
sensitivity in patients with type 2 diabetes mellitus (12). The third and last selected 
endpoint was activation of PPARα and PPARα-mediated gene expression. PPARα is an 
important factor in lipid metabolism (13, 14) and activation of PPARα has been related to 
improved lipid levels in plasmaincluding an increase in HDL cholesterol and a decrease in 
LDL cholesterol and triglyceride plasma levels (15-17).
In order to test fruits and vegetables for the selected functions in reporter gene assays, 
extraction methods for vegetables and fruits are needed which result in extracts suitable 
for testing in reporter gene assays. In chapter 2 of this thesis, methods are described to 
prepare three tomato extracts: an isoprenoid-containing tomato extract, a nonhydrolyzed 
tomato extract containing semi-polar compounds, and an enzymatically hydrolyzed 
tomato extract containing deglycosylated semi-polar compounds. EpRE-LUX reporter cells 
were exposed to these tomato extracts and all three tomato extracts were compatible 
with the EpRE-LUX reporter cells. The isoprenoid-containing chloroform extract of tomato 
fruit was unable to induce EpRE-regulated gene expression, which was in line with the 
finding that most individual isoprenoids also were unable to do so. The nonhydrolyzed 
tomato extract also failed to induce EpRE-regulated gene expression, just as the flavonoid 
glycosides failed to induce this response. The enzymatically hydrolyzed tomato extract 
was able to induce EpRE-mediated luciferase expression, both at mRNA level and at 
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protein level. Furthermore, the flavonoid aglycones quercetin, kaempferol, naringenin 
and naringenin chalcone were also able to induce EpRE-mediated gene expression and 
may therefore contribute to the induction seen with the enzymatically hydrolyzed tomato 
extract. So, tomato extracts and tomato compounds were able to induce EpRE-mediated 
gene expression in vitro. Whether tomato consumption indeed leads to EpRE-mediated 
up-regulation of phase II enzymes and to protection against cancer, should be endorsed 
by results from in vivo studies. From literature it is known that in mice, a combination of 
tomato and garlic leads to increased activity of the phase II enzyme GST and to reduced 
frequencies of chemically-induced genotoxicity (18). This indicates that tomato may 
indeed induce EpRE-mediated changes in gene expression and may thereby increase 
the levels of phase II detoxifying enzymes, which in turn may play a role in protection 
against cancer. Altogether, results presented in chapter 2 suggest that induction of EpRE-
regulated genes, such as detoxifying phase II and antioxidant enzymes, may contribute to 
the beneficial health effects of tomato (19). 
In chapter 3, two reporter gene assays, PPARγ1 CALUX and PPARγ2 CALUX, were 
developed in order to enable fast and low-cost measurement of PPARγ agonist and 
antagonist activity. These cell lines were constructed by stable transfection of U2OS cells 
with an expression vector for PPARγ1 or PPARγ2, and a pGL3-3xPPRE-tata-luc or pGL4-
3xPPRE-tata-luc reporter construct, respectively. PPARγ1 CALUX and PPARγ2 CALUX cells 
showed similar concentration-dependent luciferase induction upon exposure to several 
well-known PPARγ agonists. The potency to induce PPARγ-mediated gene expression of the 
investigated PPARγ agonists decreased in the following order: rosiglitazone > troglitazone 
= pioglitazone > netoglitazone > ciglitazone. A concentration-dependent decrease in the 
response to 50 nM rosiglitazone was observed upon addition of the PPARγ antagonists 
GW9662 or T0070907, both in PPARγ1 CALUX and PPARγ2 CALUX cells, suggesting that 
the response was indeed mediated by PPARγ activation. The PPARα agonists WY14643 
and fenofibrate failed to induce luciferase activity, confirming the specificity of these cell 
lines for PPARγ agonists. It was concluded that PPARγ1 CALUX and PPARγ2 CALUX cells 
presented in this chapter provide a reliable and useful tool to screen (bio-)chemicals for 
PPARγ agonist or antagonist activity (20).
Since beneficial effects related to tomato consumption partially overlap with those 
related to PPARγ activation, the aim of chapter 4 was to test extracts of tomato fruits and 
tomato components, including polyphenols, isoprenoids and fatty acids, for their potency 
to activate PPARγ. Thirty tomato compounds were investigated, of which seven carotenoids 
and three polyphenols were able to induce PPARγ2-mediated gene expression. This is in 
line with the findings that two extracts of tomato fruit, one isoprenoid-containing tomato 
extract and one enzymatically hydrolyzed tomato extract containing deglycosylated 
phenolic compounds, also induced PPARγ2-regulated expression at physiologically 
relevant concentrations. Furthermore, enzymatically hydrolyzed extracts of seven tomato 
varieties were all able to induce PPARγ-mediated expression, with a 1.6 fold difference 
between the least potent and the most potent variety. The two most potent varieties had 
high flavonoid content, while the two least potent varieties had low flavonoid content, 
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suggesting that the differences in potency to induce PPARγ-mediated gene expression 
may be partly explained by the differences in levels of kaempferol and naringenin and/
or other flavonoids. Mixtures of the tomato components kaempferol, naringenin and 
β-carotene were found to produce an additive effect, showing that various classes of 
bioactive compounds might be involved in induction of the PPARγ-mediated response 
observed with the tomato extracts. Activation of PPARγ has been related to improved 
insulin sensitivity in patients with type 2 diabetes mellitus and here it was shown that 
tomato and phytochemicals present in tomato are able to induce PPARγ-mediated gene 
expression. Literature data confirming that consumption of tomato also leads to PPARγ-
mediated effects on insulin sensitivity and glucose tolerance in vivo are currently lacking. 
In summary, the data in chapter 4 indicate that tomato fruits and tomato compounds are 
able to induce PPARγ-mediated gene expression, and that some tomato varieties are more 
potent than others. Moreover, these data indicate that induction of PPARγ2-mediated 
transcription by tomato compounds may contribute to the beneficial effects associated 
with tomato consumption. 
The development and validation of a stable reporter gene assay for PPARα-mediated 
gene expression, called the PPARα CALUX assay, was described in chapter 5. The PPARα 
CALUX cells showed a concentration-dependent increase of PPARα-mediated luciferase 
activity upon exposure to the PPARα agonists GW7647, GW9578, WY14643 and bezafibrate. 
The newly developed PPARα CALUX assay was then used to test tomato extracts as well 
as individual tomato components, including flavonoids and carotenoids, for their potency 
to activate PPARα-mediated gene expression. An isoprenoid-containing extract of tomato 
was able to induce PPARα-mediated gene expression, which is in line with our findings that 
β-carotene, γ-carotene and lycopene induce PPARα-mediated gene expression as well. In 
addition, it was shown that an extract of tomato containing semi-polar compounds is 
only a weak inducer of PPARα-mediated gene expression, but that enzymatic hydrolysis 
of the tomato homogenate before extraction greatly increases its potency. This is in line 
with our findings that none of the flavonoid glycosides is able to induce PPARα-mediated 
gene expression, but that the aglycones kaempferol and naringenin are able to do so. 
Furthermore, of the seven tomato varieties tested for their capacity to induce PPARα-
mediated gene expression, the varieties showing the highest potency are also the ones 
containing the highest amounts of kaempferol and naringenin. Although this suggests 
that naringenin and kaempferol would contribute to the induction of PPARα-mediated 
gene expression found with the enzymatically hydrolyzed tomato extracts, the actual 
levels of kaempferol and naringenin detected in the extracts cannot fully explain the 
high (up to 12-fold) induction found with these tomato varieties. Presumably there are 
more, yet unidentified PPARα-activating compounds present in tomato. Tomato and 
its phytochemicals were shown to induce PPARα-mediated gene expression in vitro, 
and in vivo data are needed to confirm that PPARα activation by tomato and tomato 
compounds leads to beneficial health effects in vivo. Data from literature indicate that 
tomato consumption leads to decreased blood pressure, decreased total cholesterol and 
LDL cholesterol levels, and decreased myocardial lesions after myocardial infarctions in vivo 
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(21-24), although it is not shown that these effects are PPARα-dependent. Altogether, the 
data presented in chapter 5 indicate that the beneficial effects associated with tomato 
consumption may be partly explained by induction of PPARα-mediated gene transcription 
by tomato compounds. 
In order to corroborate that reporter gene assays are capable to reveal potency 
differences between different tomato varieties, extracts of 97 different tomato accessions 
were screened for their capacity to induce EpRE-mediated reporter gene expression in 
the EpRE-LUX assay in chapter 6. There was almost three-fold difference in the observed 
luciferase activity between the least potent tomato variety and the most potent tomato 
variety. Metabolomic profiles of the 97 extracts were generated in order to identify 
phytochemicals responsible for the differences in potency between these 97 tomato 
varieties to induce EpRE-mediated gene expression. By combining the reporter gene 
assay data with the metabolic profile of each tomato extract, and performing multivariate 
analysis, it was possible to identify the flavonoid aglycone quercetin as one of the main 
compounds responsible for the ability of tomato extracts to induce EpRE-mediated gene 
expression. However, spiking the low-quercetin tomato extracts with extra quercetin did 
not always result in proportional activation. This indicates that matrix effects may play 
a role. It also seems likely that some yet unidentified compounds contribute to EpRE-
mediated gene expression induced by tomato extracts. The results presented in chapter 
6 indicate that combining data from reporter gene assays with metabolomics data of 
tomatoes presents a powerful approach towards the identification of health beneficial 
constituents of foods.
It was shown in chapters 2, 4 and 5 that reporter gene assays can be implemented in 
screening bioactive food compounds as well as whole fruit and vegetable extracts for their 
capacity to modulate transcription factor-mediated gene expression. Reporter gene assays 
are rapid and low-cost assays which are easy to perform. Using reporter gene assays, many 
compounds can be screened for their effects on gene expression mediated by a specific 
receptor, in a short period. Reporter cell lines, however, contain only one cell type, and 
therefore miss the interaction with other cell types which is occurring in tissues, organs 
and organ systems in in vivo studies. This means that results from reporter gene assays 
cannot be directly translated into in vivo effects (25). So, although our data presented 
in chapters 2, 4 and 5 indicate that tomato extracts and tomato compounds are able to 
induce EpRE-, PPARγ- and/or PPARα-mediated gene expression, in vivo experiments are 
needed to confirm that activation of these pathways by tomato and its phytochemicals 
also leads to EpRE-, PPARγ- and/or PPARα-mediated gene expression and possible related 
health effects in vivo. On the other hand, reporter gene assays are useful in a tiered 
screening approach enabling testing of many food items and/or food compounds and 
making a selection of the most interesting ones for further in vivo testing. In this way, the 
use of reporter gene assays may lead to a reduction in animal experiments. This is relevant 
in view of both economic and animal welfare perspectives. 
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In the three reporter gene assays used in this thesis, the induction found with tomato 
extracts is higher than expected based on the data of individual phytochemicals investigated 
so far. Additive and/or synergistic effects may occur in mixtures of phytochemicals, as 
reported in chapter 5 and in literature (26, 27). Furthermore, a matrix effect may enhance 
the effects of phytochemicals in whole tomato extracts but may be absent when testing 
individual compounds. For example, the cellular uptake, bioactivation and biodegradation 
of a compound might be influenced by the surrounding matrix (28). Furthermore, for 
PPARγ and PPARα, it is known that they bind to the peroxisome proliferator-response 
element (PPRE) as a heterodimer with RXR (29, 30). If tomato contains phytochemicals 
which are able to activate RXR, this may (partly) explain the high induction found with 
tomato extracts. Last but not least, other, yet unidentified compounds in tomato may be 
contributing to the effects on EpRE-, PPARγ- and PPARα-mediated gene expression.
fuTuRe PeRsPecTives
In chapter 2 of this thesis, a robust method was developed to prepare crude extracts of 
ripe tomato fruits that are compatible with cell-physiological and cell culture conditions 
and thus enable testing of these extracts in the cell-based EpRE-LUX reporter assay. It 
was shown in chapters 4 and 5 that these extraction methods also enabled the testing 
of whole tomato extracts in other reporter cell lines. Furthermore, in chapters 4, 5 and 
6 it was shown that it is possible to detect differences between extracts of different 
tomato varieties in inducing transcription factor-mediated gene expression in reporter 
gene assays. This means that reporter gene assays provide a fast and low-cost method for 
breeders to select tomato varieties with an optimal composition of bioactive ingredients 
for inducing specific health-beneficial gene expression pathways. A next step could be to 
verify that this method is also applicable to other fruits and vegetables. 
In a pilot study, nonhydrolyzed extracts and enzymatically hydrolyzed extracts of 
Brussels sprouts, Braeburn apple, broccoli and onion were prepared using the methods 
described in chapter 2 of this thesis. All extracts were compatible with cell-physiological and 
cell culture conditions and induced EpRE-mediated and PPARγ-mediated gene expression. 
Interestingly, nonhydrolyzed extracts of all four vegetables and fruits showed an induction 
in both the EpRE-LUX assay (figure 1A) and the PPARγ2 CALUX assay (figure 1B), while 
tomato only showed induction after enzymatic hydrolysis. The enzymatically hydrolyzed 
extracts of braeburn apple, broccoli and onion and Brussels sprouts gave an induction 
up to 25-fold in the EpRE-LUX assay (figure 1C) and an induction of 10- to 20-fold in the 
PPARγ CALUX assay (figure 1D). Especially broccoli and Brussels sprouts, both belonging 
to the cruciferous vegetables, showed a high capacity to induce EpRE-mediated gene 
expression. These data suggest that besides polyphenols, other compounds present in 
braeburn apple, onion, broccoli and Brussels sprouts are able to induce EpRE-mediated 
and PPARγ-mediated gene expression. Glucosinolates may be a good candidate, as they are 
present in cruciferous vegetables (like broccoli and Brussels sprouts) and as metabolites of 
glucosinolates, such as isothiocyanates have been shown before to induce EpRE-mediated 
gene expression (31, 32). 
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As a next step, it would be interesting to verify that the extraction methods described 
in chapter 2 can also be applied to processed foods, such as tomato sauce, tomato 
juice, tomato ketchup and tomato soup. Results thus obtained will reveal whether food 
processing has an effect on the capacity of tomato and its phytochemicals to induce 
health-beneficial gene expression pathways. Furthermore, it may provide a useful tool 
for food industry in selecting food items with optimal capacity to induce specific health-
beneficial gene expression pathways and/or to adapt food processing procedures to make 
products that optimally retain bioactivity.
figure 1. Luciferase activity is induced in EpRE-LUX cells (left panels, A and C) and PPARγ CALUX 
cells (right panels, B and D) upon exposure to nonhydrolyzed extracts (upper panels, A and B) and 
enzymatically hydrolyzed extracts (lower panels, C and D) of onion (white), Braeburn apple (light 
grey), broccoli (mid-grey) and Brussels sprouts (dark grey). The concentration of the extracts is given 
as gram fresh weight (FW) per liter.
In chapter 6, 97 different tomato varieties were tested for their capacity to induce EpRE-
mediated gene expression using the EpRE-LUX assay. By combining these EpRE-LUX data 
with metabolic profiles of the same tomato extracts and performing multivariate analysis, 
the flavonoid aglycone quercetin was identified as a major compound responsible for the 
ability of tomato extracts to induce EpRE-mediated gene expression. As shown in chapter 5, 
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the induction of PPARα-mediated gene expression found with enzymatically hydrolyzed 
tomato extracts cannot be fully explained by the presence of flavonoid aglycones in these 
extracts. Presumably, there are more, yet unidentified bioactive compounds present in 
the enzymatically hydrolyzed tomato extracts. Testing more tomato varieties in the PPARα 
CALUX cell line and combining these data with metabolomic profiles of these tomato 
varieties may be of use in the identification of tomato compounds contributing to the 
induction of PPARα-mediated gene expression. In the same way, the methods described 
in chapter 6 may be of use in identifying phytochemicals contributing to the induction 
of EpRE-mediated and/or PPARγ-mediated gene expression observed with extracts of 
broccoli, Brussels sprouts, Braeburn apple and onion. 
This thesis focusses on the beneficial health effects related to EpRE-mediated, PPARγ-
mediated and PPARα-mediated gene expression. However, activation of the Nrf2/EpRE 
system and of PPARγ also have been related to adverse effects for human health. 
Nrf2 has been related to cancer prevention by protecting against cancer cell formation, 
but also to cancer promotion. Permanent activation of Nrf2 has been reported to promote 
the survival of cancer cells and resistance to chemotherapy (33, 34). In some cancer 
types – including cancers in lung, gall bladder and neck – mutations of Keap1 and Nrf2 
leadingto a permanent activation of the Nrf2/EpRE system were found, which was related 
to increased survival of tumour cells and resistance of these cancer cells to chemotherapy 
(33, 34). Bioactive compounds from foods, however, will presumably lead to transient 
activation of Nrf2 and not to permanent activation. 
Besides the beneficial health effects of PPARγ activation, PPARγ activation by 
thiazolidinediones (TZDs) has also been related to adverse effects. TZDs are a group of 
PPARγ agonists shown to improve insulin sensitivity in patients suffering from diabetes 
mellitus type 2 (35, 36). Besides their effect on insulin sensitivity, well-known adverse 
effects of TZDs have been reported. First of all, compound specific adverse effects have been 
reported. Troglitazone and rosiglitazone were both taken from the market; troglitazone 
for its liver toxicity (37), and rosiglitazone due to concerns about its cardiovascular safety 
(38). Pioglitazone is still prescribed in most European countries, but in France and Germany 
it was taken from the market due to increased risk of bladder cancer (39). Furthermore, 
more general side effects have been reported. Full-PPARγ agonists – including TZDs – have 
clear therapeutic effects on insulin sensitivity and hyperglycemia, but are also related to 
adverse effects like edema, fluid retention and weight gain (40). Currently, it is believed 
that selective PPARγ modulators, SPPARMs, may have the same clinical benefits as TZDs, 
but without their adverse effects (41, 42). The SPPARM concept may be promising in the 
continuing search for new, safer PPARγ-activating drugs.
Besides the degree of PPARγ activation, also the duration of PPARγ activation plays an 
important role. It is to be expected that bioactive compounds from food lead to a transient 
activation of PPARγ maintaining metabolic flexibility. In long-term, or even permanent 
PPARγ activation (which can for example be caused by mutations), this metabolic flexibility 
may be compromised. 
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The market for functional foods is still growing and, given the EU requirements, there is 
a major interest to scientifically support beneficial effects of functional foods and their 
bioactive ingredients. In this thesis, it was shown that reporter gene assays provide a 
reliable and useful tool to screen extracts of fruits and vegetables for their capacity 
to induce transcription factor-mediated gene expression. The next question is if and 
how reporter gene assays can be useful in supporting nutrition and health claims for 
functional foods.
Health claims are defined by the European Food Safety Authority (EFSA) as “any claim 
that states, suggests or implies that a relationship exists between a food category, a food or 
one of its constituents and health.” EU regulation 1924/2006 became effective in January 
2007, stating that only health claims approved by the European Commission are allowed 
(43). Health claims are divided into article 13 claims and article 14 claims. Article 14 claims 
refer to a reduction of disease risk or to the growth, development and health of children. 
These claims need individual authorisation based on extensive scientific support. Article 
13 claims refer to the role of a food compound in growth, development and functions of 
the body; psychological and behavioural functions; or slimming, weight reduction and 
satiety. Article 13 claims are subdivided into two categories: article 13.1 claims and article 
13.5 claims. Article 13.1 claims are supported by generally accepted scientific data, while 
article 13.5 claims are based on new scientific data. Once an article 13 claim is approved it 
can be generally used without the necessity of approval for each product (43).
PPARγ activation may be an interesting target for health claims, as PPARγ activation is 
related to many beneficial effects in several diseases and physiological processes (table 1 in 
the general introduction of this thesis) and PPARγ can be activated by bioactive ingredients 
in food. A possible health claim related to PPARγ could be: “This product contains PPARγ 
agonists; PPARγ agonists increase insulin sensitivity”. This possible health claim would be 
an article 13.1 health claim, which means that once this health claim is approved, any 
product containing PPARγ agonists is allowed to contain this claim (43). The PPARγ2 CALUX 
cell line can then be used as a fast and low-cost tool to identify functional foods or food 
constituents functioning as PPARγ agonists. For the approval of such a health claim, it is 
important to provide data showing a causal relationship between consumption of the food 
product or food constituent and the beneficial health effect, preferably in human studies. 
Activation of PPARγ by thiazolidinediones (TZDs), a class of synthetic PPARγ agonists which 
were able to induce PPARγ-mediated gene expression in our newly developed PPARγ assay, 
improves insulin sensitivity in human (44-47), showing a cause-effect relationship between 
TZDs and insulin sensitivity. This mere fact may by itself not prove that the effect is PPARγ-
dependent. It has, however, been shown that the minimum effective dose (MED) of TZDs 
for antihyperglycemic activity in ob/ob mice is closely related to their EC
50 value for PPARγ 
activation in an in vitro reporter gene assay (48). These findings suggest that the influence 
of TZDs on insulin sensitivity is mediated by PPARγ. Human intervention studies showing 
an effect of natural PPARγ agonists on insulin sensitivity are presently not available. 
There is evidence, however, showing that insulin resistant volunteers had lower plasma 
concentrations of β-carotene (49) and that plasma concentrations of β-carotene and 
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lycopene are lower in subjects with impaired glucose tolerance or diabetes (50). Besides 
evidence for a cause-and-effect relationship, it is important to provide evidence showing 
that the claimed effect is relevant for human health in the target population (43). In their 
opinion on earlier health claim applications, insulin sensitivity was considered a beneficial 
physiological effect by the NDA Panel of EFSA (51).
It was shown in this thesis that reporter gene assays may give insight in the effects 
of fruit and vegetable extracts on the activation of specific transcription factors and 
subsequent modulation of gene expression patterns. By testing fruit and vegetable 
extracts in multiple reporter gene assays, a more complete picture of the overall health 
effect will be generated. For example, it would be of interest to include an assay for RXR, 
the dimerizing partner of PPARs. Including a reporter gene assay for PPARβ/δ would be 
useful to discriminate between specific agonists for one PPAR isotype and dual/pan PPAR 
agonists activating two (dual) or all three (pan) PPAR isotypes. Furthermore, reporter gene 
assays for other health-related transcription factors could be included. Insulin sensitivity 
is for example not only influenced by PPARγ, but also fork head box O1 (FOXO1) plays a 
role. FOXO1 is a major target of insulin and supresses insulin sensitivity (49). Agonists 
of FOXO1 may counteract the effects of PPARγ activation and antagonists of FOXO1 may 
amplify the effects of PPARγ agonists. Therefore, a reporter gene assay for FOXO1 may be 
an interesting addition to the presently described panel of reporter gene assays. 
Combining the results of multiple reporter gene assays with metabolomic profiling 
of these fruit and vegetable extracts may give insight in compounds contributing to the 
effects on transcription factor activation and subsequent modulation of gene expression. 
This approach of combining multiple reporter gene assays and metabolomic profiling, is 
very useful in fast screening of many food items and food compounds. Therefore, the use of 
reporter gene assays as a first tier in a tiered approach aiming at supporting health claims 
will limit the number of animal studies and human studies needed, by enabling the ranking 
and selection of highly promising food items or constituents for further in vivo testing. 
In this thesis, we focussed mainly on the polyphenols and carotenoids present in tomato. 
Flavonoids are present in tomato mainly in the form of glycosides. In EpRE-LUX, PPARγ 
CALUX and PPARα CALUX reporter gene assays, it was observed that flavonoid glycosides 
failed to induce luciferase expression, and this also holds for the nonhydrolyzed tomato 
extracts containing (amongst others) flavonoid glycosides (19, 26, 52). This may be a 
consequence of poor uptake of flavonoid glycosides into the reporter cells. Once the tomato 
extract was enzymatically hydrolyzed in order to remove glycosyl groups, its capacity to 
induce EpRE-mediated, PPARγ-mediated and PPARα-mediated gene expression drastically 
increased. In addition, it was shown in chapters 2, 4 and 5 that flavonoid aglycones, 
unlike flavonoid glycosides, were able to induce EpRE-mediated, PPARγ-mediated and 
PPARα-mediated gene expression. Deglycosylation of flavonoid glycosides also occurs 
in vivo: before or during uptake flavonoid glycosides are enzymatically deglycoslated in 
the intestine by β-glucosidase enzymes (53, 54). Once taken up, the flavonoid aglycones 
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are quickly metabolized, mainly into flavonoid glucuronides and other conjugates (54). 
Carotenoids are metabolised as well after uptake (55-57). As metabolism of flavonoids 
and carotenoids may affect their bioactivity, future studies focussing on metabolites of 
flavonoids and carotenoids would be useful. For example, liver cells and/or intestinal 
cells may be exposed to (mixtures of) food compounds and fruit and vegetable extracts. 
During exposure, metabolism of the bioactive compounds takes place and metabolites are 
excreted into the culture medium. This metabolite-containing culture medium may then 
be used to expose the reporter cells with. Lee-Hilz and colleagues showed that after 24 h 
incubating liver cells with quercetin, the culture medium contains various metabolites 
(mainly glucuronides) and that these metabolites are able to induce EpRE-mediated gene 
expression (58). 
coNcLusioN
In conclusion, the work presented in this thesis reveals that tomato extracts as well as 
phytochemicals present in tomato are able to induce gene expression controlled by the 
EpRE or mediated by the transcription factors PPARγ or PPARα. Methods were presented 
to generate extracts of fruits and vegetables which are suitable for investigation in reporter 
gene assays. In addition, three reporter gene assays, PPARγ1 CALUX assay, PPARγ2 CALUX 
assay and PPARα CALUX assay were developed and validated within this project. Last but 
not least, this thesis showed that reporter gene assays are able to pick up differences 
in modulation of transcription factor-mediated gene expression by different varieties of 
tomato. This indicates that reporter gene assays can be used as fast and useful tools to 
select crop varieties with health-beneficial traits or food processing methods that lead to 
an improved content of possible health-beneficial phytochemicals.
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Summary 
The consumption of food products with health-promoting properties, such as margarines 
with plant sterols, fruit juice enriched with calcium and cereals with (soluble) fibre, has 
increased rapidly during the last years. The present thesis provides proof-of-principle that 
reporter gene assays are effective tools to investigate the effects of functional foods and 
food compounds on transcription factor-mediated gene expression. 
In order to test fruits and vegetables for selected functions in reporter gene assays, 
extraction methods for vegetables and fruits are needed which result in extracts suitable 
for testing in reporter gene assays. In chapter 2, methods are described to prepare three 
tomato extracts: 
• a nonhydrolyzed tomato extract containing apolar compounds such as isoprenoids, 
further referred to as isoprenoid-containing tomato extract, 
• a nonhydrolyzed extract containing semi-polar compounds, further referred to as 
nonhydrolyzed tomato extract,
• an extract of enzymatically hydrolyzed tomato, containing deglycosylated semi-polar 
compounds and further referred to as hydrolyzed tomato extract. 
All three tomato extracts were compatible with cell-physiological and cell culture 
conditions and tested in the EpRE-LUX assay. Both the isoprenoid-containing chloroform 
extract of tomato fruit and most individual isoprenoids (except for neurosporene) were 
unable to induce EpRE-mediated gene expression. The nonhydrolyzed tomato extract as 
well as the flavonoid glycosides were not able to induce EpRE-mediated gene expression. 
The enzymatically hydrolyzed tomato extract, containing deglycosylated polyphenols, 
was able to induce EpRE-mediated luciferase expression at both mRNA level and protein 
level. In line with this finding, the flavonoid aglycones quercetin, kaempferol, naringenin 
and naringenin chalcone also induced EpRE-mediated gene expression and these four 
flavonoid aglycones may therefore contribute to the gene expression induction seen 
with the enzymatically hydrolyzed tomato extract. Together, the results presented in 
chapter 2 suggest that induction of EpRE-regulated genes, such as detoxifying phase II 
and antioxidant enzymes, may contribute to the beneficial health effects of tomato.
chapter 3 of this thesis describes the development and validation of two newly 
developed stable reporter gene assays; the PPARγ1 CALUX assay and the PPARγ2 CALUX. 
It was shown that the newly developed stable reporter cell lines PPARγ1 CALUX and 
PPARγ2 CALUX specifically respond to agonists for PPARγ, and that these reporter cell 
lines provide a reliable and useful tool to screen (bio-)chemicals for PPARγ agonist or 
antagonist activity.
As beneficial effects related to PPARγ activation partially overlap with those associated 
with tomato consumption, tomato components and extracts of tomato fruits were tested 
for their capacity to induce PPARγ-mediated gene expression in chapter 4. Thirty tomato 
compounds were selected based on their presence in tomato fruit and were investigated 
using the PPARγ2 CALUX cells. Of these compounds, three fatty acids, seven carotenoids 
and three polyphenols were able to induce PPARγ2-mediated gene expression. In line 
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with these findings, both the isoprenoid-containing tomato extract and the enzymatically 
hydrolyzed extract, containing deglycosylated phenolic compounds, also induced PPARγ-
mediated gene expression. These data indicate that induction of PPARγ-mediated 
transcription by tomato compounds may contribute to the beneficial effects associated 
with tomato consumption. 
In chapter 5, the development and validation of a newly developed PPARα CALUX 
reporter assay is described. Tomato extracts as well as individual tomato components, 
including flavonoids and carotenoids, were tested for their capacity to activate PPARα-
mediated gene expression using the PPARα CALUX assay. The isoprenoid-containing tomato 
extract was able to induce PPARα-mediated gene expression, which is consistent with our 
findings that β-carotene, γ-carotene and lycopene also induced PPARα-mediated gene 
expression. In addition, it was shown that the nonhydrolyzed tomato extract, containing 
semi-polar compounds, is only a weak inducer of PPARα-mediated gene expression, but 
that enzymatic hydrolysis of the tomato homogenate before extraction greatly increased 
the inducing potency. This is in line with our findings that none of the flavonoid glycosides 
is able to induce PPARα-mediated gene expression, but that the flavonoid aglycones 
kaempferol and naringenin are. 
To assess differences between tomato extracts, enzymatically hydrolyzed extracts of 
seven different tomato varieties were generated and tested for their capacity to induce 
PPARγ-mediated (chapter 4) and PPARα-mediated (chapter 5) gene expression. The 
extracts of these varieties were all able to induce both PPARγ-mediated gene expression 
and PPARα-mediated gene expression. For PPARγ-mediated gene expression, a 1.6-fold 
difference was found between the least potent and the most potent variety, and for the 
PPARα-mediated gene expression this was 1.7-fold. In both the PPARγ2 CALUX assay and 
the PPARα CALUX assay, the two most potent varieties had a high flavonoid content, 
while the two least potent varieties had a low flavonoid content. This may suggest that 
the differences between these extracts of tomato varieties in potency to induce PPARγ-
mediated gene expression or PPARα-mediated gene expression may be partly explained 
by differences in levels of kaempferol and naringenin and/or other flavonoids. However, 
kaempferol and naringenin showed relatively low induction (up to 5-fold for PPARγ-
mediated gene expression and up to 1.5-fold for PPARα-mediated gene expression) and 
cannot fully explain the high induction (up to 10-fold for PPARγ-mediated gene expression 
and up to 9-fold for PPARα-mediated gene expression) found with the hydrolyzed tomato 
extract. Presumably there are more, yet unidentified PPARγ-activating and PPARα-
activating compounds present in the hydrolyzed tomato extract. 
In chapter 6, extracts of 97 different tomato accessions were screened for their capacity 
to induce EpRE-mediated gene expression using the EpRE-LUX assay. A 3-fold difference 
in EpRE-mediated luciferase activity between the least potent tomato variety and the 
most potent tomato variety was observed. Metabolomic profiles of the 97 extracts were 
generated in order to identify phytochemicals responsible for the differences in potency of 
the 97 tomato varieties to induce EpRE-mediated gene expression. The flavonoid aglycone 
quercetin was identified as one of the main compounds responsible for the ability of 
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tomato extracts to induce EpRE-mediated gene expression, using multivariate analysis 
combining the reporter gene assay data with metabolite profiles of the same tomato 
extracts. In addition, also yet unidentified compounds correlated with the response in the 
EpRE-LUX assay and these compounds may also contribute to EpRE induction. The results 
presented in chapter 6 indicate that combining reporter gene assays and metabolomic 
profiling of tomatoes provides a powerful tool towards the identification of its health 
beneficial constituents.
Future studies to verify that the extraction methods presented in chapter 2 of this thesis 
are also applicable to other fruits and vegetables and to processed foods, would be useful. 
As metabolism of flavonoids and carotenoids may affect their bioactivity, future studies 
may also focus on the bioactivity of flavonoid and carotenoid metabolites. A further issue 
to consider in future research is under which conditions the increases in EpRE-, PPARγ- or 
PPARα-mediated gene expression may turn out to reflect adverse instead of beneficial 
health effects. In addition, in vivo validation of the possible health effects of the increased 
EpRE-, PPARγ- or PPARα-mediated gene expression would be of importance and could 
focus on the compounds and varieties defined as being most active in our present work 
using the reporter gene assays. 
In conclusion, the work presented in this thesis provides proof-of-principle that reporter 
gene assays can be implemented for screening bioactive food compounds as well as whole 
fruit and vegetable extracts for their capacity to induce transcription factor-mediated 
health-related gene expression. It was shown that reporter gene assays are able to pick up 
differences in transcription factor-mediated gene expression induced by different varieties 
of tomato. Furthermore, this thesis provides proof-of-principle that active ingredients 
contributing to the activity of the whole tomato extracts could be identified by combining 
reporter gene assays and metabolomic profiling. Our results indicate that combining 
multiple reporter gene assays and metabolomic profiling, is useful in fast screening of 
larger numbers of food items and food compounds. Therefore, the use of reporter gene 
assays as a first tier in a tiered approach aiming at supporting health claims, will limit 
the number of animal studies and human studies needed, by enabling the ranking and 
selection of highly promising food items or constituents for further in vivo testing. 
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De consumptie van voedingsmiddelen met gezondheidsbevorderende effecten, zoals 
margarine met plantensterolen, vruchtensap met toegevoegd calcium en ontbijtgranen 
met voedingsvezels, is de afgelopen jaren snel gestegen. Het is echter lastig de 
effectiviteit van dergelijke extra toevoegingen vast te stellen. Dit proefschrift laat zien 
dat reportergen-assays effectieve instrumenten zijn om dergelijke functionele effecten 
van voedingsmiddelen en bioactieve stoffen uit voedingsmiddelen te onderzoeken door 
gebruik te maken van genexpressie gemedieerd door verschillende transcriptie factoren. 
Om groenten en fruit te kunnen testen in reportergen-assays, zijn extractiemethoden 
nodig om groente- en fruitextracten te maken die geschikt zijn voor gebruik in 
reportergen-assays. In hoofdstuk 2 worden methoden beschreven om drie verschillende 
tomatenextracten te bereiden: 
• een ongehydrolyseerd tomatenextract dat apolaire stoffen zoals isoprenoïden bevat 
en verder isoprenoïden-bevattend tomatenextract zal worden genoemd, 
• een ongehydrolyseerd tomatenextract dat semi-polaire stoffen bevat en verder 
ongehydrolyseerd tomatenextract genoemd zal worden, 
• en een enzymatisch gehydrolyseerd tomatenextract dat gedeglycosyleerde semi-
polaire stoffen bevat en verder gehydrolyseerd tomatenextract genoemd zal worden. 
Alle drie de tomatenextracten verstoorden de celfysiologische en celkweekcondities 
niet en werden in een van de gebruikte gen-expressieassays, de nrf2-gemedieerde EpRE-LUX 
reportergen-assay, getest. Zowel het isoprenoïden-bevattend tomatenextract als de 
meeste individuele isoprenoïden (met uitzondering van neurosporeen) waren niet in staat 
EpRE-gemedieerde genexpressie te induceren. ook het ongehydrolyseerde tomatenextract 
en flavonoïd-glycosiden waren niet in staat om EpRE-gemedieerde genexpressie te 
induceren. Het enzymatisch gehydrolyseerde extract, dat gedeglycosyleerde polyfenolen 
bevat, was wel in staat EpRE-gemedieerde genexpressie te induceren, zowel op mRNA-
niveau als op eiwitniveau. In lijn met deze bevindingen bleken ook de flavonoid-aglyconen 
quercetine, kaempferol, naringenine en naringenine chalcone EpRE-gemedieerde 
genexpressie te induceren. Deze vier flavonoïden zouden dus bij kunnen dragen aan de 
inductie die waargenomen werd met het enzymatisch gehydrolyseerde tomatenextract. 
Samen wijzen de resultaten, gepresenteerd in hoofdstuk 2, erop dat de inductie van EpRE-
gereguleerde genen, zoals ontgiftende fase II-enzymen en antioxidant-enzymen, zouden 
kunnen bijdragen aan de gezondheidsbevorderende effecten van tomaten. 
hoofdstuk 3 van dit proefschrift beschrijft de ontwikkeling en validatie van twee nieuwe, 
stabiele transcriptiefactor-gemedieerde gen expressie assays: de PPARγ1 CALUX-assay en 
de PPARγ2 CALUX-assay. De data in dit hoofdstuk laten zien dat deze reportercellijnen 
specifiek reageren op agonisten voor PPARγ en dat deze reportercellijnen een betrouwbaar 
en bruikbaar instrument zijn om bioactieve stoffen te screenen op PPARγ-agonistische of 
-antagonistische activiteit. 
Omdat de gezondheidsbevorderende effecten gerelateerd aan PPARγ-activatie deels 
overlappen met effecten geassocieerd met tomatenconsumptie, zijn in hoofdstuk 4 
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tomatenextracten en tomateninhoudsstoffen getest op hun capaciteit om PPARγ-
gemedieerde genexpressie te induceren. Dertig stoffen werden geselecteerd op basis 
van hun aanwezigheid in tomaat en werden onderzocht in de PPARγ2 CALUX-assay. 
Van deze tomatenstoffen waren drie vetzuren, zeven carotenoïden en drie polyfenolen 
in staat PPARγ2-gemedieerde genexpressie te induceren. In lijn met deze bevindingen 
induceerden ook het isoprenoïden-bevattende tomatenextract en het enzymatisch 
gehydrolyseerde tomatenextract de PPARγ-gemedieerde genexpressie. Deze resultaten 
wijzen erop dat de inductie van PPARγ-gemedieerde genexpressie door tomatenstoffen 
zou kunnen bijdragen aan de gezondheidsbevorderende effecten die geassocieerd zijn 
met tomatenconsumptie. 
In hoofdstuk 5 wordt de ontwikkeling en validatie van de PPARα CALUX transcriptiefactor-
gemedieerde genexpressie-assay beschreven. Vervolgens zijn tomatenextracten en individuele 
tomateninhoudsstoffen met behulp van deze nieuwe PPARα CALUX-assay getest op hun 
capaciteit om PPARα-gemedieerde genexpressie te induceren. Het isoprenoïd-bevattende 
extract was in staat PPARα-gemedieerde genexpressie te induceren, wat overeenkomt met de 
bevinding dat β-caroteen, γ-caroteen en lycopeen ook in staat zijn om PPARα-gemedieerde 
genexpressie te induceren. Daarnaast gaf het ongehydrolyseerde tomatenextract een zwakke 
inductie van PPARα-gemedieerde genexpressie, maar enzymatische hydrolyse van tomaat 
voorafgaande aan extractie, leidde tot een aanzienlijke verhoging van de inductiecapaciteit. 
Dit is in overeenstemmingmet onze bevindingen dat geen van de flavonoïd-glycosiden in 
staat was PPARα-gemedieerde genexpressie te induceren, maar dat de flavonoïd-aglyconen 
kaempferol en naringenine daartoe wel in staat waren. 
Om verschillen tussen tomatenextracten te onderzoeken, werden enzymatisch 
gehydrolyseerde extracten gemaakt van zeven verschillende tomatenvariëteiten en 
getest op hun capaciteit om PPARγ-gemedieerde (hoofdstuk 4) en PPARα-gemedieerde 
(hoofdstuk 5) genexpressie te induceren. De extracten van deze variëteiten waren allemaal 
in staat om zowel PPARγ-gemedieerde als PPARα-gemedieerde genexpressie te induceren. 
Voor PPARγ-gemedieerde genexpressie werd een verschil van 1.6-fold waargenomen 
tussen de meest potente en de minst potente variëteit, en voor PPARα-gemedieerde 
genexpressie was dat 1.7-fold. Zowel in de PPARγ2 CALUX assay als in de PPARα CALUX 
assay hadden de twee meest potente tomatenvariëteiten ook een hoog gehalte aan 
flavonoïden, terwijl de twee minst potente tomatenvariëteiten een laag gehalte aan 
flavonoïden hadden. Dit zou erop kunnen wijzen dat de verschillen in capaciteit om PPARγ-
gemedieerde genexpressie of PPARα-gemedieerde genexpressie te induceren, deels 
verklaard kunnen worden door verschillen in de gehaltes aan kaempferol, naringenine en 
andere flavonoïden. Kaempferol en naringenine lieten echter een relatief lage inductie zien 
(tot vijfvoudige inductie voor PPARγ-gemedieerde genexpressie en tot 1.5-fold inductie 
voor PPARα-gemedieerde genexpressie) en kunnen de hoge inductie (tot tienvoudige 
inductie voor PPARγ-gemedieerde genexpressie en tot negenvoudige inductie voor PPARα-
gemedieerde genexpressie) waargenomen met het gehydrolyseerde tomatenextract, niet 
volledig verklaren. Waarschijnlijk zijn er meer – tot nu toe ongeïdentificeerde – stoffen 
aanwezig in tomaat die PPARγ en/of PPARα kunnen activeren. 
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In hoofdstuk 6 zijn extracten van 97 verschillende tomatenvariëteiten met behulp 
van de EpRE-LUX assay gescreend op hun capaciteit om EpRE-gemedieerde genexpressie 
te induceren. Er werd een drievoudig verschil in EpRE-gemedieerde genexpressie 
waargenomen tussen de minst potente variëteit en de meest potente variëteit. Van alle 
97 tomatenvariëteiten werden metabolietprofielen gemaakt om stoffen te identificeren 
die verantwoordelijk zijn voor deze verschillen in genexpressie inducerende capaciteit. 
Door het combineren van genexpressiegegevens uit de reportergen-assay met de 
metabolietprofielen in een multivariate analyse werd quercetine geïdentificeerd als een 
van de belangrijkste stoffen die verantwoordelijk zou kunnen zijn voor de capaciteit van 
tomatenextracten om EpRE-gemedieerde genexpressie te induceren. Daarnaast lieten ook 
nog ongeïdentificeerde stoffen een goede correlatie zien met de respons in de EpRE-LUX 
cellen. De in dit hoofdstuk beschreven resultaten laten zien dat het combineren van 
reportergen-assays met metabolietanalyse een nuttige aanpak kan zijn in de identificatie 
van gezondheidsbevorderende stoffen in tomaat.
Toekomstige studies die laten zien of de extractiemethoden, gepresenteerd in hoofdstuk 2, 
ook toepasbaar zijn op andere groenten en fruit en op bewerkte voedingsmiddelen zouden 
nuttig zijn. Omdat metabolisme van flavonoïden en carotenoïden hun bioactiviteit kan 
beïnvloeden, is het van belang dat de bioactiviteit van de metabolieten van flavonoïden en 
carotenoïden nader wordt onderzocht. Een andere kwestie om nader te onderzoeken, is 
onder welke condities de inductie van EpRE-, PPARγ-, of PPARα-gemedieerde genexpressie 
zou kunnen leiden tot nadelige in plaats van heilzame gezondheidseffecten. Daarnaast zou 
een in vivo-validatie van de mogelijke gezondheidseffecten van een toename in EpRE-, 
PPARγ- of PPARα-gemedieerde genexpressie van belang zijn en daarin zou men kunnen 
focussen op de stoffen en variëteiten die in dit proefschrift zijn aangeduid als meest actief. 
Samenvattend laat het in dit proefschrift gepresenteerde werk zien dat transcriptiefactor-
gemedieerde genexpressie-assays kunnen worden ingezet in de effect-screening van 
bioactieve stoffen en van groente- en fruitextracten. De assays zijn in staat verschillen 
tussen tomatenvariëteiten ten aanzien van de inductie van transcriptiefactor-gemedieerde 
genexpressie, zichtbaar te maken. Daarnaast laat dit proefschrift zien dat actieve 
componenten die bijdragen aan de activiteit van tomatenextracten, kunnen worden 
geïdentificeerd door het combineren van reportergen-assaydata en metabolietprofielen 
van die extracten. Onze resultaten wijzen erop dat deze combinatie van reportergen-
assays met metabolietprofielen bruikbaar is voor het snel screenen van grotere aantallen 
voedingsmiddelen en inhoudsstoffen. Het gebruik van reportergen-assays als eerste 
fase in een stapsgewijze benadering om gezondheidsclaims te onderbouwen, zal het 
aantal benodigde dierstudies en humane studies beperken, omdat veelbelovende 
voedingsmiddelen en hun inhoudsstoffen kunnen worden geselecteerd en alleen deze 
verder getest hoeven te worden. 
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